{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Automated Question-Answer Generation from Pharmaceutical Data\n",
    "\n",
    "This notebook systematically generates question-answer pairs from pharmaceutical data sources including:\n",
    "1. PubMed target passages\n",
    "2. DrugBank tables\n",
    "3. Related pharmaceutical data\n",
    "\n",
    "Each QA pair will include:\n",
    "- Question\n",
    "- Answer\n",
    "- Source text/passage\n",
    "- Related table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Import required libraries\n",
    "import os\n",
    "import pandas as pd\n",
    "import json\n",
    "from pathlib import Path\n",
    "from openai import OpenAI\n",
    "import csv\n",
    "from tqdm import tqdm\n",
    "from collections import defaultdict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Configuration and paths\n",
    "PUBMED_TARGETS_DIR = 'inputs/pubmed-targets'\n",
    "DRUGBANK_TABLES_DIR = 'inputs/drugbank-tables'\n",
    "MAPPING_FILE = 'inputs/pubmed-drugbank-tables.gt'\n",
    "OUTPUT_FILE = 'passage_output.gt'\n",
    "\n",
    "# Initialize your LLM API key if needed\n",
    "# os.environ[\"OPENAI_API_KEY\"]\n",
    "client = OpenAI()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_passage_table_mapping():\n",
    "    \"\"\"Load the mapping between passages and their relevant tables\"\"\"\n",
    "    mapping = defaultdict(list)\n",
    "    with open(MAPPING_FILE, 'r') as f:\n",
    "        for line in f:\n",
    "            passage_id, table_name = line.strip().split(',')\n",
    "            mapping[passage_id].append(table_name)\n",
    "    # print(\"mapping\", mapping)\n",
    "    return mapping\n",
    "\n",
    "def load_target_passages():\n",
    "    \"\"\"Load all target passages from the pubmed-targets directory\"\"\"\n",
    "    passages = {}\n",
    "    target_files = Path(PUBMED_TARGETS_DIR).glob('Target-*')\n",
    "    \n",
    "    for file_path in target_files:\n",
    "        target_id = file_path.name\n",
    "        with open(file_path, 'r') as f:\n",
    "            passages[target_id] = f.read()\n",
    "    # print(\"passages\", passages)\n",
    "    return passages\n",
    "\n",
    "def load_drugbank_tables():\n",
    "    \"\"\"Load all relevant DrugBank tables\"\"\"\n",
    "    tables = {}\n",
    "    csv_files = Path(DRUGBANK_TABLES_DIR).glob('*.csv')\n",
    "    \n",
    "    for file_path in csv_files:\n",
    "        table_name = file_path.stem\n",
    "        tables[table_name] = pd.read_csv(file_path)\n",
    "    \n",
    "    # print(\"tables\", tables)\n",
    "    return tables"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_relevant_table_content(tables, table_names, max_rows=5):\n",
    "    \"\"\"Extract relevant content from tables for context\"\"\"\n",
    "    print(\"Debug - Available tables:\", tables.keys())\n",
    "    print(\"Debug - Looking for table_names:\", table_names)\n",
    "\n",
    "    table_content = {}\n",
    "    for table_name in table_names:\n",
    "        # Remove .csv extension if present\n",
    "        base_table_name = table_name.replace('.csv', '')\n",
    "        \n",
    "        if base_table_name in tables:\n",
    "            df = tables[base_table_name]\n",
    "            table_content[base_table_name] = {\n",
    "                'columns': list(df.columns),\n",
    "                'sample': df.head(max_rows).to_dict('records')\n",
    "            }\n",
    "        else:\n",
    "            print(f\"Debug - Table '{base_table_name}' not found in available tables\")\n",
    "    return table_content\n",
    "\n",
    "def generate_questions_for_passage(passage_id, passage_text, tables, relevant_table_names, model=\"gpt-4o\"):\n",
    "    \"\"\"Generate questions for a given passage and its relevant tables using LLM\"\"\"\n",
    "\n",
    "    # print(\"tables\", tables)\n",
    "    # print(\"relevant_table_names\", relevant_table_names)\n",
    "    \n",
    "    # Limit passage length if too long (e.g., first 1000 characters)\n",
    "    passage_text = passage_text[:1000] + \"...\" if len(passage_text) > 1000 else passage_text\n",
    "    \n",
    "    # Limit to maximum 3 relevant tables\n",
    "    relevant_table_names = relevant_table_names[:3]\n",
    "    \n",
    "    # Get relevant table content\n",
    "    table_content = get_relevant_table_content(tables, relevant_table_names)\n",
    "\n",
    "    \n",
    "    prompt = f\"\"\"\n",
    "    Given the following passage and related tables, generate 3-5 meaningful question-answer pairs.\n",
    "    IMPORTANT: Each question MUST be answerable using information from ONLY the passage.\n",
    "    Only generate questions that require information from the passage.\n",
    "    Focus on pharmaceutical and medical aspects.\n",
    "    \n",
    "    \n",
    "    Passage (ID: {passage_id}):\n",
    "    {passage_text}\n",
    "    \n",
    "    Related Tables:\n",
    "    {json.dumps(table_content, indent=2)}\n",
    "    \n",
    "    Generate questions in the following format:\n",
    "    1. question: [specific question about drug/treatment]\n",
    "       answer: [detailed answer combining information from passage and tables]\n",
    "       text: [passage ID if information from passage was used (e.g. Target-123456789)]\n",
    "       table: [None]\n",
    "    \n",
    "    Ensure every question uses information from both the passage and at least one table.\n",
    "    \"\"\"\n",
    "    \n",
    "    # Call your LLM here with the prompt\n",
    "    response = client.chat.completions.create(\n",
    "        model=model,\n",
    "        messages=[\n",
    "            {\"role\": \"system\", \"content\": \"You are a medical and pharmaceutical expert tasked with generating detailed question-answer pairs about drugs and treatments.\"},\n",
    "            {\"role\": \"user\", \"content\": prompt}\n",
    "        ],\n",
    "        temperature=0.7\n",
    "    )\n",
    "\n",
    "    print(response.choices[0].message.content)\n",
    "    \n",
    "    # Parse the response into structured QA pairs\n",
    "    qa_pairs = parse_llm_response(response.choices[0].message.content, passage_id)\n",
    "    return qa_pairs\n",
    "\n",
    "def parse_llm_response(response_text, passage_id):\n",
    "    \"\"\"Parse the LLM response into structured QA pairs\"\"\"\n",
    "    qa_pairs = []\n",
    "    \n",
    "    # Split the response into individual QA entries\n",
    "    entries = response_text.strip().split('\\n\\n')\n",
    "    \n",
    "    for entry in entries:\n",
    "        if not entry.strip():\n",
    "            continue\n",
    "            \n",
    "        lines = entry.strip().split('\\n')\n",
    "        current_qa = {\n",
    "            'question': '',\n",
    "            'answer': '',\n",
    "            'text': passage_id,\n",
    "            'table': 'None'  # Default value\n",
    "        }\n",
    "        \n",
    "        for line in lines:\n",
    "            line = line.strip()\n",
    "            # Skip empty lines and numbering\n",
    "            if not line or line.replace('.', '').strip().isdigit():\n",
    "                continue\n",
    "                \n",
    "            # Parse each field using more robust splitting\n",
    "            if 'question:' in line:\n",
    "                current_qa['question'] = line.split('question:', 1)[1].strip()\n",
    "            elif 'answer:' in line:\n",
    "                current_qa['answer'] = line.split('answer:', 1)[1].strip()\n",
    "            elif 'text:' in line:\n",
    "                current_qa['text'] = line.split('text:', 1)[1].strip()\n",
    "            elif 'table:' in line:\n",
    "                table_value = line.split('table:', 1)[1].strip()\n",
    "                # Handle NA, N/A, None cases\n",
    "                current_qa['table'] = 'None' if table_value.upper() in ['NA', 'N/A', 'NONE'] else table_value\n",
    "        \n",
    "        # Only add complete QA pairs that have both question and answer\n",
    "        if current_qa['question'] and current_qa['answer']:\n",
    "            qa_pairs.append(current_qa.copy())  # Use copy to avoid reference issues\n",
    "    \n",
    "    return qa_pairs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "def main():\n",
    "    # Load mappings and data\n",
    "    print(\"Loading passage-table mappings...\")\n",
    "    passage_table_mapping = load_passage_table_mapping()\n",
    "    \n",
    "    print(\"Loading target passages...\")\n",
    "    passages = load_target_passages()\n",
    "    \n",
    "    print(\"Loading DrugBank tables...\")\n",
    "    tables = load_drugbank_tables()\n",
    "    \n",
    "    # Initialize output list\n",
    "    qa_pairs = []\n",
    "    \n",
    "    # Process each passage with its relevant tables\n",
    "    for passage_id, passage_text in tqdm(list(passages.items())[:150]):\n",
    "        if passage_id in passage_table_mapping:\n",
    "            relevant_tables = passage_table_mapping[passage_id]\n",
    "            # print(passage_id, passage_text, tables, relevant_tables)\n",
    "            \n",
    "            # Generate QA pairs using the passage and its relevant tables\n",
    "            new_qa_pairs = generate_questions_for_passage(\n",
    "                passage_id,\n",
    "                passage_text,\n",
    "                tables,\n",
    "                relevant_tables\n",
    "            )\n",
    "            # new_qa_pairs = []\n",
    "            print(new_qa_pairs)\n",
    "            qa_pairs.extend(new_qa_pairs)\n",
    "        else:\n",
    "            print(f\"No table mapping found for passage {passage_id}\")\n",
    "    \n",
    "    # Save results\n",
    "    with open(OUTPUT_FILE, 'w', newline='') as f:\n",
    "        writer = csv.writer(f, quoting=csv.QUOTE_ALL)\n",
    "        writer.writerow(['question', 'answer', 'text', 'table'])  # header\n",
    "        for qa_pair in qa_pairs:\n",
    "            writer.writerow([\n",
    "                qa_pair['question'],\n",
    "                qa_pair['answer'],\n",
    "                qa_pair['text'],\n",
    "                qa_pair['table']\n",
    "            ])\n",
    "        \n",
    "    print(f\"Generated {len(qa_pairs)} question-answer pairs\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading passage-table mappings...\n",
      "Loading target passages...\n",
      "Loading DrugBank tables...\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_35722/2028544267.py:30: DtypeWarning: Columns (5,6) have mixed types. Specify dtype option on import or set low_memory=False.\n",
      "  tables[table_name] = pd.read_csv(file_path)\n",
      "  0%|          | 0/150 [00:00<?, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  1%|          | 1/150 [00:04<11:18,  4.55s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the primary clinical use of Flumazenil, and what is its preferred route of administration?\n",
      "   answer: Flumazenil is primarily used to reverse the effects of benzodiazepine sedation. It has a low bioavailability when administered orally, so the preferred route of administration is intravenous.\n",
      "   text: Target-8693922\n",
      "   table: None\n",
      "\n",
      "2. question: How does Flumazenil interact with benzodiazepines when administered before or with them?\n",
      "   answer: When Flumazenil is administered before or with other benzodiazepines, it modifies their effects. The extent of this modification depends on factors such as the dose, duration of effect, and the relative receptor affinity of the agonist.\n",
      "   text: Target-8693922\n",
      "   table: None\n",
      "\n",
      "3. question: What are the indications for using Flumazenil in a clinical setting?\n",
      "   answer: The indications for using Flumazenil include the reversal of benzodiazepine-induced sedation, termination of benzodiazepine-induced anesthesia, return of spontaneous respiration and consciousness in intensive care patients, and the treatment of paradoxical reactions to benzodiazepines.\n",
      "   text: Target-8693922\n",
      "   table: None\n",
      "[{'question': 'What is the primary clinical use of Flumazenil, and what is its preferred route of administration?', 'answer': 'Flumazenil is primarily used to reverse the effects of benzodiazepine sedation. It has a low bioavailability when administered orally, so the preferred route of administration is intravenous.', 'text': 'Target-8693922', 'table': 'None'}, {'question': 'How does Flumazenil interact with benzodiazepines when administered before or with them?', 'answer': 'When Flumazenil is administered before or with other benzodiazepines, it modifies their effects. The extent of this modification depends on factors such as the dose, duration of effect, and the relative receptor affinity of the agonist.', 'text': 'Target-8693922', 'table': 'None'}, {'question': 'What are the indications for using Flumazenil in a clinical setting?', 'answer': 'The indications for using Flumazenil include the reversal of benzodiazepine-induced sedation, termination of benzodiazepine-induced anesthesia, return of spontaneous respiration and consciousness in intensive care patients, and the treatment of paradoxical reactions to benzodiazepines.', 'text': 'Target-8693922', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  1%|▏         | 2/150 [00:08<10:26,  4.23s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the affinity range for dicyclomine, trihexyphenidyl, and pirenzepine for the M1 muscarinic receptor subtype, and how does it compare to atropine?\n",
      "   answer: Dicyclomine, trihexyphenidyl, and pirenzepine have an affinity range of 3.7-14 nM for the M1 muscarinic receptor subtype, which is slightly lower than that of atropine, which has an affinity of 1.6 nM.\n",
      "   text: Target-2432979\n",
      "   table: None\n",
      "\n",
      "2. question: How do the affinity profiles of dicyclomine, trihexyphenidyl, and pirenzepine differ for cardiac and glandular (salivary) membranes when compared to atropine?\n",
      "   answer: Dicyclomine, trihexyphenidyl, and pirenzepine display low affinity for cardiac receptors and intermediate affinity for glandular receptors, while atropine shows similar affinities for both these peripheral muscarinic subtypes.\n",
      "   text: Target-2432979\n",
      "   table: None\n",
      "\n",
      "3. question: Based on the passage, which muscarinic receptor subtype do dicyclomine, trihexyphenidyl, and pirenzepine have the highest affinity for, and what does this suggest about their selectivity?\n",
      "   answer: Dicyclomine, trihexyphenidyl, and pirenzepine have the highest affinity for the M1 muscarinic receptor subtype, suggesting they are more selective for cortical rather than peripheral muscarinic subtypes such as cardiac and glandular receptors.\n",
      "   text: Target-2432979\n",
      "   table: None\n",
      "[{'question': 'What is the affinity range for dicyclomine, trihexyphenidyl, and pirenzepine for the M1 muscarinic receptor subtype, and how does it compare to atropine?', 'answer': 'Dicyclomine, trihexyphenidyl, and pirenzepine have an affinity range of 3.7-14 nM for the M1 muscarinic receptor subtype, which is slightly lower than that of atropine, which has an affinity of 1.6 nM.', 'text': 'Target-2432979', 'table': 'None'}, {'question': 'How do the affinity profiles of dicyclomine, trihexyphenidyl, and pirenzepine differ for cardiac and glandular (salivary) membranes when compared to atropine?', 'answer': 'Dicyclomine, trihexyphenidyl, and pirenzepine display low affinity for cardiac receptors and intermediate affinity for glandular receptors, while atropine shows similar affinities for both these peripheral muscarinic subtypes.', 'text': 'Target-2432979', 'table': 'None'}, {'question': 'Based on the passage, which muscarinic receptor subtype do dicyclomine, trihexyphenidyl, and pirenzepine have the highest affinity for, and what does this suggest about their selectivity?', 'answer': 'Dicyclomine, trihexyphenidyl, and pirenzepine have the highest affinity for the M1 muscarinic receptor subtype, suggesting they are more selective for cortical rather than peripheral muscarinic subtypes such as cardiac and glandular receptors.', 'text': 'Target-2432979', 'table': 'None'}]\n",
      "No table mapping found for passage Target-15686733\n",
      "No table mapping found for passage Target-19852077\n",
      "No table mapping found for passage Target-8214760\n",
      "No table mapping found for passage Target-16276979\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  5%|▍         | 7/150 [00:16<05:02,  2.11s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the mechanism of action for balsalazide in the treatment of ulcerative colitis?\n",
      "   answer: Balsalazide is a prodrug of 5-aminosalicylate (5-ASA) that utilizes azoreduction by colonic bacteria to achieve a sustained release of active 5-ASA throughout the colon. This mechanism is critical for its effectiveness in treating ulcerative colitis.\n",
      "   text: Target-19743890\n",
      "   table: None\n",
      "\n",
      "2. question: How does balsalazide compare to mesalamine in terms of inducing remission in ulcerative colitis?\n",
      "   answer: Balsalazide has been shown to induce symptomatic remission in ulcerative colitis both more swiftly and more frequently compared to mesalamine, according to recent clinical trial data.\n",
      "   text: Target-19743890\n",
      "   table: None\n",
      "\n",
      "3. question: What is the recommended dose of balsalazide for inducing remission in symptomatic ulcerative colitis?\n",
      "   answer: A recent clinical trial has demonstrated that balsalazide at a dose of 6.7 grams per day is superior to placebo in inducing remission in symptomatic ulcerative colitis.\n",
      "   text: Target-19743890\n",
      "   table: None\n",
      "\n",
      "4. question: What is the safety profile of balsalazide compared to other oral 5-ASA agents?\n",
      "   answer: Balsalazide is well tolerated, with a safety profile comparable to other oral 5-ASA agents, making it a viable option for the treatment of ulcerative colitis.\n",
      "   text: Target-19743890\n",
      "   table: None\n",
      "\n",
      "5. question: What databases were reviewed to obtain current data on balsalazide?\n",
      "   answer: The systematic review of published literature was performed on PubMed using the search terms 'Balsalazide' and 'Colazal(TM)', and the Cochrane database was also reviewed to gather current data on balsalazide.\n",
      "   text: Target-19743890\n",
      "   table: None\n",
      "[{'question': 'What is the mechanism of action for balsalazide in the treatment of ulcerative colitis?', 'answer': 'Balsalazide is a prodrug of 5-aminosalicylate (5-ASA) that utilizes azoreduction by colonic bacteria to achieve a sustained release of active 5-ASA throughout the colon. This mechanism is critical for its effectiveness in treating ulcerative colitis.', 'text': 'Target-19743890', 'table': 'None'}, {'question': 'How does balsalazide compare to mesalamine in terms of inducing remission in ulcerative colitis?', 'answer': 'Balsalazide has been shown to induce symptomatic remission in ulcerative colitis both more swiftly and more frequently compared to mesalamine, according to recent clinical trial data.', 'text': 'Target-19743890', 'table': 'None'}, {'question': 'What is the recommended dose of balsalazide for inducing remission in symptomatic ulcerative colitis?', 'answer': 'A recent clinical trial has demonstrated that balsalazide at a dose of 6.7 grams per day is superior to placebo in inducing remission in symptomatic ulcerative colitis.', 'text': 'Target-19743890', 'table': 'None'}, {'question': 'What is the safety profile of balsalazide compared to other oral 5-ASA agents?', 'answer': 'Balsalazide is well tolerated, with a safety profile comparable to other oral 5-ASA agents, making it a viable option for the treatment of ulcerative colitis.', 'text': 'Target-19743890', 'table': 'None'}, {'question': 'What databases were reviewed to obtain current data on balsalazide?', 'answer': \"The systematic review of published literature was performed on PubMed using the search terms 'Balsalazide' and 'Colazal(TM)', and the Cochrane database was also reviewed to gather current data on balsalazide.\", 'text': 'Target-19743890', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  5%|▌         | 8/150 [00:25<07:58,  3.37s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the mechanism of action of valdecoxib described in the passage?\n",
      "   answer: Valdecoxib is described as a potent and selective inhibitor of COX-2. It functions by inhibiting the cyclooxygenase-2 enzyme, which is part of the prostaglandin-endoperoxide synthases family, involved in the inflammatory process.\n",
      "   text: Target-10715145\n",
      "   table: None\n",
      "\n",
      "2. question: What is the role of isoxazoles in the context of valdecoxib?\n",
      "   answer: Isoxazoles are part of the chemical structure of valdecoxib, specifically mentioned as 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, indicating that isoxazole forms a component of the molecule that contributes to its COX-2 inhibitory properties.\n",
      "   text: Target-10715145\n",
      "   table: None\n",
      "\n",
      "3. question: How is valdecoxib categorized in terms of its pharmaceutical class?\n",
      "   answer: Valdecoxib is categorized as a non-steroidal anti-inflammatory agent (NSAID), which is used to reduce inflammation and pain in conditions like experimental arthritis.\n",
      "   text: Target-10715145\n",
      "   table: None\n",
      "\n",
      "4. question: In what organisms is valdecoxib's effect primarily studied, according to the passage?\n",
      "   answer: The passage mentions that valdecoxib's effects are studied in both humans and animals, specifically rats, for its COX-2 inhibitory and anti-inflammatory properties.\n",
      "   text: Target-10715145\n",
      "   table: None\n",
      "\n",
      "5. question: What additional molecular components are associated with valdecoxib's function as a COX-2 inhibitor?\n",
      "   answer: In addition to being a COX-2 inhibitor, valdecoxib is related to enzyme inhibitors, membrane proteins, and prostaglandin-endoperoxide synthases, which are involved in its mechanism of action regarding inflammation and edema reduction.\n",
      "   text: Target-10715145\n",
      "   table: None\n",
      "[{'question': 'What is the mechanism of action of valdecoxib described in the passage?', 'answer': 'Valdecoxib is described as a potent and selective inhibitor of COX-2. It functions by inhibiting the cyclooxygenase-2 enzyme, which is part of the prostaglandin-endoperoxide synthases family, involved in the inflammatory process.', 'text': 'Target-10715145', 'table': 'None'}, {'question': 'What is the role of isoxazoles in the context of valdecoxib?', 'answer': 'Isoxazoles are part of the chemical structure of valdecoxib, specifically mentioned as 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, indicating that isoxazole forms a component of the molecule that contributes to its COX-2 inhibitory properties.', 'text': 'Target-10715145', 'table': 'None'}, {'question': 'How is valdecoxib categorized in terms of its pharmaceutical class?', 'answer': 'Valdecoxib is categorized as a non-steroidal anti-inflammatory agent (NSAID), which is used to reduce inflammation and pain in conditions like experimental arthritis.', 'text': 'Target-10715145', 'table': 'None'}, {'question': \"In what organisms is valdecoxib's effect primarily studied, according to the passage?\", 'answer': \"The passage mentions that valdecoxib's effects are studied in both humans and animals, specifically rats, for its COX-2 inhibitory and anti-inflammatory properties.\", 'text': 'Target-10715145', 'table': 'None'}, {'question': \"What additional molecular components are associated with valdecoxib's function as a COX-2 inhibitor?\", 'answer': 'In addition to being a COX-2 inhibitor, valdecoxib is related to enzyme inhibitors, membrane proteins, and prostaglandin-endoperoxide synthases, which are involved in its mechanism of action regarding inflammation and edema reduction.', 'text': 'Target-10715145', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  6%|▌         | 9/150 [00:39<13:06,  5.57s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What analytical methods were used in the study to detect amoxicillin modification of human serum albumin, and how do these methods compare to the information provided in the drugbank-drug table?\n",
      "   answer: The study used multiple reaction monitoring (MRM), precursor ion scan (PIS), and data-dependent and targeted MS/MS analyses to detect the modification of human serum albumin by amoxicillin. These methods were performed using HPLC coupled to a triple quadrupole MS analyzer and a nano-LC system coupled to a high-resolution MS system (LTQ Orbitrap XL). In comparison, the drugbank-drug table provides information about drugs like Lepirudin and Cetuximab, which are analyzed using different recombinant DNA technologies rather than mass spectrometry.\n",
      "   text: Target-25088930\n",
      "   table: drugbank-drug\n",
      "\n",
      "2. question: How does the modification site of human serum albumin by amoxicillin in the study relate to the production method of Lepirudin according to the drugbank-drug table?\n",
      "   answer: The study identified Lys 190 as the only modification site of human serum albumin by amoxicillin. This modification is a specific chemical interaction, whereas Lepirudin, as described in the drugbank-drug table, is produced via yeast cells and involves a substitution of leucine for isoleucine at the N-terminal end and the absence of a sulfate group on tyrosine, representing a different type of molecular modification.\n",
      "   text: Target-25088930\n",
      "   table: drugbank-drug\n",
      "\n",
      "3. question: How does the oral administration regimen of amoxicillin in the study compare to the administration details of drugs like Cetuximab and Dornase alfa provided in the drugbank-drug table?\n",
      "   answer: The study involved the oral administration of amoxicillin at 1 g every 8 hours for 48 hours. In contrast, Cetuximab is administered as part of a regimen costing approximately $30,790 for an eight-week course, and Dornase alfa is administered using recombinant DNA technology involving genetically modified cells, indicating differences in administration routes and costs compared to the simple oral regimen of amoxicillin.\n",
      "   text: Target-25088930\n",
      "   table: drugbank-drug\n",
      "\n",
      "4. question: What does the study reveal about the specificity of human serum albumin modification by amoxicillin, and how does this relate to the specificity of Cetuximab described in the drugbank-drug table?\n",
      "   answer: The study reveals that Lys 190 is the specific site of modification on human serum albumin by amoxicillin, indicating a high level of specificity in the interaction. In comparison, Cetuximab specifically binds to the epidermal growth factor receptor (EGFr), illustrating specificity in targeted therapeutic action as described in the drugbank-drug table.\n",
      "   text: Target-25088930\n",
      "   table: drugbank-drug\n",
      "[{'question': 'What analytical methods were used in the study to detect amoxicillin modification of human serum albumin, and how do these methods compare to the information provided in the drugbank-drug table?', 'answer': 'The study used multiple reaction monitoring (MRM), precursor ion scan (PIS), and data-dependent and targeted MS/MS analyses to detect the modification of human serum albumin by amoxicillin. These methods were performed using HPLC coupled to a triple quadrupole MS analyzer and a nano-LC system coupled to a high-resolution MS system (LTQ Orbitrap XL). In comparison, the drugbank-drug table provides information about drugs like Lepirudin and Cetuximab, which are analyzed using different recombinant DNA technologies rather than mass spectrometry.', 'text': 'Target-25088930', 'table': 'drugbank-drug'}, {'question': 'How does the modification site of human serum albumin by amoxicillin in the study relate to the production method of Lepirudin according to the drugbank-drug table?', 'answer': 'The study identified Lys 190 as the only modification site of human serum albumin by amoxicillin. This modification is a specific chemical interaction, whereas Lepirudin, as described in the drugbank-drug table, is produced via yeast cells and involves a substitution of leucine for isoleucine at the N-terminal end and the absence of a sulfate group on tyrosine, representing a different type of molecular modification.', 'text': 'Target-25088930', 'table': 'drugbank-drug'}, {'question': 'How does the oral administration regimen of amoxicillin in the study compare to the administration details of drugs like Cetuximab and Dornase alfa provided in the drugbank-drug table?', 'answer': 'The study involved the oral administration of amoxicillin at 1 g every 8 hours for 48 hours. In contrast, Cetuximab is administered as part of a regimen costing approximately $30,790 for an eight-week course, and Dornase alfa is administered using recombinant DNA technology involving genetically modified cells, indicating differences in administration routes and costs compared to the simple oral regimen of amoxicillin.', 'text': 'Target-25088930', 'table': 'drugbank-drug'}, {'question': 'What does the study reveal about the specificity of human serum albumin modification by amoxicillin, and how does this relate to the specificity of Cetuximab described in the drugbank-drug table?', 'answer': 'The study reveals that Lys 190 is the specific site of modification on human serum albumin by amoxicillin, indicating a high level of specificity in the interaction. In comparison, Cetuximab specifically binds to the epidermal growth factor receptor (EGFr), illustrating specificity in targeted therapeutic action as described in the drugbank-drug table.', 'text': 'Target-25088930', 'table': 'drugbank-drug'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  7%|▋         | 10/150 [00:42<11:58,  5.13s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the protein binding percentage of nifedipine in serum, and how does it compare to its binding in albumin solution?\n",
      "   answer: In serum from four healthy volunteers, nifedipine showed a mean fraction bound of 0.992 +/- 0.008. This binding percentage is similar to its binding in albumin solution, which had a mean fraction bound of 0.970 +/- 0.012, indicating that albumin is likely the major binding protein for nifedipine in serum. \n",
      "   text: Target-2872322\n",
      "   table: None\n",
      "\n",
      "2. question: How does the binding of nifedipine in alpha 1-acid glycoprotein (AAG) solutions vary with AAG concentration?\n",
      "   answer: The binding of nifedipine in AAG solutions is proportional to the AAG concentration, with the fraction bound ranging from 0.514 +/- 0.059 to 0.755 +/- 0.035 in solutions containing 50 and 150 mg % AAG, respectively.\n",
      "   text: Target-2872322\n",
      "   table: None\n",
      "\n",
      "3. question: What does the passage suggest about the linearity of nifedipine binding in various protein solutions?\n",
      "   answer: The passage indicates that the binding of nifedipine in all protein solutions, including serum, albumin, and AAG, was linear.\n",
      "   text: Target-2872322\n",
      "   table: None\n",
      "[{'question': 'What is the protein binding percentage of nifedipine in serum, and how does it compare to its binding in albumin solution?', 'answer': 'In serum from four healthy volunteers, nifedipine showed a mean fraction bound of 0.992 +/- 0.008. This binding percentage is similar to its binding in albumin solution, which had a mean fraction bound of 0.970 +/- 0.012, indicating that albumin is likely the major binding protein for nifedipine in serum.', 'text': 'Target-2872322', 'table': 'None'}, {'question': 'How does the binding of nifedipine in alpha 1-acid glycoprotein (AAG) solutions vary with AAG concentration?', 'answer': 'The binding of nifedipine in AAG solutions is proportional to the AAG concentration, with the fraction bound ranging from 0.514 +/- 0.059 to 0.755 +/- 0.035 in solutions containing 50 and 150 mg % AAG, respectively.', 'text': 'Target-2872322', 'table': 'None'}, {'question': 'What does the passage suggest about the linearity of nifedipine binding in various protein solutions?', 'answer': 'The passage indicates that the binding of nifedipine in all protein solutions, including serum, albumin, and AAG, was linear.', 'text': 'Target-2872322', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  7%|▋         | 11/150 [00:48<12:14,  5.29s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How do the blocking manners of nifedipine, mibefradil, and efonidipine differ when targeting T-type Ca2+ channels?\n",
      "   answer: Nifedipine blocks T-type Ca2+ channel currents mainly in a tonic manner, mibefradil in a use-dependent manner, and efonidipine using a combination of both tonic and use-dependent manners.\n",
      "   text: Target-16899990\n",
      "   table: None\n",
      "\n",
      "2. question: What are the IC50 values of nifedipine for blocking T-type and L-type Ca2+ channel currents?\n",
      "   answer: The IC50 values of nifedipine are 1.2 micromol/l for T-type Ca2+ channel currents and 0.14 nmol/l for L-type Ca2+ channel currents.\n",
      "   text: Target-16899990\n",
      "   table: None\n",
      "\n",
      "3. question: Which calcium channel blocker showed the highest affinity for T-type Ca2+ channels, and what is its IC50 value?\n",
      "   answer: Efonidipine showed the highest affinity for T-type Ca2+ channels, with an IC50 value of 0.35 micromol/l.\n",
      "   text: Target-16899990\n",
      "   table: None\n",
      "\n",
      "4. question: What is the chemical classification of efonidipine, and how does it compare in terms of blocking T-type Ca2+ channels to other similar compounds?\n",
      "   answer: Efonidipine is a dihydropyridine analogue and it blocks T-type Ca2+ channels using a combination of tonic and use-dependent manners, showing a high affinity compared to nifedipine and mibefradil.\n",
      "   text: Target-16899990\n",
      "   table: None\n",
      "\n",
      "5. question: Which type of Ca2+ channel current does efonidipine have the lowest IC50 value for, and what is that value?\n",
      "   answer: Efonidipine has the lowest IC50 value for L-type Ca2+ channel currents, with a value of 1.8 nmol/l.\n",
      "   text: Target-16899990\n",
      "   table: None\n",
      "[{'question': 'How do the blocking manners of nifedipine, mibefradil, and efonidipine differ when targeting T-type Ca2+ channels?', 'answer': 'Nifedipine blocks T-type Ca2+ channel currents mainly in a tonic manner, mibefradil in a use-dependent manner, and efonidipine using a combination of both tonic and use-dependent manners.', 'text': 'Target-16899990', 'table': 'None'}, {'question': 'What are the IC50 values of nifedipine for blocking T-type and L-type Ca2+ channel currents?', 'answer': 'The IC50 values of nifedipine are 1.2 micromol/l for T-type Ca2+ channel currents and 0.14 nmol/l for L-type Ca2+ channel currents.', 'text': 'Target-16899990', 'table': 'None'}, {'question': 'Which calcium channel blocker showed the highest affinity for T-type Ca2+ channels, and what is its IC50 value?', 'answer': 'Efonidipine showed the highest affinity for T-type Ca2+ channels, with an IC50 value of 0.35 micromol/l.', 'text': 'Target-16899990', 'table': 'None'}, {'question': 'What is the chemical classification of efonidipine, and how does it compare in terms of blocking T-type Ca2+ channels to other similar compounds?', 'answer': 'Efonidipine is a dihydropyridine analogue and it blocks T-type Ca2+ channels using a combination of tonic and use-dependent manners, showing a high affinity compared to nifedipine and mibefradil.', 'text': 'Target-16899990', 'table': 'None'}, {'question': 'Which type of Ca2+ channel current does efonidipine have the lowest IC50 value for, and what is that value?', 'answer': 'Efonidipine has the lowest IC50 value for L-type Ca2+ channel currents, with a value of 1.8 nmol/l.', 'text': 'Target-16899990', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  8%|▊         | 12/150 [00:53<11:59,  5.22s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What was the initial daily dose of topiramate (TPM) used in the study on patients with severe myoclonic epilepsy in infancy (SMEI) and refractory seizures?\n",
      "   answer: The initial daily dose of topiramate (TPM) used in the study was 0.5-1 mg/kg, followed by a 2-week titration at increments of 1-3 mg/kg/24 h up to a maximum daily dose of 12 mg/kg.\n",
      "   text: Target-11948006\n",
      "   table: None\n",
      "\n",
      "2. question: What types of adverse events were observed in patients during the topiramate (TPM) study for severe myoclonic epilepsy in infancy (SMEI)?\n",
      "   answer: Mild to moderate adverse events observed in the study included weight loss, hypermenorrhoea, renal microlithiasis, nervousness, and dysarthric speech.\n",
      "   text: Target-11948006\n",
      "   table: None\n",
      "\n",
      "3. question: How did the addition of topiramate (TPM) impact seizure frequency in the study participants with severe myoclonic epilepsy in infancy (SMEI)?\n",
      "   answer: After a mean period of 11.9 months, three patients (16.7%) had 100% fewer seizures and ten patients (55.5%) experienced more than a 50% decrease in seizures. No patient experienced a worsening of seizures.\n",
      "   text: Target-11948006\n",
      "   table: None\n",
      "\n",
      "4. question: What was the age range of the patients involved in the topiramate (TPM) study for severe myoclonic epilepsy in infancy (SMEI) and refractory seizures?\n",
      "   answer: The age range of the patients involved in the study was 2-21 years, with a mean age of 9 years.\n",
      "   text: Target-11948006\n",
      "   table: None\n",
      "\n",
      "5. question: What was the purpose of adding topiramate (TPM) to the treatment regimen in the study on severe myoclonic epilepsy in infancy (SMEI)?\n",
      "   answer: The purpose of adding topiramate (TPM) to the treatment regimen was to evaluate its efficacy and safety as an add-on therapy in patients with severe myoclonic epilepsy in infancy (SMEI) and refractory seizures.\n",
      "   text: Target-11948006\n",
      "   table: None\n",
      "[{'question': 'What was the initial daily dose of topiramate (TPM) used in the study on patients with severe myoclonic epilepsy in infancy (SMEI) and refractory seizures?', 'answer': 'The initial daily dose of topiramate (TPM) used in the study was 0.5-1 mg/kg, followed by a 2-week titration at increments of 1-3 mg/kg/24 h up to a maximum daily dose of 12 mg/kg.', 'text': 'Target-11948006', 'table': 'None'}, {'question': 'What types of adverse events were observed in patients during the topiramate (TPM) study for severe myoclonic epilepsy in infancy (SMEI)?', 'answer': 'Mild to moderate adverse events observed in the study included weight loss, hypermenorrhoea, renal microlithiasis, nervousness, and dysarthric speech.', 'text': 'Target-11948006', 'table': 'None'}, {'question': 'How did the addition of topiramate (TPM) impact seizure frequency in the study participants with severe myoclonic epilepsy in infancy (SMEI)?', 'answer': 'After a mean period of 11.9 months, three patients (16.7%) had 100% fewer seizures and ten patients (55.5%) experienced more than a 50% decrease in seizures. No patient experienced a worsening of seizures.', 'text': 'Target-11948006', 'table': 'None'}, {'question': 'What was the age range of the patients involved in the topiramate (TPM) study for severe myoclonic epilepsy in infancy (SMEI) and refractory seizures?', 'answer': 'The age range of the patients involved in the study was 2-21 years, with a mean age of 9 years.', 'text': 'Target-11948006', 'table': 'None'}, {'question': 'What was the purpose of adding topiramate (TPM) to the treatment regimen in the study on severe myoclonic epilepsy in infancy (SMEI)?', 'answer': 'The purpose of adding topiramate (TPM) to the treatment regimen was to evaluate its efficacy and safety as an add-on therapy in patients with severe myoclonic epilepsy in infancy (SMEI) and refractory seizures.', 'text': 'Target-11948006', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  9%|▊         | 13/150 [01:00<13:04,  5.73s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does mitotane affect chemoresistant cancer cells, and what is the role of P-glycoprotein in this process?\n",
      "   answer: Mitotane potentiates the cytotoxicity of chemotherapeutic drugs in cancer cells that exhibit chemoresistance due to P-glycoprotein, an efflux pump involved in cancer multidrug resistance. The study aimed to explore whether mitotane sensitizes ACC cells to the cytotoxic effects of doxorubicin by acting on P-gp. The passage indicates that the majority of ACC expresses high levels of P-gp, contributing to their chemoresistance.\n",
      "   text: Target-25096913\n",
      "   table: drugbank-transporters\n",
      "\n",
      "2. question: What was the method used to measure the activity and expression of P-glycoprotein in the study involving mitotane and doxorubicin?\n",
      "   answer: The study measured P-glycoprotein activity using calcein and P-gp-Glo assays, and P-gp expression was evaluated by Western blot analysis. This was part of an investigation into whether mitotane can sensitize ACC cells to doxorubicin's cytotoxic effects.\n",
      "   text: Target-25096913\n",
      "   table: drugbank-transporters\n",
      "\n",
      "3. question: What is the significance of using mitotane at concentrations lower than those reached in vivo in the study on ACC cells?\n",
      "   answer: The study aimed to explore whether mitotane, at concentrations lower than those currently reached in vivo, could sensitize ACC cells to the cytotoxic effects of doxorubicin. This approach is significant because it investigates the potential for increased therapeutic effectiveness while possibly reducing side effects associated with higher doses.\n",
      "   text: Target-25096913\n",
      "   table: None\n",
      "[{'question': 'How does mitotane affect chemoresistant cancer cells, and what is the role of P-glycoprotein in this process?', 'answer': 'Mitotane potentiates the cytotoxicity of chemotherapeutic drugs in cancer cells that exhibit chemoresistance due to P-glycoprotein, an efflux pump involved in cancer multidrug resistance. The study aimed to explore whether mitotane sensitizes ACC cells to the cytotoxic effects of doxorubicin by acting on P-gp. The passage indicates that the majority of ACC expresses high levels of P-gp, contributing to their chemoresistance.', 'text': 'Target-25096913', 'table': 'drugbank-transporters'}, {'question': 'What was the method used to measure the activity and expression of P-glycoprotein in the study involving mitotane and doxorubicin?', 'answer': \"The study measured P-glycoprotein activity using calcein and P-gp-Glo assays, and P-gp expression was evaluated by Western blot analysis. This was part of an investigation into whether mitotane can sensitize ACC cells to doxorubicin's cytotoxic effects.\", 'text': 'Target-25096913', 'table': 'drugbank-transporters'}, {'question': 'What is the significance of using mitotane at concentrations lower than those reached in vivo in the study on ACC cells?', 'answer': 'The study aimed to explore whether mitotane, at concentrations lower than those currently reached in vivo, could sensitize ACC cells to the cytotoxic effects of doxorubicin. This approach is significant because it investigates the potential for increased therapeutic effectiveness while possibly reducing side effects associated with higher doses.', 'text': 'Target-25096913', 'table': 'None'}]\n",
      "No table mapping found for passage Target-8627562\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 10%|█         | 15/150 [01:13<13:37,  6.05s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the role of the renal basolateral organic anion transporter-1 (Oat1) in the kidney, and how does it relate to mercapturic acids?\n",
      "   answer: The renal basolateral organic anion transporter-1 (Oat1) in the kidney mediates the uptake of organic anions from the bloodstream in exchange for intracellular alpha-ketoglutarate. The study in the passage suggests that mercapturic acids are substrates for Oat1, as their inhibition of [(3)H]p-aminohippuric acid (PAH) uptake in Oat1-expressing Xenopus laevis oocytes was competitive. This implies that mercapturic acids may be transported by Oat1 in the kidney.\n",
      "   text: Target-11641438\n",
      "   table: None\n",
      "\n",
      "2. question: Which drugs in the related tables might be involved in the transport of organic anions similar to mercapturic acids?\n",
      "   answer: The related tables mention transporters such as P-glycoprotein 1 and the Canalicular multispecific organic anion transporter 1 in humans, although their specific action is unknown. These transporters may be involved in the transport of organic anions similar to mercapturic acids, akin to the function of Oat1 in the kidney.\n",
      "   text: None\n",
      "   table: drugbank-transporters\n",
      "\n",
      "3. question: How does the inhibition mechanism of mercapturic acids in the Oat1 transporter study support their role as substrates?\n",
      "   answer: The inhibition of [(3)H]p-aminohippuric acid (PAH) uptake by mercapturic acids was competitive, which supports the hypothesis that these compounds are substrates for Oat1. The competitive nature of the inhibition implies that mercapturic acids and PAH likely bind to the same site on Oat1, supporting their role as substrates.\n",
      "   text: Target-11641438\n",
      "   table: None\n",
      "\n",
      "4. question: Can you identify any similarities between the Oat1 transport mechanism in rats and any human transporters listed in the tables?\n",
      "   answer: The Oat1 transporter in rats is involved in the uptake of organic anions from the bloodstream, and similarly, the Canalicular multispecific organic anion transporter 1 in humans, though its specific action is unknown, may perform a related function in humans. Both transporters are implicated in the movement of organic anions, which could include substrates like mercapturic acids.\n",
      "   text: Target-11641438\n",
      "   table: drugbank-transporters\n",
      "\n",
      "5. question: What evidence supports mercapturic acids as substrates for the Oat1 transporter in the study?\n",
      "   answer: The evidence supporting mercapturic acids as substrates for the Oat1 transporter comes from the competitive inhibition of [(3)H]p-aminohippuric acid (PAH) uptake by mercapturic acids, such as S-(2,4-dinitrophenyl)-N-acetyl-L-cysteine (DNP-NAC) and N-acetyl-leukotriene E(4), in Oat1-expressing Xenopus laevis oocytes. This competitive inhibition is consistent with the hypothesis that mercapturic acids are substrates for Oat1.\n",
      "   text: Target-11641438\n",
      "   table: None\n",
      "[{'question': 'What is the role of the renal basolateral organic anion transporter-1 (Oat1) in the kidney, and how does it relate to mercapturic acids?', 'answer': 'The renal basolateral organic anion transporter-1 (Oat1) in the kidney mediates the uptake of organic anions from the bloodstream in exchange for intracellular alpha-ketoglutarate. The study in the passage suggests that mercapturic acids are substrates for Oat1, as their inhibition of [(3)H]p-aminohippuric acid (PAH) uptake in Oat1-expressing Xenopus laevis oocytes was competitive. This implies that mercapturic acids may be transported by Oat1 in the kidney.', 'text': 'Target-11641438', 'table': 'None'}, {'question': 'Which drugs in the related tables might be involved in the transport of organic anions similar to mercapturic acids?', 'answer': 'The related tables mention transporters such as P-glycoprotein 1 and the Canalicular multispecific organic anion transporter 1 in humans, although their specific action is unknown. These transporters may be involved in the transport of organic anions similar to mercapturic acids, akin to the function of Oat1 in the kidney.', 'text': 'None', 'table': 'drugbank-transporters'}, {'question': 'How does the inhibition mechanism of mercapturic acids in the Oat1 transporter study support their role as substrates?', 'answer': 'The inhibition of [(3)H]p-aminohippuric acid (PAH) uptake by mercapturic acids was competitive, which supports the hypothesis that these compounds are substrates for Oat1. The competitive nature of the inhibition implies that mercapturic acids and PAH likely bind to the same site on Oat1, supporting their role as substrates.', 'text': 'Target-11641438', 'table': 'None'}, {'question': 'Can you identify any similarities between the Oat1 transport mechanism in rats and any human transporters listed in the tables?', 'answer': 'The Oat1 transporter in rats is involved in the uptake of organic anions from the bloodstream, and similarly, the Canalicular multispecific organic anion transporter 1 in humans, though its specific action is unknown, may perform a related function in humans. Both transporters are implicated in the movement of organic anions, which could include substrates like mercapturic acids.', 'text': 'Target-11641438', 'table': 'drugbank-transporters'}, {'question': 'What evidence supports mercapturic acids as substrates for the Oat1 transporter in the study?', 'answer': 'The evidence supporting mercapturic acids as substrates for the Oat1 transporter comes from the competitive inhibition of [(3)H]p-aminohippuric acid (PAH) uptake by mercapturic acids, such as S-(2,4-dinitrophenyl)-N-acetyl-L-cysteine (DNP-NAC) and N-acetyl-leukotriene E(4), in Oat1-expressing Xenopus laevis oocytes. This competitive inhibition is consistent with the hypothesis that mercapturic acids are substrates for Oat1.', 'text': 'Target-11641438', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 11%|█         | 16/150 [01:22<15:09,  6.79s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the evidence for transporter-mediated uptake of cerivastatin in human hepatocytes, and how does cyclosporin A affect this process?\n",
      "   answer: The evidence for transporter-mediated uptake of cerivastatin (CER) in human hepatocytes is demonstrated by kinetic analyses, which revealed K(m) values for the uptake of [(14)C]CER within the range of 3 to 18 microM. More than 70% of the total uptake at therapeutic CER concentrations was accounted for by a saturable process, indicating transporter-mediated uptake. Cyclosporin A (CsA) inhibits this uptake with K(i) values between 0.3 to 0.7 microM, indicating a strong inhibitory effect on the transporter-mediated process.\n",
      "   text: Target-12538813\n",
      "   table: None\n",
      "\n",
      "2. question: How does cyclosporin A affect the OATP2-mediated uptake of cerivastatin, and what is the significance of the K(i) value in this interaction?\n",
      "   answer: Cyclosporin A significantly inhibits the OATP2-mediated uptake of cerivastatin in human organic anion transporting polypeptide-2 (OATP2)-expressing Madin-Darby canine kidney cells (MDCKII), with a K(i) value of 0.2 microM. The low K(i) value signifies that CsA is a potent inhibitor of the OATP2-mediated uptake of cerivastatin, suggesting a strong interaction between CsA and this transporter system.\n",
      "   text: Target-12538813\n",
      "   table: None\n",
      "\n",
      "3. question: What is the role of organic anion transporting polypeptides (OATPs) in the drug-drug interaction between cerivastatin and cyclosporin A, and which table lists similar transporters?\n",
      "   answer: Organic anion transporting polypeptides (OATPs), specifically OATP2, play a crucial role in the drug-drug interaction between cerivastatin (CER) and cyclosporin A (CsA) by mediating the uptake of CER into cells. This uptake is significantly inhibited by CsA, suggesting that OATPs are key to understanding this interaction. A table listing similar transporters is the \"drugbank-transporters\" table, which contains information on various transporters expressed in humans, such as P-glycoprotein 1 and the bile salt export pump, although specific entries for OATP2 are not provided in the sample.\n",
      "   text: Target-12538813\n",
      "   table: drugbank-transporters\n",
      "[{'question': 'What is the evidence for transporter-mediated uptake of cerivastatin in human hepatocytes, and how does cyclosporin A affect this process?', 'answer': 'The evidence for transporter-mediated uptake of cerivastatin (CER) in human hepatocytes is demonstrated by kinetic analyses, which revealed K(m) values for the uptake of [(14)C]CER within the range of 3 to 18 microM. More than 70% of the total uptake at therapeutic CER concentrations was accounted for by a saturable process, indicating transporter-mediated uptake. Cyclosporin A (CsA) inhibits this uptake with K(i) values between 0.3 to 0.7 microM, indicating a strong inhibitory effect on the transporter-mediated process.', 'text': 'Target-12538813', 'table': 'None'}, {'question': 'How does cyclosporin A affect the OATP2-mediated uptake of cerivastatin, and what is the significance of the K(i) value in this interaction?', 'answer': 'Cyclosporin A significantly inhibits the OATP2-mediated uptake of cerivastatin in human organic anion transporting polypeptide-2 (OATP2)-expressing Madin-Darby canine kidney cells (MDCKII), with a K(i) value of 0.2 microM. The low K(i) value signifies that CsA is a potent inhibitor of the OATP2-mediated uptake of cerivastatin, suggesting a strong interaction between CsA and this transporter system.', 'text': 'Target-12538813', 'table': 'None'}, {'question': 'What is the role of organic anion transporting polypeptides (OATPs) in the drug-drug interaction between cerivastatin and cyclosporin A, and which table lists similar transporters?', 'answer': 'Organic anion transporting polypeptides (OATPs), specifically OATP2, play a crucial role in the drug-drug interaction between cerivastatin (CER) and cyclosporin A (CsA) by mediating the uptake of CER into cells. This uptake is significantly inhibited by CsA, suggesting that OATPs are key to understanding this interaction. A table listing similar transporters is the \"drugbank-transporters\" table, which contains information on various transporters expressed in humans, such as P-glycoprotein 1 and the bile salt export pump, although specific entries for OATP2 are not provided in the sample.', 'text': 'Target-12538813', 'table': 'drugbank-transporters'}]\n",
      "No table mapping found for passage Target-11888331\n",
      "No table mapping found for passage Target-19660006\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 13%|█▎        | 19/150 [01:32<10:46,  4.94s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What experimental method was used to determine the binding characteristics of ketoprofen enantiomers, and how does this relate to any drug listed in the DrugBank tables?\n",
      "   answer: Equilibrium dialysis supported by ultrafiltration was used to determine the binding characteristics of R(-) and S(+) ketoprofen enantiomers. This method does not directly relate to any specific drug listed in the DrugBank tables, but it is a common technique used in pharmaceutical research for analyzing drug-protein interactions.\n",
      "   text: Target-11022905\n",
      "   table: None\n",
      "\n",
      "2. question: How do the binding characteristics of R(-) and S(+) ketoprofen potentially affect the pharmacological properties of a biotech drug like Etanercept?\n",
      "   answer: While the passage describes the binding characteristics of R(-) and S(+) ketoprofen, it does not directly reference Etanercept. However, understanding enantioselective protein binding is crucial in drug development, including for biotech drugs like Etanercept, to ensure proper efficacy and safety profiles. Etanercept, being a biotech drug, would also require detailed binding studies to ensure its therapeutic action.\n",
      "   text: Target-11022905\n",
      "   table: DB00005\n",
      "\n",
      "3. question: What was the effect of octanoic acid (OA) on the free concentration ratio of ketoprofen enantiomers, and does this have any implications for the production of drugs like Lepirudin?\n",
      "   answer: The passage mentions that the effect of octanoic acid (OA) on the free concentration ratio of R(-) and S(+) ketoprofen was considered in the study. Although Lepirudin is a biotech drug and not directly related to ketoprofen, understanding such interactions is important in the formulation of intravenous solutions, like those used for Lepirudin, to avoid potential interferences in drug delivery.\n",
      "   text: Target-11022905\n",
      "   table: DB00001\n",
      "\n",
      "4. question: How might the presence of hippuric acid (HA) interfere with the binding of ketoprofen, and what significance does this have for drugs like Dornase alfa?\n",
      "   answer: The passage mentions that the presence of hippuric acid (HA) was considered for its effect on the free concentration ratio of ketoprofen enantiomers. Although Dornase alfa is a biosynthetic enzyme and not directly related to ketoprofen, the consideration of interference by compounds like HA is relevant in ensuring the stability and activity of enzyme-based drugs, such as Dornase alfa, during formulation and storage.\n",
      "   text: Target-11022905\n",
      "   table: DB00003\n",
      "[{'question': 'What experimental method was used to determine the binding characteristics of ketoprofen enantiomers, and how does this relate to any drug listed in the DrugBank tables?', 'answer': 'Equilibrium dialysis supported by ultrafiltration was used to determine the binding characteristics of R(-) and S(+) ketoprofen enantiomers. This method does not directly relate to any specific drug listed in the DrugBank tables, but it is a common technique used in pharmaceutical research for analyzing drug-protein interactions.', 'text': 'Target-11022905', 'table': 'None'}, {'question': 'How do the binding characteristics of R(-) and S(+) ketoprofen potentially affect the pharmacological properties of a biotech drug like Etanercept?', 'answer': 'While the passage describes the binding characteristics of R(-) and S(+) ketoprofen, it does not directly reference Etanercept. However, understanding enantioselective protein binding is crucial in drug development, including for biotech drugs like Etanercept, to ensure proper efficacy and safety profiles. Etanercept, being a biotech drug, would also require detailed binding studies to ensure its therapeutic action.', 'text': 'Target-11022905', 'table': 'DB00005'}, {'question': 'What was the effect of octanoic acid (OA) on the free concentration ratio of ketoprofen enantiomers, and does this have any implications for the production of drugs like Lepirudin?', 'answer': 'The passage mentions that the effect of octanoic acid (OA) on the free concentration ratio of R(-) and S(+) ketoprofen was considered in the study. Although Lepirudin is a biotech drug and not directly related to ketoprofen, understanding such interactions is important in the formulation of intravenous solutions, like those used for Lepirudin, to avoid potential interferences in drug delivery.', 'text': 'Target-11022905', 'table': 'DB00001'}, {'question': 'How might the presence of hippuric acid (HA) interfere with the binding of ketoprofen, and what significance does this have for drugs like Dornase alfa?', 'answer': 'The passage mentions that the presence of hippuric acid (HA) was considered for its effect on the free concentration ratio of ketoprofen enantiomers. Although Dornase alfa is a biosynthetic enzyme and not directly related to ketoprofen, the consideration of interference by compounds like HA is relevant in ensuring the stability and activity of enzyme-based drugs, such as Dornase alfa, during formulation and storage.', 'text': 'Target-11022905', 'table': 'DB00003'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 13%|█▎        | 20/150 [01:36<10:33,  4.88s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What class of anthelmintics is used for chemoprophylaxis in controlling Dirofilaria immitis infections in dogs, and how do they function at the molecular level?\n",
      "   answer: The avermectin/milbemycin (A/M) class of anthelmintics, which includes ivermectin, is used for chemoprophylaxis in controlling Dirofilaria immitis infections in dogs. These drugs act at invertebrate glutamate-gated chloride channels (GluCl), which is an important molecular target for these anthelmintics in vivo.\n",
      "   text: Target-15313134\n",
      "   table: None\n",
      "\n",
      "2. question: Which specific gene is associated with the GluCl subunits in Dirofilaria immitis, and how does alternative splicing in this gene compare across different species?\n",
      "   answer: The GluCl subunits in Dirofilaria immitis are associated with the avr-14 gene. Although alternative splicing of avr-14 is conserved across species, the processing of the mature GluClalpha3A mRNA in D. immitis differs from that in Caenorhabditis elegans and Haemonchus contortus.\n",
      "   text: Target-15313134\n",
      "   table: None\n",
      "\n",
      "3. question: What experimental technique was used to study the GluCl subunits in Dirofilaria immitis, and what organism was used in this study?\n",
      "   answer: Two-electrode voltage clamp recordings were used to study the GluCl subunits in Dirofilaria immitis. Xenopus oocytes were used in this study, which were injected with subunit-specific cRNAs to facilitate the recordings.\n",
      "   text: Target-15313134\n",
      "   table: None\n",
      "[{'question': 'What class of anthelmintics is used for chemoprophylaxis in controlling Dirofilaria immitis infections in dogs, and how do they function at the molecular level?', 'answer': 'The avermectin/milbemycin (A/M) class of anthelmintics, which includes ivermectin, is used for chemoprophylaxis in controlling Dirofilaria immitis infections in dogs. These drugs act at invertebrate glutamate-gated chloride channels (GluCl), which is an important molecular target for these anthelmintics in vivo.', 'text': 'Target-15313134', 'table': 'None'}, {'question': 'Which specific gene is associated with the GluCl subunits in Dirofilaria immitis, and how does alternative splicing in this gene compare across different species?', 'answer': 'The GluCl subunits in Dirofilaria immitis are associated with the avr-14 gene. Although alternative splicing of avr-14 is conserved across species, the processing of the mature GluClalpha3A mRNA in D. immitis differs from that in Caenorhabditis elegans and Haemonchus contortus.', 'text': 'Target-15313134', 'table': 'None'}, {'question': 'What experimental technique was used to study the GluCl subunits in Dirofilaria immitis, and what organism was used in this study?', 'answer': 'Two-electrode voltage clamp recordings were used to study the GluCl subunits in Dirofilaria immitis. Xenopus oocytes were used in this study, which were injected with subunit-specific cRNAs to facilitate the recordings.', 'text': 'Target-15313134', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 14%|█▍        | 21/150 [01:44<12:00,  5.58s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What are the primary uses for second-generation histamine H(1) receptor antagonists, and how do they compare to first-generation agents in terms of adverse effects?\n",
      "   answer: Second-generation histamine H(1) receptor antagonists are primarily used for the treatment of allergic rhinitis (AR) and chronic idiopathic urticaria (CIU). They were developed to be effective while reducing the adverse effects commonly associated with first-generation agents.\n",
      "   text: Target-18336052\n",
      "   table: None\n",
      "\n",
      "2. question: How do second-generation antihistamines like desloratadine, fexofenadine, and levocetirizine interact with the central nervous system (CNS)?\n",
      "   answer: Second-generation antihistamines, including desloratadine, fexofenadine, and levocetirizine, have a limited effect on the central nervous system (CNS), which is a favorable characteristic compared to some first-generation antihistamines.\n",
      "   text: Target-18336052\n",
      "   table: None\n",
      "\n",
      "3. question: What is the significance of the binding affinity of second-generation antihistamines to the H(1) receptor, and how does this vary among different compounds?\n",
      "   answer: Second-generation antihistamines are highly selective for the H(1) receptor, with some compounds binding with high affinity. There is, however, marked heterogeneity in binding affinities among different compounds within this class, which can affect their efficacy and safety profiles.\n",
      "   text: Target-18336052\n",
      "   table: None\n",
      "\n",
      "4. question: What are the implications of second-generation antihistamines not causing significant drug-drug interactions?\n",
      "   answer: The lack of significant drug-drug interactions in second-generation antihistamines, such as desloratadine, fexofenadine, and levocetirizine, suggests that they can be used more safely in combination with other medications, reducing the risk of adverse reactions or reduced efficacy.\n",
      "   text: Target-18336052\n",
      "   table: None\n",
      "\n",
      "5. question: Why is the absence of major cytochrome P450 inhibition important in the context of second-generation antihistamines?\n",
      "   answer: The absence of major cytochrome P450 inhibition in second-generation antihistamines like desloratadine and fexofenadine is important because it minimizes the potential for pharmacokinetic interactions with other drugs metabolized by this enzyme system, enhancing the safety profile of these medications.\n",
      "   text: Target-18336052\n",
      "   table: None\n",
      "[{'question': 'What are the primary uses for second-generation histamine H(1) receptor antagonists, and how do they compare to first-generation agents in terms of adverse effects?', 'answer': 'Second-generation histamine H(1) receptor antagonists are primarily used for the treatment of allergic rhinitis (AR) and chronic idiopathic urticaria (CIU). They were developed to be effective while reducing the adverse effects commonly associated with first-generation agents.', 'text': 'Target-18336052', 'table': 'None'}, {'question': 'How do second-generation antihistamines like desloratadine, fexofenadine, and levocetirizine interact with the central nervous system (CNS)?', 'answer': 'Second-generation antihistamines, including desloratadine, fexofenadine, and levocetirizine, have a limited effect on the central nervous system (CNS), which is a favorable characteristic compared to some first-generation antihistamines.', 'text': 'Target-18336052', 'table': 'None'}, {'question': 'What is the significance of the binding affinity of second-generation antihistamines to the H(1) receptor, and how does this vary among different compounds?', 'answer': 'Second-generation antihistamines are highly selective for the H(1) receptor, with some compounds binding with high affinity. There is, however, marked heterogeneity in binding affinities among different compounds within this class, which can affect their efficacy and safety profiles.', 'text': 'Target-18336052', 'table': 'None'}, {'question': 'What are the implications of second-generation antihistamines not causing significant drug-drug interactions?', 'answer': 'The lack of significant drug-drug interactions in second-generation antihistamines, such as desloratadine, fexofenadine, and levocetirizine, suggests that they can be used more safely in combination with other medications, reducing the risk of adverse reactions or reduced efficacy.', 'text': 'Target-18336052', 'table': 'None'}, {'question': 'Why is the absence of major cytochrome P450 inhibition important in the context of second-generation antihistamines?', 'answer': 'The absence of major cytochrome P450 inhibition in second-generation antihistamines like desloratadine and fexofenadine is important because it minimizes the potential for pharmacokinetic interactions with other drugs metabolized by this enzyme system, enhancing the safety profile of these medications.', 'text': 'Target-18336052', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 15%|█▍        | 22/150 [01:50<11:47,  5.52s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the proposed mechanism by which salmeterol achieves its long duration of action in treating asthma?\n",
      "   answer: Salmeterol, a long-acting beta2-adrenergic receptor agonist, is proposed to achieve its long duration of action by binding with very high affinity at a second site on the receptor, termed the \"exosite\". This exosite binding is believed to contribute significantly to its prolonged therapeutic effect.\n",
      "   text: Target-10471277\n",
      "   table: None\n",
      "\n",
      "2. question: What experimental approach was used to investigate the binding of salmeterol to the beta 2AR exosite?\n",
      "   answer: To investigate the binding of salmeterol to the beta 2AR exosite, researchers designed and synthesized an agonist photoaffinity label, [(125)I]iodoazidosalmeterol ([125I]IAS). This compound was used in experiments such as direct adenylyl cyclase activation and guinea pig tracheal relaxation assays, where it behaved essentially the same as the parent drug, salmeterol.\n",
      "   text: Target-10471277\n",
      "   table: None\n",
      "\n",
      "3. question: How does the behavior of [(125)I]iodoazidosalmeterol ([125I]IAS) compare to salmeterol in biological assays?\n",
      "   answer: [(125)I]iodoazidosalmeterol ([125I]IAS) behaves essentially the same as salmeterol in direct adenylyl cyclase activation, effects on adenylyl cyclase after pretreatment of intact cells, and guinea pig tracheal relaxation assays.\n",
      "   text: Target-10471277\n",
      "   table: None\n",
      "[{'question': 'What is the proposed mechanism by which salmeterol achieves its long duration of action in treating asthma?', 'answer': 'Salmeterol, a long-acting beta2-adrenergic receptor agonist, is proposed to achieve its long duration of action by binding with very high affinity at a second site on the receptor, termed the \"exosite\". This exosite binding is believed to contribute significantly to its prolonged therapeutic effect.', 'text': 'Target-10471277', 'table': 'None'}, {'question': 'What experimental approach was used to investigate the binding of salmeterol to the beta 2AR exosite?', 'answer': 'To investigate the binding of salmeterol to the beta 2AR exosite, researchers designed and synthesized an agonist photoaffinity label, [(125)I]iodoazidosalmeterol ([125I]IAS). This compound was used in experiments such as direct adenylyl cyclase activation and guinea pig tracheal relaxation assays, where it behaved essentially the same as the parent drug, salmeterol.', 'text': 'Target-10471277', 'table': 'None'}, {'question': 'How does the behavior of [(125)I]iodoazidosalmeterol ([125I]IAS) compare to salmeterol in biological assays?', 'answer': '[(125)I]iodoazidosalmeterol ([125I]IAS) behaves essentially the same as salmeterol in direct adenylyl cyclase activation, effects on adenylyl cyclase after pretreatment of intact cells, and guinea pig tracheal relaxation assays.', 'text': 'Target-10471277', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 15%|█▌        | 23/150 [01:57<12:45,  6.02s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the affinity of loperamide for the human mu opioid receptor, and how does it compare to its affinity for delta and kappa opioid receptors?\n",
      "   answer: Loperamide exhibits a potent affinity for the human mu opioid receptor with a Ki value of 3 nM. In comparison, its affinity for the delta opioid receptor is significantly lower, with a Ki value of 48 nM, and even lower for the kappa opioid receptor, with a Ki value of 1156 nM.\n",
      "   text: Target-10087042\n",
      "   table: None\n",
      "\n",
      "2. question: How does loperamide affect cAMP accumulation in Chinese hamster ovary cells transfected with the human mu opioid receptor?\n",
      "   answer: Loperamide inhibits forskolin-stimulated cAMP accumulation in these cells with an IC50 of 25 nM, demonstrating its effectiveness in modulating intracellular signaling pathways associated with the mu opioid receptor.\n",
      "   text: Target-10087042\n",
      "   table: None\n",
      "\n",
      "3. question: What was the effect of intra-articular injection of loperamide in the inflamed rat knee joint, and how was this effect modified by naloxone?\n",
      "   answer: The intra-articular injection of 0.3 mg of loperamide into the inflamed rat knee joint resulted in potent antinociception to knee compression. This antinociceptive effect was antagonized by naloxone, indicating that the effect was mediated through opioid receptors.\n",
      "   text: Target-10087042\n",
      "   table: None\n",
      "\n",
      "4. question: How does loperamide stimulate [35S]guanosine-5'-O-(3-thio)triphosphate binding in Chinese hamster ovary cells?\n",
      "   answer: Loperamide potently stimulates [35S]guanosine-5'-O-(3-thio)triphosphate binding with an EC50 of 56 nM, indicating its role in activating G-protein coupled signaling pathways linked to the human mu opioid receptor.\n",
      "   text: Target-10087042\n",
      "   table: None\n",
      "\n",
      "5. question: What was the result of injecting loperamide into the contralateral knee joint or via the intramuscular route in the study?\n",
      "   answer: Injection of loperamide into the contralateral knee joint or via the intramuscular route failed to inhibit compression-induced changes in blood pressure, suggesting that the antinociceptive effects of loperamide are localized and specific to the site of inflammation when administered directly.\n",
      "   text: Target-10087042\n",
      "   table: None\n",
      "[{'question': 'What is the affinity of loperamide for the human mu opioid receptor, and how does it compare to its affinity for delta and kappa opioid receptors?', 'answer': 'Loperamide exhibits a potent affinity for the human mu opioid receptor with a Ki value of 3 nM. In comparison, its affinity for the delta opioid receptor is significantly lower, with a Ki value of 48 nM, and even lower for the kappa opioid receptor, with a Ki value of 1156 nM.', 'text': 'Target-10087042', 'table': 'None'}, {'question': 'How does loperamide affect cAMP accumulation in Chinese hamster ovary cells transfected with the human mu opioid receptor?', 'answer': 'Loperamide inhibits forskolin-stimulated cAMP accumulation in these cells with an IC50 of 25 nM, demonstrating its effectiveness in modulating intracellular signaling pathways associated with the mu opioid receptor.', 'text': 'Target-10087042', 'table': 'None'}, {'question': 'What was the effect of intra-articular injection of loperamide in the inflamed rat knee joint, and how was this effect modified by naloxone?', 'answer': 'The intra-articular injection of 0.3 mg of loperamide into the inflamed rat knee joint resulted in potent antinociception to knee compression. This antinociceptive effect was antagonized by naloxone, indicating that the effect was mediated through opioid receptors.', 'text': 'Target-10087042', 'table': 'None'}, {'question': \"How does loperamide stimulate [35S]guanosine-5'-O-(3-thio)triphosphate binding in Chinese hamster ovary cells?\", 'answer': \"Loperamide potently stimulates [35S]guanosine-5'-O-(3-thio)triphosphate binding with an EC50 of 56 nM, indicating its role in activating G-protein coupled signaling pathways linked to the human mu opioid receptor.\", 'text': 'Target-10087042', 'table': 'None'}, {'question': 'What was the result of injecting loperamide into the contralateral knee joint or via the intramuscular route in the study?', 'answer': 'Injection of loperamide into the contralateral knee joint or via the intramuscular route failed to inhibit compression-induced changes in blood pressure, suggesting that the antinociceptive effects of loperamide are localized and specific to the site of inflammation when administered directly.', 'text': 'Target-10087042', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 16%|█▌        | 24/150 [02:05<13:37,  6.49s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What enzyme is responsible for the 4'-hydroxylation of diclofenac, and how was its activity measured in the study?\n",
      "   answer: The cytochrome P450 enzyme CYP2C9 is responsible for the 4'-hydroxylation of diclofenac. Its activity was measured using the ex vivo formation of prostaglandin E2 and thromboxane B2, which reflect COX-2 and COX-1 activity, respectively.\n",
      "   text: Target-12534640\n",
      "   table: None\n",
      "\n",
      "2. question: How were the concentrations of diclofenac and its metabolite measured in the study, and what does this indicate about the methodology used?\n",
      "   answer: The concentrations of diclofenac and 4'-hydroxydiclofenac were quantified in plasma using reversed phase high-performance liquid chromatography (h.p.l.c.) after oral intake of a 50 mg dose of diclofenac. This indicates a precise analytical methodology was employed to assess the pharmacokinetics of diclofenac.\n",
      "   text: Target-12534640\n",
      "   table: None\n",
      "\n",
      "3. question: What genetic variants of CYP2C9 were studied, and how were participants selected based on these variants?\n",
      "   answer: The study focused on the CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) amino acid variants. Participants were selected based on genotyping, with 20 participants having all allelic combinations of these CYP2C9 variants.\n",
      "   text: Target-12534640\n",
      "   table: None\n",
      "\n",
      "4. question: What is the role of thromboxane B2 in the study, and what does it reflect?\n",
      "   answer: Thromboxane B2 was measured as a surrogate marker in the study to reflect COX-1 activity. This measurement helped assess the pharmacological activity of diclofenac.\n",
      "   text: Target-12534640\n",
      "   table: None\n",
      "[{'question': \"What enzyme is responsible for the 4'-hydroxylation of diclofenac, and how was its activity measured in the study?\", 'answer': \"The cytochrome P450 enzyme CYP2C9 is responsible for the 4'-hydroxylation of diclofenac. Its activity was measured using the ex vivo formation of prostaglandin E2 and thromboxane B2, which reflect COX-2 and COX-1 activity, respectively.\", 'text': 'Target-12534640', 'table': 'None'}, {'question': 'How were the concentrations of diclofenac and its metabolite measured in the study, and what does this indicate about the methodology used?', 'answer': \"The concentrations of diclofenac and 4'-hydroxydiclofenac were quantified in plasma using reversed phase high-performance liquid chromatography (h.p.l.c.) after oral intake of a 50 mg dose of diclofenac. This indicates a precise analytical methodology was employed to assess the pharmacokinetics of diclofenac.\", 'text': 'Target-12534640', 'table': 'None'}, {'question': 'What genetic variants of CYP2C9 were studied, and how were participants selected based on these variants?', 'answer': 'The study focused on the CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) amino acid variants. Participants were selected based on genotyping, with 20 participants having all allelic combinations of these CYP2C9 variants.', 'text': 'Target-12534640', 'table': 'None'}, {'question': 'What is the role of thromboxane B2 in the study, and what does it reflect?', 'answer': 'Thromboxane B2 was measured as a surrogate marker in the study to reflect COX-1 activity. This measurement helped assess the pharmacological activity of diclofenac.', 'text': 'Target-12534640', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 17%|█▋        | 25/150 [02:10<12:39,  6.08s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the primary mechanism of action of Disulfiram (Antabuse) in the treatment of alcohol dependence?\n",
      "   answer: Disulfiram (Antabuse) is used for aversive treatment of alcohol dependence by inhibiting aldehyde dehydrogenase. This inhibition increases serum aldehyde concentration after alcohol ingestion, leading to the disulfiram-ethanol reaction, which includes symptoms like flushing, nausea, dyspnea, tremor, and confusion.\n",
      "   text: Target-17220694\n",
      "   table: None\n",
      "\n",
      "2. question: What adverse reaction occurred in a patient after ingesting alcohol 18 hours post-disulfiram treatment, and what treatment was effective in managing this reaction?\n",
      "   answer: A patient experienced generalized flushing, tremor, and refractive hypotension after ingesting alcohol 18 hours post-disulfiram treatment. Initial volume resuscitation and dopamine infusion failed to restore blood pressure, but administration of noradrenaline was effective in returning blood pressure to normal range.\n",
      "   text: Target-17220694\n",
      "   table: None\n",
      "\n",
      "3. question: What are some of the typical symptoms of a disulfiram-ethanol reaction?\n",
      "   answer: Typical symptoms of a disulfiram-ethanol reaction include flushing, nausea, dyspnea, tremor, and confusion, which are generally self-limiting.\n",
      "   text: Target-17220694\n",
      "   table: None\n",
      "\n",
      "4. question: What specific advantage does noradrenaline offer in the treatment of severe disulfiram-ethanol reaction cases?\n",
      "   answer: Noradrenaline is advantageous in treating severe cases of disulfiram-ethanol reaction, particularly those involving life-threatening arterial hypotension, as it can effectively restore blood pressure when initial treatments fail.\n",
      "   text: Target-17220694\n",
      "   table: None\n",
      "[{'question': 'What is the primary mechanism of action of Disulfiram (Antabuse) in the treatment of alcohol dependence?', 'answer': 'Disulfiram (Antabuse) is used for aversive treatment of alcohol dependence by inhibiting aldehyde dehydrogenase. This inhibition increases serum aldehyde concentration after alcohol ingestion, leading to the disulfiram-ethanol reaction, which includes symptoms like flushing, nausea, dyspnea, tremor, and confusion.', 'text': 'Target-17220694', 'table': 'None'}, {'question': 'What adverse reaction occurred in a patient after ingesting alcohol 18 hours post-disulfiram treatment, and what treatment was effective in managing this reaction?', 'answer': 'A patient experienced generalized flushing, tremor, and refractive hypotension after ingesting alcohol 18 hours post-disulfiram treatment. Initial volume resuscitation and dopamine infusion failed to restore blood pressure, but administration of noradrenaline was effective in returning blood pressure to normal range.', 'text': 'Target-17220694', 'table': 'None'}, {'question': 'What are some of the typical symptoms of a disulfiram-ethanol reaction?', 'answer': 'Typical symptoms of a disulfiram-ethanol reaction include flushing, nausea, dyspnea, tremor, and confusion, which are generally self-limiting.', 'text': 'Target-17220694', 'table': 'None'}, {'question': 'What specific advantage does noradrenaline offer in the treatment of severe disulfiram-ethanol reaction cases?', 'answer': 'Noradrenaline is advantageous in treating severe cases of disulfiram-ethanol reaction, particularly those involving life-threatening arterial hypotension, as it can effectively restore blood pressure when initial treatments fail.', 'text': 'Target-17220694', 'table': 'None'}]\n",
      "No table mapping found for passage Target-10223928\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 18%|█▊        | 27/150 [02:12<07:53,  3.85s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "I'm sorry, but I can't create questions that combine information from both the passage and the tables because the passage and tables provided do not have overlapping information or direct connections. I can, however, create questions using only the passage. Would you like me to proceed with that?\n",
      "[]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 19%|█▊        | 28/150 [02:20<09:59,  4.91s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What was the average maximum dosage of minoxidil administered to the hypertensive patients in the study?\n",
      "   answer: The average maximum dosage of minoxidil administered to the hypertensive patients was 27.9 +/- 6.0 mg/day (M +/- SD).\n",
      "   text: Target-790007\n",
      "   table: None\n",
      "\n",
      "2. question: How did minoxidil affect the systolic and diastolic blood pressure of the hypertensive patients?\n",
      "   answer: Minoxidil reduced the average systolic blood pressure from 195 +/- 18 to 159 +/- 7 mm Hg (M +/- SD). It also reduced the mean diastolic blood pressure from 120 +/- 8.3 to 92.5 +/- 8 mm Hg (p less than 0.01).\n",
      "   text: Target-790007\n",
      "   table: None\n",
      "\n",
      "3. question: What was the change in plasma renin activity after treatment with minoxidil in resting conditions?\n",
      "   answer: After treatment with minoxidil, the plasma renin activity in resting conditions decreased significantly from 59 +/- 6.4 ng/ml/16 h (M +/- SE) to 42.7 +/- 3.3 ng/ml/16 h.\n",
      "   text: Target-790007\n",
      "   table: None\n",
      "\n",
      "4. question: What types of hypertension were present in the patients involved in the minoxidil study?\n",
      "   answer: The study involved 12 patients with essential hypertension and 9 patients with renal hypertension.\n",
      "   text: Target-790007\n",
      "   table: None\n",
      "\n",
      "5. question: What other antihypertensive agents had the patients been treated with before minoxidil, and were they effective?\n",
      "   answer: Before minoxidil, the patients had been treated with reserpine, saluretics, hydralazine, alpha-methyldopa, and clonidine, but these treatments did not result in any significant reduction in blood pressure.\n",
      "   text: Target-790007\n",
      "   table: None\n",
      "[{'question': 'What was the average maximum dosage of minoxidil administered to the hypertensive patients in the study?', 'answer': 'The average maximum dosage of minoxidil administered to the hypertensive patients was 27.9 +/- 6.0 mg/day (M +/- SD).', 'text': 'Target-790007', 'table': 'None'}, {'question': 'How did minoxidil affect the systolic and diastolic blood pressure of the hypertensive patients?', 'answer': 'Minoxidil reduced the average systolic blood pressure from 195 +/- 18 to 159 +/- 7 mm Hg (M +/- SD). It also reduced the mean diastolic blood pressure from 120 +/- 8.3 to 92.5 +/- 8 mm Hg (p less than 0.01).', 'text': 'Target-790007', 'table': 'None'}, {'question': 'What was the change in plasma renin activity after treatment with minoxidil in resting conditions?', 'answer': 'After treatment with minoxidil, the plasma renin activity in resting conditions decreased significantly from 59 +/- 6.4 ng/ml/16 h (M +/- SE) to 42.7 +/- 3.3 ng/ml/16 h.', 'text': 'Target-790007', 'table': 'None'}, {'question': 'What types of hypertension were present in the patients involved in the minoxidil study?', 'answer': 'The study involved 12 patients with essential hypertension and 9 patients with renal hypertension.', 'text': 'Target-790007', 'table': 'None'}, {'question': 'What other antihypertensive agents had the patients been treated with before minoxidil, and were they effective?', 'answer': 'Before minoxidil, the patients had been treated with reserpine, saluretics, hydralazine, alpha-methyldopa, and clonidine, but these treatments did not result in any significant reduction in blood pressure.', 'text': 'Target-790007', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 19%|█▉        | 29/150 [02:28<11:26,  5.67s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the effect of the S248F mutation on the human neuronal alpha4beta2 nicotinic receptors' sensitivity to carbamazepine?\n",
      "   answer: The S248F mutation in the human neuronal alpha4beta2 nicotinic receptors results in a threefold increase in sensitivity to carbamazepine, a drug used to treat partial epilepsies. This mutation is associated with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE).\n",
      "   text: Target-12110613\n",
      "   table: None\n",
      "\n",
      "2. question: What are the binding characteristics of carbamazepine on mutant neuronal alpha4beta2 nicotinic receptors?\n",
      "   answer: In the mutant neuronal alpha4beta2 nicotinic receptors, Phe248 residues serve as the main component of carbamazepine binding sites. The mutant also shows a higher number of blocking binding sites and a predicted higher affinity for carbamazepine compared to the normal receptor.\n",
      "   text: Target-12110613\n",
      "   table: None\n",
      "\n",
      "3. question: How does the S248F mutation affect the conductance and recovery from desensitization of human neuronal alpha4beta2 nicotinic receptors?\n",
      "   answer: The S248F mutation results in the human neuronal alpha4beta2 nicotinic receptors having a lower conductance and a slower recovery from desensitization.\n",
      "   text: Target-12110613\n",
      "   table: None\n",
      "\n",
      "4. question: What structural feature of the mutant nicotinic receptor influences the reduced calcium permeability observed?\n",
      "   answer: The reduced calcium permeability in the mutant nicotinic receptor is potentially due to a defective mechanism of dehydration, which is influenced by the physicochemical properties of the Phe248 side chains, including size and cation-pi interaction.\n",
      "   text: Target-12110613\n",
      "   table: None\n",
      "\n",
      "5. question: What are the implications of the S248F mutation for the treatment of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) with carbamazepine?\n",
      "   answer: The S248F mutation leads to an enhanced sensitivity to carbamazepine, which implies that individuals with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) may respond differently to carbamazepine treatment due to the increased drug sensitivity and altered receptor properties.\n",
      "   text: Target-12110613\n",
      "   table: None\n",
      "[{'question': \"What is the effect of the S248F mutation on the human neuronal alpha4beta2 nicotinic receptors' sensitivity to carbamazepine?\", 'answer': 'The S248F mutation in the human neuronal alpha4beta2 nicotinic receptors results in a threefold increase in sensitivity to carbamazepine, a drug used to treat partial epilepsies. This mutation is associated with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE).', 'text': 'Target-12110613', 'table': 'None'}, {'question': 'What are the binding characteristics of carbamazepine on mutant neuronal alpha4beta2 nicotinic receptors?', 'answer': 'In the mutant neuronal alpha4beta2 nicotinic receptors, Phe248 residues serve as the main component of carbamazepine binding sites. The mutant also shows a higher number of blocking binding sites and a predicted higher affinity for carbamazepine compared to the normal receptor.', 'text': 'Target-12110613', 'table': 'None'}, {'question': 'How does the S248F mutation affect the conductance and recovery from desensitization of human neuronal alpha4beta2 nicotinic receptors?', 'answer': 'The S248F mutation results in the human neuronal alpha4beta2 nicotinic receptors having a lower conductance and a slower recovery from desensitization.', 'text': 'Target-12110613', 'table': 'None'}, {'question': 'What structural feature of the mutant nicotinic receptor influences the reduced calcium permeability observed?', 'answer': 'The reduced calcium permeability in the mutant nicotinic receptor is potentially due to a defective mechanism of dehydration, which is influenced by the physicochemical properties of the Phe248 side chains, including size and cation-pi interaction.', 'text': 'Target-12110613', 'table': 'None'}, {'question': 'What are the implications of the S248F mutation for the treatment of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) with carbamazepine?', 'answer': 'The S248F mutation leads to an enhanced sensitivity to carbamazepine, which implies that individuals with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) may respond differently to carbamazepine treatment due to the increased drug sensitivity and altered receptor properties.', 'text': 'Target-12110613', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 20%|██        | 30/150 [02:33<10:56,  5.47s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the approved use of Lenalidomide (Revlimid) in patients with Myelodysplastic Syndromes (MDS)?\n",
      "   answer: Lenalidomide (Revlimid) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality, with or without additional cytogenetic abnormalities.\n",
      "   text: Target-18805433\n",
      "   table: None\n",
      "\n",
      "2. question: What is the mechanism by which Lenalidomide demonstrates efficacy in treating Myelodysplastic Syndromes (MDS)?\n",
      "   answer: Lenalidomide is considered to be anti-angiogenic, which means it can inhibit the formation of new blood vessels. This property appears to be related to its efficacy in patients with Myelodysplastic Syndromes (MDS).\n",
      "   text: Target-18805433\n",
      "   table: None\n",
      "\n",
      "3. question: In what combination is Lenalidomide used for the treatment of multiple myeloma and what is the requirement for its use?\n",
      "   answer: Lenalidomide is used in combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy.\n",
      "   text: Target-18805433\n",
      "   table: None\n",
      "[{'question': 'What is the approved use of Lenalidomide (Revlimid) in patients with Myelodysplastic Syndromes (MDS)?', 'answer': 'Lenalidomide (Revlimid) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality, with or without additional cytogenetic abnormalities.', 'text': 'Target-18805433', 'table': 'None'}, {'question': 'What is the mechanism by which Lenalidomide demonstrates efficacy in treating Myelodysplastic Syndromes (MDS)?', 'answer': 'Lenalidomide is considered to be anti-angiogenic, which means it can inhibit the formation of new blood vessels. This property appears to be related to its efficacy in patients with Myelodysplastic Syndromes (MDS).', 'text': 'Target-18805433', 'table': 'None'}, {'question': 'In what combination is Lenalidomide used for the treatment of multiple myeloma and what is the requirement for its use?', 'answer': 'Lenalidomide is used in combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy.', 'text': 'Target-18805433', 'table': 'None'}]\n",
      "No table mapping found for passage Target-18311418\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 21%|██▏       | 32/150 [02:35<06:50,  3.48s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "I'm sorry, but I must clarify that I am unable to generate questions that combine information from both the passage and tables as the task requires. The passage's content is focused on the effects of morphine and its metabolite M6G on food intake and opioid receptor activity, while the tables provide unrelated drug information. However, I can generate questions based solely on the passage. Would you like me to proceed with that approach?\n",
      "[]\n",
      "No table mapping found for passage Target-12534644\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 23%|██▎       | 34/150 [02:39<05:31,  2.85s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What receptors are involved in the vasoconstriction effect of dihydroergotamine in vagosympathectomized dogs?\n",
      "   answer: Dihydroergotamine produces external carotid vasoconstriction in vagosympathectomized dogs through the activation of 5-HT(1B/1D) receptors and alpha(2)-adrenoceptors.\n",
      "   text: Target-14744615\n",
      "   table: None\n",
      "\n",
      "2. question: How does dihydroergotamine affect blood pressure and heart rate during its vasoconstriction effect?\n",
      "   answer: Dihydroergotamine decreases external carotid blood flow dose-dependently without affecting blood pressure or heart rate.\n",
      "   text: Target-14744615\n",
      "   table: None\n",
      "\n",
      "3. question: What is the role of SB224289 in the study of dihydroergotamine's effects on carotid vasoconstriction?\n",
      "   answer: SB224289, an antagonist of the 5-HT(1B) receptor, partly blocks the vasoconstriction effect induced by dihydroergotamine when administered intravenously to dogs.\n",
      "   text: Target-14744615\n",
      "   table: None\n",
      "\n",
      "4. question: What happens to the vasoconstriction response when dogs are pretreated with both SB224289 and rauwolscine?\n",
      "   answer: The vasoconstriction response induced by dihydroergotamine is markedly blocked when dogs are pretreated with both SB224289 and rauwolscine.\n",
      "   text: Target-14744615\n",
      "   table: None\n",
      "\n",
      "5. question: Is the carotid vasoconstriction response to dihydroergotamine affected by the antagonist BRL15572?\n",
      "   answer: The carotid vasoconstriction response to dihydroergotamine is unaffected by the antagonist BRL15572.\n",
      "   text: Target-14744615\n",
      "   table: None\n",
      "[{'question': 'What receptors are involved in the vasoconstriction effect of dihydroergotamine in vagosympathectomized dogs?', 'answer': 'Dihydroergotamine produces external carotid vasoconstriction in vagosympathectomized dogs through the activation of 5-HT(1B/1D) receptors and alpha(2)-adrenoceptors.', 'text': 'Target-14744615', 'table': 'None'}, {'question': 'How does dihydroergotamine affect blood pressure and heart rate during its vasoconstriction effect?', 'answer': 'Dihydroergotamine decreases external carotid blood flow dose-dependently without affecting blood pressure or heart rate.', 'text': 'Target-14744615', 'table': 'None'}, {'question': \"What is the role of SB224289 in the study of dihydroergotamine's effects on carotid vasoconstriction?\", 'answer': 'SB224289, an antagonist of the 5-HT(1B) receptor, partly blocks the vasoconstriction effect induced by dihydroergotamine when administered intravenously to dogs.', 'text': 'Target-14744615', 'table': 'None'}, {'question': 'What happens to the vasoconstriction response when dogs are pretreated with both SB224289 and rauwolscine?', 'answer': 'The vasoconstriction response induced by dihydroergotamine is markedly blocked when dogs are pretreated with both SB224289 and rauwolscine.', 'text': 'Target-14744615', 'table': 'None'}, {'question': 'Is the carotid vasoconstriction response to dihydroergotamine affected by the antagonist BRL15572?', 'answer': 'The carotid vasoconstriction response to dihydroergotamine is unaffected by the antagonist BRL15572.', 'text': 'Target-14744615', 'table': 'None'}]\n",
      "No table mapping found for passage Target-10722500\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 24%|██▍       | 36/150 [02:46<06:06,  3.21s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does the antagonist naltrindole (NTI) affect sufentanil-induced respiratory impairment in dogs, and is there any associated drug information available?\n",
      "   answer: Naltrindole (NTI), a highly selective antagonist, can reverse sufentanil-induced respiratory impairment in a dose-related manner. It increases PaO2 from 57 to 81 mmHg and lowers PaCO2 from 52.1 to 49.2 mmHg. However, specific drug information about naltrindole is not provided in the available tables.\n",
      "   text: Target-1330549\n",
      "   table: None\n",
      "\n",
      "2. question: What role do delta-receptors play in opioid-related respiratory impairment, according to the passage, and is there any related drug information in the tables?\n",
      "   answer: The passage suggests that it is still uncertain whether mu- and/or delta-receptors are mainly involved in opioid-related respiratory impairment. The use of selective antagonists like naltrindole (NTI) and naltriben (NTB) indicates the involvement of delta-receptors in mediating sufentanil-related respiratory depression. However, no specific drug information about these receptors is detailed in the tables.\n",
      "   text: Target-1330549\n",
      "   table: None\n",
      "\n",
      "3. question: What is the effect of naltriben (NTB) antagonism on sufentanil-induced respiratory depression in dogs, and is there any additional information available in the tables?\n",
      "   answer: Naltriben (NTB) antagonism at doses of 40-80-160 micrograms kg-1 increases PaO2 from 48.4 to 91.2 mmHg and reduces PaCO2 from 46.9 to 37.6 mmHg, indicating its effectiveness in reversing sufentanil-induced respiratory depression. No additional drug information about naltriben is provided in the tables.\n",
      "   text: Target-1330549\n",
      "   table: None\n",
      "\n",
      "4. question: How does the passage describe the mechanism of action of central analgesics, and is there any related drug data linked in the tables?\n",
      "   answer: The passage describes that analgesia induced by central analgesics is generally mediated through the mu-receptor. However, there is no direct link to specific drug data or drugbank entries in the tables related to central analgesics or the mu-receptor.\n",
      "   text: Target-1330549\n",
      "   table: None\n",
      "\n",
      "5. question: Is there any information on the synthesis or FDA status of naltrindole or naltriben in the provided tables?\n",
      "   answer: The tables do not provide any information regarding the synthesis, FDA status, or other specific details about naltrindole or naltriben. The tables focus on other drugs not directly mentioned in the passage.\n",
      "   text: Target-1330549\n",
      "   table: None\n",
      "[{'question': 'How does the antagonist naltrindole (NTI) affect sufentanil-induced respiratory impairment in dogs, and is there any associated drug information available?', 'answer': 'Naltrindole (NTI), a highly selective antagonist, can reverse sufentanil-induced respiratory impairment in a dose-related manner. It increases PaO2 from 57 to 81 mmHg and lowers PaCO2 from 52.1 to 49.2 mmHg. However, specific drug information about naltrindole is not provided in the available tables.', 'text': 'Target-1330549', 'table': 'None'}, {'question': 'What role do delta-receptors play in opioid-related respiratory impairment, according to the passage, and is there any related drug information in the tables?', 'answer': 'The passage suggests that it is still uncertain whether mu- and/or delta-receptors are mainly involved in opioid-related respiratory impairment. The use of selective antagonists like naltrindole (NTI) and naltriben (NTB) indicates the involvement of delta-receptors in mediating sufentanil-related respiratory depression. However, no specific drug information about these receptors is detailed in the tables.', 'text': 'Target-1330549', 'table': 'None'}, {'question': 'What is the effect of naltriben (NTB) antagonism on sufentanil-induced respiratory depression in dogs, and is there any additional information available in the tables?', 'answer': 'Naltriben (NTB) antagonism at doses of 40-80-160 micrograms kg-1 increases PaO2 from 48.4 to 91.2 mmHg and reduces PaCO2 from 46.9 to 37.6 mmHg, indicating its effectiveness in reversing sufentanil-induced respiratory depression. No additional drug information about naltriben is provided in the tables.', 'text': 'Target-1330549', 'table': 'None'}, {'question': 'How does the passage describe the mechanism of action of central analgesics, and is there any related drug data linked in the tables?', 'answer': 'The passage describes that analgesia induced by central analgesics is generally mediated through the mu-receptor. However, there is no direct link to specific drug data or drugbank entries in the tables related to central analgesics or the mu-receptor.', 'text': 'Target-1330549', 'table': 'None'}, {'question': 'Is there any information on the synthesis or FDA status of naltrindole or naltriben in the provided tables?', 'answer': 'The tables do not provide any information regarding the synthesis, FDA status, or other specific details about naltrindole or naltriben. The tables focus on other drugs not directly mentioned in the passage.', 'text': 'Target-1330549', 'table': 'None'}]\n",
      "No table mapping found for passage Target-11602509\n",
      "No table mapping found for passage Target-8667235\n",
      "No table mapping found for passage Target-16584282\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 27%|██▋       | 40/150 [02:52<04:16,  2.33s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the primary therapeutic use of dofetilide and how does it function at the cellular level?\n",
      "   answer: Dofetilide is primarily used for the conversion of atrial fibrillation and flutter to sinus rhythm and for maintaining sinus rhythm after conversion. At the cellular level, it selectively blocks the rapid component of the cardiac ion channel delayed rectifier current, leading to an increase in the action potential duration and effective refractory period of the myocyte, thereby terminating reentrant tachyarrhythmias.\n",
      "   text: Target-17187453\n",
      "   table: None\n",
      "\n",
      "2. question: What are the precautions to minimize the risk of torsades de pointes when using dofetilide?\n",
      "   answer: To minimize the risk of torsades de pointes when using dofetilide, dosage adjustment is necessary based on creatinine clearance and QT(c) interval. Additionally, it is important to select patients without known risk factors for torsades and to initiate treatment in a monitored hospital setting for the first three days.\n",
      "   text: Target-17187453\n",
      "   table: None\n",
      "\n",
      "3. question: How does dofetilide's effect on mortality compare to other antiarrhythmic agents in patients with recent myocardial infarction?\n",
      "   answer: Unlike other antiarrhythmic agents, oral dofetilide did not increase mortality in patients with a recent myocardial infarction.\n",
      "   text: Target-17187453\n",
      "   table: None\n",
      "\n",
      "4. question: What is the mechanism by which dofetilide prevents the re-induction of tachyarrhythmias?\n",
      "   answer: Dofetilide prevents the re-induction of tachyarrhythmias by increasing the action potential duration and effective refractory period of the myocyte through selective blocking of the rapid component of the cardiac ion channel delayed rectifier current.\n",
      "   text: Target-17187453\n",
      "   table: None\n",
      "\n",
      "5. question: Why is it recommended to initiate dofetilide treatment in a hospital setting?\n",
      "   answer: Initiating dofetilide treatment in a monitored hospital setting is recommended to closely monitor the patient for the first three days, which helps to minimize the risk of torsades de pointes by allowing for appropriate dosage adjustments based on creatinine clearance and QT(c) interval.\n",
      "   text: Target-17187453\n",
      "   table: None\n",
      "[{'question': 'What is the primary therapeutic use of dofetilide and how does it function at the cellular level?', 'answer': 'Dofetilide is primarily used for the conversion of atrial fibrillation and flutter to sinus rhythm and for maintaining sinus rhythm after conversion. At the cellular level, it selectively blocks the rapid component of the cardiac ion channel delayed rectifier current, leading to an increase in the action potential duration and effective refractory period of the myocyte, thereby terminating reentrant tachyarrhythmias.', 'text': 'Target-17187453', 'table': 'None'}, {'question': 'What are the precautions to minimize the risk of torsades de pointes when using dofetilide?', 'answer': 'To minimize the risk of torsades de pointes when using dofetilide, dosage adjustment is necessary based on creatinine clearance and QT(c) interval. Additionally, it is important to select patients without known risk factors for torsades and to initiate treatment in a monitored hospital setting for the first three days.', 'text': 'Target-17187453', 'table': 'None'}, {'question': \"How does dofetilide's effect on mortality compare to other antiarrhythmic agents in patients with recent myocardial infarction?\", 'answer': 'Unlike other antiarrhythmic agents, oral dofetilide did not increase mortality in patients with a recent myocardial infarction.', 'text': 'Target-17187453', 'table': 'None'}, {'question': 'What is the mechanism by which dofetilide prevents the re-induction of tachyarrhythmias?', 'answer': 'Dofetilide prevents the re-induction of tachyarrhythmias by increasing the action potential duration and effective refractory period of the myocyte through selective blocking of the rapid component of the cardiac ion channel delayed rectifier current.', 'text': 'Target-17187453', 'table': 'None'}, {'question': 'Why is it recommended to initiate dofetilide treatment in a hospital setting?', 'answer': 'Initiating dofetilide treatment in a monitored hospital setting is recommended to closely monitor the patient for the first three days, which helps to minimize the risk of torsades de pointes by allowing for appropriate dosage adjustments based on creatinine clearance and QT(c) interval.', 'text': 'Target-17187453', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 27%|██▋       | 41/150 [02:58<05:13,  2.88s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the role of clopidogrel in blood platelet function, and how does it relate to the P2Y12 receptor?\n",
      "   answer: Clopidogrel acts as a platelet aggregation inhibitor by interacting with the P2Y12 receptor, which is a purinergic receptor. This interaction is clinically relevant as it prevents blood platelets from aggregating, thereby reducing the risk of thrombosis.\n",
      "   text: Target-14668029\n",
      "   table: None\n",
      "\n",
      "2. question: How is the interaction of clopidogrel with the P2Y12 receptor relevant to its classification as a drug?\n",
      "   answer: Clopidogrel is classified as a purinergic P2Y receptor antagonist, specifically targeting the P2Y12 receptor. This classification is significant because its mechanism of action involves inhibiting platelet aggregation, which is essential for its therapeutic use in preventing cardiovascular events.\n",
      "   text: Target-14668029\n",
      "   table: None\n",
      "\n",
      "3. question: What is the molecular sequence data's relevance to clopidogrel's mechanism of action?\n",
      "   answer: The molecular sequence data is relevant to clopidogrel's mechanism of action as it helps in understanding the specific interactions at the amino acid level between clopidogrel and the P2Y12 receptor. This detailed understanding is crucial for elucidating its role in inhibiting platelet aggregation.\n",
      "   text: Target-14668029\n",
      "   table: None\n",
      "\n",
      "4. question: What are the similarities between clopidogrel and ticlopidine concerning their target receptors?\n",
      "   answer: Both clopidogrel and ticlopidine target the P2Y12 receptor, acting as purinergic P2Y receptor antagonists. This similarity highlights their role as platelet aggregation inhibitors, used to reduce the risk of thrombotic events.\n",
      "   text: Target-14668029\n",
      "   table: None\n",
      "\n",
      "5. question: In what organisms are the interactions of clopidogrel with the P2Y12 receptor studied, according to the passage?\n",
      "   answer: The interactions of clopidogrel with the P2Y12 receptor are studied in both humans and animals, which is important for understanding its efficacy and safety across different biological systems.\n",
      "   text: Target-14668029\n",
      "   table: None\n",
      "[{'question': 'What is the role of clopidogrel in blood platelet function, and how does it relate to the P2Y12 receptor?', 'answer': 'Clopidogrel acts as a platelet aggregation inhibitor by interacting with the P2Y12 receptor, which is a purinergic receptor. This interaction is clinically relevant as it prevents blood platelets from aggregating, thereby reducing the risk of thrombosis.', 'text': 'Target-14668029', 'table': 'None'}, {'question': 'How is the interaction of clopidogrel with the P2Y12 receptor relevant to its classification as a drug?', 'answer': 'Clopidogrel is classified as a purinergic P2Y receptor antagonist, specifically targeting the P2Y12 receptor. This classification is significant because its mechanism of action involves inhibiting platelet aggregation, which is essential for its therapeutic use in preventing cardiovascular events.', 'text': 'Target-14668029', 'table': 'None'}, {'question': \"What is the molecular sequence data's relevance to clopidogrel's mechanism of action?\", 'answer': \"The molecular sequence data is relevant to clopidogrel's mechanism of action as it helps in understanding the specific interactions at the amino acid level between clopidogrel and the P2Y12 receptor. This detailed understanding is crucial for elucidating its role in inhibiting platelet aggregation.\", 'text': 'Target-14668029', 'table': 'None'}, {'question': 'What are the similarities between clopidogrel and ticlopidine concerning their target receptors?', 'answer': 'Both clopidogrel and ticlopidine target the P2Y12 receptor, acting as purinergic P2Y receptor antagonists. This similarity highlights their role as platelet aggregation inhibitors, used to reduce the risk of thrombotic events.', 'text': 'Target-14668029', 'table': 'None'}, {'question': 'In what organisms are the interactions of clopidogrel with the P2Y12 receptor studied, according to the passage?', 'answer': 'The interactions of clopidogrel with the P2Y12 receptor are studied in both humans and animals, which is important for understanding its efficacy and safety across different biological systems.', 'text': 'Target-14668029', 'table': 'None'}]\n",
      "No table mapping found for passage Target-23516440\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 29%|██▊       | 43/150 [03:03<04:50,  2.71s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What was the study focus in the passage regarding the antitumor drugs ametantrone and mitoxantrone?\n",
      "   answer: The study focused on the intercalative binding of the antitumor drugs ametantrone and mitoxantrone to the dodecamer duplex d(CGCGAGCTCGCG)2 using molecular dynamics in water with the GROMOS 87 force field. Various binding orientations were tested, and it was found that mitoxantrone had a more favorable energy in its intercalation complex with the duplex.\n",
      "   text: Target-9701490\n",
      "   table: None\n",
      "\n",
      "2. question: How were the differences between the intercalation complexes of ametantrone and mitoxantrone analyzed in the study?\n",
      "   answer: The study analyzed differences between the intercalation complexes of ametantrone and mitoxantrone with the dodecamer duplex by examining the energetically favorable binding orientations and discussing the molecular nature of the interactions. The mitoxantrone complex was noted to have more favorable energy compared to ametantrone.\n",
      "   text: Target-9701490\n",
      "   table: None\n",
      "\n",
      "3. question: What experimental method was employed in the study for analyzing the binding of antitumor drugs to DNA?\n",
      "   answer: The study employed molecular dynamics simulations in water using the GROMOS 87 force field to analyze the binding of the antitumor drugs ametantrone and mitoxantrone to a dodecamer DNA duplex.\n",
      "   text: Target-9701490\n",
      "   table: None\n",
      "[{'question': 'What was the study focus in the passage regarding the antitumor drugs ametantrone and mitoxantrone?', 'answer': 'The study focused on the intercalative binding of the antitumor drugs ametantrone and mitoxantrone to the dodecamer duplex d(CGCGAGCTCGCG)2 using molecular dynamics in water with the GROMOS 87 force field. Various binding orientations were tested, and it was found that mitoxantrone had a more favorable energy in its intercalation complex with the duplex.', 'text': 'Target-9701490', 'table': 'None'}, {'question': 'How were the differences between the intercalation complexes of ametantrone and mitoxantrone analyzed in the study?', 'answer': 'The study analyzed differences between the intercalation complexes of ametantrone and mitoxantrone with the dodecamer duplex by examining the energetically favorable binding orientations and discussing the molecular nature of the interactions. The mitoxantrone complex was noted to have more favorable energy compared to ametantrone.', 'text': 'Target-9701490', 'table': 'None'}, {'question': 'What experimental method was employed in the study for analyzing the binding of antitumor drugs to DNA?', 'answer': 'The study employed molecular dynamics simulations in water using the GROMOS 87 force field to analyze the binding of the antitumor drugs ametantrone and mitoxantrone to a dodecamer DNA duplex.', 'text': 'Target-9701490', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 29%|██▉       | 44/150 [03:11<06:35,  3.73s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What was the dosage of cetirizine used in the study, and how does cetirizine function as an antihistamine?\n",
      "   answer: In the study, cetirizine was administered at a dosage of 20 mg. Cetirizine functions as a second-generation antihistamine, which means it acts as a histamine H1-receptor antagonist to alleviate symptoms of allergic disorders with reduced sedative effects compared to first-generation antihistamines.\n",
      "   text: Target-15286093\n",
      "   table: None\n",
      "\n",
      "2. question: How was histamine H1-receptor occupancy (H1RO) measured in the study, and why is it significant for evaluating antihistamines?\n",
      "   answer: Histamine H1-receptor occupancy (H1RO) was measured using positron emission tomography (PET) with (11)C-doxepin in the study. This measurement is significant for evaluating antihistamines as it provides an objective metric for assessing how effectively the drug can block histamine receptors in the brain, which is crucial for understanding the sedative effects and efficacy of the antihistamine.\n",
      "   text: Target-15286093\n",
      "   table: None\n",
      "\n",
      "3. question: What was the purpose of including hydroxyzine as a positive control in the study, and how does it relate to the study's aim?\n",
      "   answer: Hydroxyzine was included as a positive control in the study to provide a benchmark for comparing the sedative effects of the second-generation antihistamines, fexofenadine and cetirizine. It is a first-generation antihistamine known for its sedative properties, allowing researchers to evaluate the relative sedative profiles of the second-generation antihistamines under investigation.\n",
      "   text: Target-15286093\n",
      "   table: None\n",
      "[{'question': 'What was the dosage of cetirizine used in the study, and how does cetirizine function as an antihistamine?', 'answer': 'In the study, cetirizine was administered at a dosage of 20 mg. Cetirizine functions as a second-generation antihistamine, which means it acts as a histamine H1-receptor antagonist to alleviate symptoms of allergic disorders with reduced sedative effects compared to first-generation antihistamines.', 'text': 'Target-15286093', 'table': 'None'}, {'question': 'How was histamine H1-receptor occupancy (H1RO) measured in the study, and why is it significant for evaluating antihistamines?', 'answer': 'Histamine H1-receptor occupancy (H1RO) was measured using positron emission tomography (PET) with (11)C-doxepin in the study. This measurement is significant for evaluating antihistamines as it provides an objective metric for assessing how effectively the drug can block histamine receptors in the brain, which is crucial for understanding the sedative effects and efficacy of the antihistamine.', 'text': 'Target-15286093', 'table': 'None'}, {'question': \"What was the purpose of including hydroxyzine as a positive control in the study, and how does it relate to the study's aim?\", 'answer': 'Hydroxyzine was included as a positive control in the study to provide a benchmark for comparing the sedative effects of the second-generation antihistamines, fexofenadine and cetirizine. It is a first-generation antihistamine known for its sedative properties, allowing researchers to evaluate the relative sedative profiles of the second-generation antihistamines under investigation.', 'text': 'Target-15286093', 'table': 'None'}]\n",
      "No table mapping found for passage Target-16445595\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 31%|███       | 46/150 [03:16<05:36,  3.23s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What happens to cyanocobalamin (vitamin B12) in Spirometra mansonoides spargana, and is there any FDA-approved product related to vitamin B12 in the tables?\n",
      "   answer: In Spirometra mansonoides spargana, cyanocobalamin (vitamin B12) is metabolized to adenosylcobalamin and hydroxocobalamin, with no methylcobalamin detected. The passage does not list any FDA-approved products related to vitamin B12 in the provided tables.\n",
      "   text: Target-18565\n",
      "   table: drugbank-drugs_links\n",
      "\n",
      "2. question: Which enzyme that requires adenosylcobalamin was found in Spirometra mansonoides spargana, and is there any connection to the drugs listed in the tables?\n",
      "   answer: The enzyme methylmalonyl CoA mutase, which requires adenosylcobalamin, was found in Spirometra mansonoides spargana. There is no direct connection between this enzyme and the drugs listed in the provided tables.\n",
      "   text: Target-18565\n",
      "   table: drugbank-drug\n",
      "\n",
      "3. question: How long is the biological half-life of vitamin B12 in spargana, and does any drug in the sample tables relate to vitamin B12 metabolism?\n",
      "   answer: The biological half-life of vitamin B12 in spargana is about 7 weeks. None of the drugs in the sample tables directly relate to vitamin B12 metabolism.\n",
      "   text: Target-18565\n",
      "   table: drugbank-drug\n",
      "[{'question': 'What happens to cyanocobalamin (vitamin B12) in Spirometra mansonoides spargana, and is there any FDA-approved product related to vitamin B12 in the tables?', 'answer': 'In Spirometra mansonoides spargana, cyanocobalamin (vitamin B12) is metabolized to adenosylcobalamin and hydroxocobalamin, with no methylcobalamin detected. The passage does not list any FDA-approved products related to vitamin B12 in the provided tables.', 'text': 'Target-18565', 'table': 'drugbank-drugs_links'}, {'question': 'Which enzyme that requires adenosylcobalamin was found in Spirometra mansonoides spargana, and is there any connection to the drugs listed in the tables?', 'answer': 'The enzyme methylmalonyl CoA mutase, which requires adenosylcobalamin, was found in Spirometra mansonoides spargana. There is no direct connection between this enzyme and the drugs listed in the provided tables.', 'text': 'Target-18565', 'table': 'drugbank-drug'}, {'question': 'How long is the biological half-life of vitamin B12 in spargana, and does any drug in the sample tables relate to vitamin B12 metabolism?', 'answer': 'The biological half-life of vitamin B12 in spargana is about 7 weeks. None of the drugs in the sample tables directly relate to vitamin B12 metabolism.', 'text': 'Target-18565', 'table': 'drugbank-drug'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 31%|███▏      | 47/150 [03:21<06:07,  3.57s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What organism is the Oatp1 transporter, which mediates the uptake of enalapril, originally cloned from?\n",
      "   answer: The Oatp1 transporter, which mediates the uptake of enalapril, is originally cloned from rat liver.\n",
      "   text: Target-9794920\n",
      "   table: None\n",
      "\n",
      "2. question: Which other substances, besides enalapril, are transported by oatp1 in the study?\n",
      "   answer: Besides enalapril, oatp1 also transports estrone sulfate (E1S), taurolithocholic acid sulfate (TLCAS), and the glutathione conjugate of bromosulfophthalein (BSPGSH).\n",
      "   text: Target-9794920\n",
      "   table: None\n",
      "\n",
      "3. question: What is the role of zinc in the study of enalapril uptake by oatp1 in HeLa cells?\n",
      "   answer: In the study, zinc acts as an inducer for the expression of oatp1 in transfected HeLa cells. Without zinc induction, the cells do not express oatp1 and consequently fail to uptake enalapril.\n",
      "   text: Target-9794920\n",
      "   table: None\n",
      "\n",
      "4. question: Which drug class does enalapril belong to, and what is its primary mechanism of action?\n",
      "   answer: Enalapril belongs to the class of angiotensin-converting enzyme (ACE) inhibitors, and its primary mechanism of action is to inhibit the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure.\n",
      "   text: Target-9794920\n",
      "   table: None\n",
      "\n",
      "5. question: How was the uptake of enalapril studied in the HeLa cell line experiment, and what was the range of enalapril concentrations used?\n",
      "   answer: The uptake of enalapril was studied in a HeLa cell line stably transfected with oatp1-cDNA, using [3H]enalapril to measure uptake. The concentration range of enalapril used was from 1 to 800 micromol/L.\n",
      "   text: Target-9794920\n",
      "   table: None\n",
      "[{'question': 'What organism is the Oatp1 transporter, which mediates the uptake of enalapril, originally cloned from?', 'answer': 'The Oatp1 transporter, which mediates the uptake of enalapril, is originally cloned from rat liver.', 'text': 'Target-9794920', 'table': 'None'}, {'question': 'Which other substances, besides enalapril, are transported by oatp1 in the study?', 'answer': 'Besides enalapril, oatp1 also transports estrone sulfate (E1S), taurolithocholic acid sulfate (TLCAS), and the glutathione conjugate of bromosulfophthalein (BSPGSH).', 'text': 'Target-9794920', 'table': 'None'}, {'question': 'What is the role of zinc in the study of enalapril uptake by oatp1 in HeLa cells?', 'answer': 'In the study, zinc acts as an inducer for the expression of oatp1 in transfected HeLa cells. Without zinc induction, the cells do not express oatp1 and consequently fail to uptake enalapril.', 'text': 'Target-9794920', 'table': 'None'}, {'question': 'Which drug class does enalapril belong to, and what is its primary mechanism of action?', 'answer': 'Enalapril belongs to the class of angiotensin-converting enzyme (ACE) inhibitors, and its primary mechanism of action is to inhibit the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure.', 'text': 'Target-9794920', 'table': 'None'}, {'question': 'How was the uptake of enalapril studied in the HeLa cell line experiment, and what was the range of enalapril concentrations used?', 'answer': 'The uptake of enalapril was studied in a HeLa cell line stably transfected with oatp1-cDNA, using [3H]enalapril to measure uptake. The concentration range of enalapril used was from 1 to 800 micromol/L.', 'text': 'Target-9794920', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 32%|███▏      | 48/150 [03:25<06:29,  3.82s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What type of receptor does solifenacin target, and how was its selectivity tested in the study?\n",
      "   answer: Solifenacin targets the M(3) muscarinic receptor and its selectivity was tested using muscarinic receptor subtype knockout (KO) mice in the bladder and submandibular gland, with measurements taken via a radioligand binding assay using [N-methyl-(3)H]scopolamine. The drugbank tables do not provide direct additional information on solifenacin, but the passage details this study.\n",
      "   text: Target-19446545\n",
      "   table: None\n",
      "\n",
      "2. question: How does the binding activity of solifenacin compare between M(2)R KO mice bladder and submandibular gland tissues?\n",
      "   answer: In M(2)R KO mice, there was little difference in the receptor binding activities of solifenacin between the bladder and submandibular gland tissues, suggesting equal affinity for residual (predominantly M(3) subtype) muscarinic receptors in both tissues.\n",
      "   text: Target-19446545\n",
      "   table: None\n",
      "\n",
      "3. question: How does solifenacin's oral administration activity compare to that of oxybutynin in terms of binding muscarinic receptors?\n",
      "   answer: Compared with oral oxybutynin, oral administration of solifenacin exerted a significantly greater activity to bind muscarinic receptors, indicating a higher selectivity and potentially more effective treatment for overactive bladder.\n",
      "   text: Target-19446545\n",
      "   table: None\n",
      "\n",
      "4. question: What method was used to measure muscarinic receptor binding in the study, and how might this relate to solifenacin's therapeutic effects?\n",
      "   answer: The study used a radioligand binding assay with [N-methyl-(3)H]scopolamine ([(3)H]NMS) to measure muscarinic receptor binding. This method allows for precise measurement of drug-receptor interactions, which is crucial for determining solifenacin's effectiveness and selectivity in treating overactive bladder.\n",
      "   text: Target-19446545\n",
      "   table: None\n",
      "[{'question': 'What type of receptor does solifenacin target, and how was its selectivity tested in the study?', 'answer': 'Solifenacin targets the M(3) muscarinic receptor and its selectivity was tested using muscarinic receptor subtype knockout (KO) mice in the bladder and submandibular gland, with measurements taken via a radioligand binding assay using [N-methyl-(3)H]scopolamine. The drugbank tables do not provide direct additional information on solifenacin, but the passage details this study.', 'text': 'Target-19446545', 'table': 'None'}, {'question': 'How does the binding activity of solifenacin compare between M(2)R KO mice bladder and submandibular gland tissues?', 'answer': 'In M(2)R KO mice, there was little difference in the receptor binding activities of solifenacin between the bladder and submandibular gland tissues, suggesting equal affinity for residual (predominantly M(3) subtype) muscarinic receptors in both tissues.', 'text': 'Target-19446545', 'table': 'None'}, {'question': \"How does solifenacin's oral administration activity compare to that of oxybutynin in terms of binding muscarinic receptors?\", 'answer': 'Compared with oral oxybutynin, oral administration of solifenacin exerted a significantly greater activity to bind muscarinic receptors, indicating a higher selectivity and potentially more effective treatment for overactive bladder.', 'text': 'Target-19446545', 'table': 'None'}, {'question': \"What method was used to measure muscarinic receptor binding in the study, and how might this relate to solifenacin's therapeutic effects?\", 'answer': \"The study used a radioligand binding assay with [N-methyl-(3)H]scopolamine ([(3)H]NMS) to measure muscarinic receptor binding. This method allows for precise measurement of drug-receptor interactions, which is crucial for determining solifenacin's effectiveness and selectivity in treating overactive bladder.\", 'text': 'Target-19446545', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 33%|███▎      | 49/150 [03:31<07:00,  4.17s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What methods were used to determine almotriptan plasma concentrations in the study assessing its interaction with verapamil?\n",
      "   answer: Almotriptan plasma concentrations were determined by liquid chromatography-tandem mass spectrometry in the study assessing its interaction with verapamil.\n",
      "   text: Target-10824628\n",
      "   table: None\n",
      "\n",
      "2. question: How was the safety of combining almotriptan and verapamil monitored in the study?\n",
      "   answer: The safety of combining almotriptan and verapamil was monitored through blood pressure and pulse measurements, electrocardiography, and adverse event monitoring.\n",
      "   text: Target-10824628\n",
      "   table: None\n",
      "\n",
      "3. question: Can you describe the dosage regimen for almotriptan and verapamil used in the study?\n",
      "   answer: In the study, participants received 120-mg sustained-release verapamil tablets twice daily for 7 days and a 12.5-mg almotriptan tablet on day 7. In another phase, they received only a 12.5-mg almotriptan tablet on day 7.\n",
      "   text: Target-10824628\n",
      "   table: None\n",
      "\n",
      "4. question: What statistical method was used to compare pharmacokinetic parameters and vital sign data in the almotriptan and verapamil interaction study?\n",
      "   answer: ANOVA (Analysis of Variance) was used for statistical comparisons of pharmacokinetic parameters and vital sign data in the study.\n",
      "   text: Target-10824628\n",
      "   table: None\n",
      "\n",
      "5. question: What was the objective of the study involving almotriptan and verapamil, and which receptor does almotriptan target?\n",
      "   answer: The objective of the study was to assess the interaction between almotriptan, a 5-HT1B/1D-receptor agonist used to treat migraines, and verapamil, which serves as a prophylactic agent for migraines.\n",
      "   text: Target-10824628\n",
      "   table: None\n",
      "[{'question': 'What methods were used to determine almotriptan plasma concentrations in the study assessing its interaction with verapamil?', 'answer': 'Almotriptan plasma concentrations were determined by liquid chromatography-tandem mass spectrometry in the study assessing its interaction with verapamil.', 'text': 'Target-10824628', 'table': 'None'}, {'question': 'How was the safety of combining almotriptan and verapamil monitored in the study?', 'answer': 'The safety of combining almotriptan and verapamil was monitored through blood pressure and pulse measurements, electrocardiography, and adverse event monitoring.', 'text': 'Target-10824628', 'table': 'None'}, {'question': 'Can you describe the dosage regimen for almotriptan and verapamil used in the study?', 'answer': 'In the study, participants received 120-mg sustained-release verapamil tablets twice daily for 7 days and a 12.5-mg almotriptan tablet on day 7. In another phase, they received only a 12.5-mg almotriptan tablet on day 7.', 'text': 'Target-10824628', 'table': 'None'}, {'question': 'What statistical method was used to compare pharmacokinetic parameters and vital sign data in the almotriptan and verapamil interaction study?', 'answer': 'ANOVA (Analysis of Variance) was used for statistical comparisons of pharmacokinetic parameters and vital sign data in the study.', 'text': 'Target-10824628', 'table': 'None'}, {'question': 'What was the objective of the study involving almotriptan and verapamil, and which receptor does almotriptan target?', 'answer': 'The objective of the study was to assess the interaction between almotriptan, a 5-HT1B/1D-receptor agonist used to treat migraines, and verapamil, which serves as a prophylactic agent for migraines.', 'text': 'Target-10824628', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 33%|███▎      | 50/150 [03:34<06:46,  4.07s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: Which fluoroquinolone was the only one for which no resistant Neisseria gonorrhoeae mutants were obtained in the study?\n",
      "   answer: Gemifloxacin was the only quinolone tested for which resistant mutants were not obtained in the study.\n",
      "   text: Target-11581235\n",
      "   table: None\n",
      "\n",
      "2. question: What was unique about the N. gonorrhoeae mutant obtained with trovafloxacin at 4 x MIC?\n",
      "   answer: The N. gonorrhoeae mutant obtained with trovafloxacin at 4 x MIC presented a stable increase in the MIC of this quinolone without a novel mutation in the gyrA and parC genes, and it did not show any increase in the MIC of the other quinolones tested.\n",
      "   text: Target-11581235\n",
      "   table: None\n",
      "\n",
      "3. question: What was the general observation about the frequency of mutation for all quinolones tested in the study?\n",
      "   answer: The frequency of mutation was low for all the quinolones tested in the study.\n",
      "   text: Target-11581235\n",
      "   table: None\n",
      "\n",
      "4. question: What role do the gyrA and parC genes play in the study of Neisseria gonorrhoeae mutants?\n",
      "   answer: The study found that the stable increase in MIC for trovafloxacin in one N. gonorrhoeae mutant was not attributable to novel mutations in the gyrA and parC genes.\n",
      "   text: Target-11581235\n",
      "   table: None\n",
      "\n",
      "5. question: How many clinical isolates of Neisseria gonorrhoeae were used in the study and what were their characteristics regarding nalidixic acid susceptibility?\n",
      "   answer: The study used four clinical isolates of Neisseria gonorrhoeae, two of which were susceptible to nalidixic acid and two resistant.\n",
      "   text: Target-11581235\n",
      "   table: None\n",
      "[{'question': 'Which fluoroquinolone was the only one for which no resistant Neisseria gonorrhoeae mutants were obtained in the study?', 'answer': 'Gemifloxacin was the only quinolone tested for which resistant mutants were not obtained in the study.', 'text': 'Target-11581235', 'table': 'None'}, {'question': 'What was unique about the N. gonorrhoeae mutant obtained with trovafloxacin at 4 x MIC?', 'answer': 'The N. gonorrhoeae mutant obtained with trovafloxacin at 4 x MIC presented a stable increase in the MIC of this quinolone without a novel mutation in the gyrA and parC genes, and it did not show any increase in the MIC of the other quinolones tested.', 'text': 'Target-11581235', 'table': 'None'}, {'question': 'What was the general observation about the frequency of mutation for all quinolones tested in the study?', 'answer': 'The frequency of mutation was low for all the quinolones tested in the study.', 'text': 'Target-11581235', 'table': 'None'}, {'question': 'What role do the gyrA and parC genes play in the study of Neisseria gonorrhoeae mutants?', 'answer': 'The study found that the stable increase in MIC for trovafloxacin in one N. gonorrhoeae mutant was not attributable to novel mutations in the gyrA and parC genes.', 'text': 'Target-11581235', 'table': 'None'}, {'question': 'How many clinical isolates of Neisseria gonorrhoeae were used in the study and what were their characteristics regarding nalidixic acid susceptibility?', 'answer': 'The study used four clinical isolates of Neisseria gonorrhoeae, two of which were susceptible to nalidixic acid and two resistant.', 'text': 'Target-11581235', 'table': 'None'}]\n",
      "No table mapping found for passage Target-8216357\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 35%|███▍      | 52/150 [03:41<06:09,  3.77s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does thyroid function potentially influence the pharmacokinetics of digoxin?\n",
      "   answer: Thyroid function can alter the pharmacokinetics of digoxin due to its influence on the intestinal expression of P-glycoprotein. The passage suggests that thyroid hormones may regulate P-glycoprotein, thereby affecting the disposition of drugs like digoxin that are substrates of this transporter.\n",
      "   text: Target-12235446\n",
      "   table: drugbank-transporters\n",
      "\n",
      "2. question: What was the method used to assess the expression of P-glycoprotein in the study, and what was the observed change after levothyroxine administration?\n",
      "   answer: The study measured duodenal expression of P-glycoprotein by reverse transcriptase-polymerase chain reaction of MDR1 mRNA and immunohistochemical examination. After coadministration with levothyroxine, there was a 1.4-fold increase in duodenal MDR1 mRNA expression and immunoreactive P-glycoprotein.\n",
      "   text: Target-12235446\n",
      "   table: None\n",
      "\n",
      "3. question: What role does P-glycoprotein play in the disposition of drugs, and how might this be relevant to the use of levothyroxine?\n",
      "   answer: P-glycoprotein acts as a transporter that affects the disposition of drugs that are its substrates. The study suggests that thyroid hormones, such as those affected by levothyroxine administration, might regulate P-glycoprotein, thereby influencing the pharmacokinetics of P-glycoprotein substrates like talinolol and potentially digoxin.\n",
      "   text: Target-12235446\n",
      "   table: drugbank-transporters\n",
      "\n",
      "4. question: What was the demographic composition of the study participants, and how might this influence the study's findings?\n",
      "   answer: The study included 8 healthy volunteers, consisting of 4 men and 4 women, with an age range of 22-29 years and body weight between 59-89 kg. This specific demographic might limit the generalizability of the study findings to other populations, such as older adults or those with different health conditions.\n",
      "   text: Target-12235446\n",
      "   table: None\n",
      "\n",
      "5. question: Which specific drug was used to assess the pharmacokinetics of a P-glycoprotein substrate in the study, and what dosages were administered?\n",
      "   answer: The pharmacokinetics of the P-glycoprotein substrate talinolol were assessed in the study. Participants received talinolol via intravenous administration at a dosage of 30 mg and oral administration at a dosage of 100 mg.\n",
      "   text: Target-12235446\n",
      "   table: None\n",
      "[{'question': 'How does thyroid function potentially influence the pharmacokinetics of digoxin?', 'answer': 'Thyroid function can alter the pharmacokinetics of digoxin due to its influence on the intestinal expression of P-glycoprotein. The passage suggests that thyroid hormones may regulate P-glycoprotein, thereby affecting the disposition of drugs like digoxin that are substrates of this transporter.', 'text': 'Target-12235446', 'table': 'drugbank-transporters'}, {'question': 'What was the method used to assess the expression of P-glycoprotein in the study, and what was the observed change after levothyroxine administration?', 'answer': 'The study measured duodenal expression of P-glycoprotein by reverse transcriptase-polymerase chain reaction of MDR1 mRNA and immunohistochemical examination. After coadministration with levothyroxine, there was a 1.4-fold increase in duodenal MDR1 mRNA expression and immunoreactive P-glycoprotein.', 'text': 'Target-12235446', 'table': 'None'}, {'question': 'What role does P-glycoprotein play in the disposition of drugs, and how might this be relevant to the use of levothyroxine?', 'answer': 'P-glycoprotein acts as a transporter that affects the disposition of drugs that are its substrates. The study suggests that thyroid hormones, such as those affected by levothyroxine administration, might regulate P-glycoprotein, thereby influencing the pharmacokinetics of P-glycoprotein substrates like talinolol and potentially digoxin.', 'text': 'Target-12235446', 'table': 'drugbank-transporters'}, {'question': \"What was the demographic composition of the study participants, and how might this influence the study's findings?\", 'answer': 'The study included 8 healthy volunteers, consisting of 4 men and 4 women, with an age range of 22-29 years and body weight between 59-89 kg. This specific demographic might limit the generalizability of the study findings to other populations, such as older adults or those with different health conditions.', 'text': 'Target-12235446', 'table': 'None'}, {'question': 'Which specific drug was used to assess the pharmacokinetics of a P-glycoprotein substrate in the study, and what dosages were administered?', 'answer': 'The pharmacokinetics of the P-glycoprotein substrate talinolol were assessed in the study. Participants received talinolol via intravenous administration at a dosage of 30 mg and oral administration at a dosage of 100 mg.', 'text': 'Target-12235446', 'table': 'None'}]\n",
      "No table mapping found for passage Target-15268978\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 36%|███▌      | 54/150 [03:46<05:20,  3.34s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the mechanism of action of eletriptan in treating migraines, and how does it compare with sumatriptan?\n",
      "   answer: Eletriptan is a second-generation triptan with high affinity for 5-HT(1B/1D) receptors and is effective in treating migraines with or without aura. It works by causing constriction of blood vessels like the middle meningeal and coronary arteries and the saphenous vein. Sumatriptan, another triptan, also induces similar vessel constrictions. The study in the passage compared the effects of eletriptan and sumatriptan, demonstrating that both drugs work through 5-HT(1B/1D) receptors, as contractions can be antagonized by the selective receptor antagonist GR125743. The highest concentration of eletriptan caused relaxation in the middle meningeal artery, which suggests a differential effect at high doses compared to sumatriptan.\n",
      "   text: Target-11050304\n",
      "   table: None\n",
      "\n",
      "2. question: How does the presence of a 5-HT(1B/1D) receptor antagonist affect the action of eletriptan and sumatriptan on blood vessels?\n",
      "   answer: The presence of a selective 5-HT(1B/1D) receptor antagonist, GR125743, antagonizes the contractions induced by both eletriptan and sumatriptan on the blood vessels tested, such as the middle meningeal artery. This indicates that the effects of eletriptan and sumatriptan are mediated through the 5-HT(1B/1D) receptors.\n",
      "   text: Target-11050304\n",
      "   table: None\n",
      "\n",
      "3. question: What was the observed effect of eletriptan at high concentrations on the middle meningeal artery?\n",
      "   answer: At the highest concentration (100 microM), eletriptan caused relaxation of the middle meningeal artery, which contrasts with its general action of causing constriction at lower concentrations. This suggests a unique pharmacological profile for eletriptan at different concentrations.\n",
      "   text: Target-11050304\n",
      "   table: None\n",
      "\n",
      "Note: The questions and answers provided only utilize information from the passage as the tables did not contain relevant information about eletriptan or sumatriptan. Therefore, the questions focus on the detailed pharmacological effects and mechanisms described in the passage.\n",
      "[{'question': 'What is the mechanism of action of eletriptan in treating migraines, and how does it compare with sumatriptan?', 'answer': 'Eletriptan is a second-generation triptan with high affinity for 5-HT(1B/1D) receptors and is effective in treating migraines with or without aura. It works by causing constriction of blood vessels like the middle meningeal and coronary arteries and the saphenous vein. Sumatriptan, another triptan, also induces similar vessel constrictions. The study in the passage compared the effects of eletriptan and sumatriptan, demonstrating that both drugs work through 5-HT(1B/1D) receptors, as contractions can be antagonized by the selective receptor antagonist GR125743. The highest concentration of eletriptan caused relaxation in the middle meningeal artery, which suggests a differential effect at high doses compared to sumatriptan.', 'text': 'Target-11050304', 'table': 'None'}, {'question': 'How does the presence of a 5-HT(1B/1D) receptor antagonist affect the action of eletriptan and sumatriptan on blood vessels?', 'answer': 'The presence of a selective 5-HT(1B/1D) receptor antagonist, GR125743, antagonizes the contractions induced by both eletriptan and sumatriptan on the blood vessels tested, such as the middle meningeal artery. This indicates that the effects of eletriptan and sumatriptan are mediated through the 5-HT(1B/1D) receptors.', 'text': 'Target-11050304', 'table': 'None'}, {'question': 'What was the observed effect of eletriptan at high concentrations on the middle meningeal artery?', 'answer': 'At the highest concentration (100 microM), eletriptan caused relaxation of the middle meningeal artery, which contrasts with its general action of causing constriction at lower concentrations. This suggests a unique pharmacological profile for eletriptan at different concentrations.', 'text': 'Target-11050304', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 37%|███▋      | 55/150 [03:51<05:34,  3.52s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the significance of food in the absorption of fenofibrate?\n",
      "   answer: Fenofibrate is extensively absorbed only in the presence of food, which suggests that taking the medication with meals could enhance its bioavailability.\n",
      "   text: Target-3318449\n",
      "   table: None\n",
      "\n",
      "2. question: Why should fenofibrate not be used in patients with renal failure?\n",
      "   answer: Fenofibrate should not be used in patients with renal failure because it is not dialyzable and has a markedly prolonged half-life in such patients, increasing the risk of drug accumulation and potential toxicity.\n",
      "   text: Target-3318449\n",
      "   table: None\n",
      "\n",
      "3. question: How is fenofibrate primarily excreted from the body, and what does this imply about its route of elimination?\n",
      "   answer: Most of fenofibrate is excreted as a conjugate in the urine, indicating that renal excretion is the primary route of elimination for this drug.\n",
      "   text: Target-3318449\n",
      "   table: None\n",
      "\n",
      "4. question: What role does albumin play in the transportation of fenofibrate in the bloodstream?\n",
      "   answer: Albumin plays a crucial role in transporting fenofibrate through the bloodstream, suggesting that the drug binds to plasma proteins for its distribution within the body.\n",
      "   text: Target-3318449\n",
      "   table: None\n",
      "\n",
      "5. question: Considering the steady-state dosing of fenofibrate, what is its plasma half-life and how does this impact dosing frequency?\n",
      "   answer: At steady state with usual doses of 100 mg three times daily, the plasma half-life of fenofibrate approximates 30 hours, which influences the dosing frequency to maintain therapeutic levels of the drug in the bloodstream.\n",
      "   text: Target-3318449\n",
      "   table: None\n",
      "[{'question': 'What is the significance of food in the absorption of fenofibrate?', 'answer': 'Fenofibrate is extensively absorbed only in the presence of food, which suggests that taking the medication with meals could enhance its bioavailability.', 'text': 'Target-3318449', 'table': 'None'}, {'question': 'Why should fenofibrate not be used in patients with renal failure?', 'answer': 'Fenofibrate should not be used in patients with renal failure because it is not dialyzable and has a markedly prolonged half-life in such patients, increasing the risk of drug accumulation and potential toxicity.', 'text': 'Target-3318449', 'table': 'None'}, {'question': 'How is fenofibrate primarily excreted from the body, and what does this imply about its route of elimination?', 'answer': 'Most of fenofibrate is excreted as a conjugate in the urine, indicating that renal excretion is the primary route of elimination for this drug.', 'text': 'Target-3318449', 'table': 'None'}, {'question': 'What role does albumin play in the transportation of fenofibrate in the bloodstream?', 'answer': 'Albumin plays a crucial role in transporting fenofibrate through the bloodstream, suggesting that the drug binds to plasma proteins for its distribution within the body.', 'text': 'Target-3318449', 'table': 'None'}, {'question': 'Considering the steady-state dosing of fenofibrate, what is its plasma half-life and how does this impact dosing frequency?', 'answer': 'At steady state with usual doses of 100 mg three times daily, the plasma half-life of fenofibrate approximates 30 hours, which influences the dosing frequency to maintain therapeutic levels of the drug in the bloodstream.', 'text': 'Target-3318449', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 37%|███▋      | 56/150 [03:56<06:05,  3.89s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does tramadol affect norepinephrine uptake in the context of norepinephrine transporter (NET) function?\n",
      "   answer: Tramadol inhibits the desipramine-sensitive uptake of [3H]-norepinephrine ([3H]-NE) in a concentration-dependent manner, with a 50% inhibitory concentration of 21.5 +/- 6.0 microM. This inhibition occurs through competition for the norepinephrine transporter (NET), as indicated by the increased apparent Michaelis constant without changing the maximal velocity. The inhibition constant (K(i)) is 13.7 microM.\n",
      "   text: Target-11916794\n",
      "   table: None\n",
      "\n",
      "2. question: What experimental methods were used to study the binding of tramadol in the passage?\n",
      "   answer: The study characterized [14C]-tramadol binding in cultured bovine adrenal medullary cells and also assessed the effect of tramadol on [3H]-norepinephrine ([3H]-NE) uptake and [3H]-desipramine binding to plasma membranes isolated from bovine adrenal medulla.\n",
      "   text: Target-11916794\n",
      "   table: None\n",
      "\n",
      "3. question: What is the relationship between tramadol and [3H]-desipramine binding based on the passage?\n",
      "   answer: Tramadol inhibits the specific binding of [3H]-desipramine to plasma membranes. Scatchard analysis of [3H]-desipramine binding reveals that tramadol increases the apparent Michaelis constant, suggesting competitive inhibition.\n",
      "   text: Target-11916794\n",
      "   table: None\n",
      "\n",
      "4. question: What type of drug is tramadol, and how is its mode of action described in the passage?\n",
      "   answer: Tramadol is described as a widely used analgesic, although its mode of action is not well understood. The passage focuses on studying its effect on norepinephrine transporter function.\n",
      "   text: Target-11916794\n",
      "   table: None\n",
      "[{'question': 'How does tramadol affect norepinephrine uptake in the context of norepinephrine transporter (NET) function?', 'answer': 'Tramadol inhibits the desipramine-sensitive uptake of [3H]-norepinephrine ([3H]-NE) in a concentration-dependent manner, with a 50% inhibitory concentration of 21.5 +/- 6.0 microM. This inhibition occurs through competition for the norepinephrine transporter (NET), as indicated by the increased apparent Michaelis constant without changing the maximal velocity. The inhibition constant (K(i)) is 13.7 microM.', 'text': 'Target-11916794', 'table': 'None'}, {'question': 'What experimental methods were used to study the binding of tramadol in the passage?', 'answer': 'The study characterized [14C]-tramadol binding in cultured bovine adrenal medullary cells and also assessed the effect of tramadol on [3H]-norepinephrine ([3H]-NE) uptake and [3H]-desipramine binding to plasma membranes isolated from bovine adrenal medulla.', 'text': 'Target-11916794', 'table': 'None'}, {'question': 'What is the relationship between tramadol and [3H]-desipramine binding based on the passage?', 'answer': 'Tramadol inhibits the specific binding of [3H]-desipramine to plasma membranes. Scatchard analysis of [3H]-desipramine binding reveals that tramadol increases the apparent Michaelis constant, suggesting competitive inhibition.', 'text': 'Target-11916794', 'table': 'None'}, {'question': 'What type of drug is tramadol, and how is its mode of action described in the passage?', 'answer': 'Tramadol is described as a widely used analgesic, although its mode of action is not well understood. The passage focuses on studying its effect on norepinephrine transporter function.', 'text': 'Target-11916794', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 38%|███▊      | 57/150 [04:03<07:25,  4.79s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does glibenclamide affect the antinociceptive effect of fentanyl in the study?\n",
      "   answer: Glibenclamide, a selective blocker of ATP-sensitive K+ channels, dose-dependently antagonized the antinociception induced by fentanyl, as observed in the study with male Wistar rats.\n",
      "   text: Target-15665994\n",
      "   table: None\n",
      "\n",
      "2. question: What is the role of fentanyl in the study, and what receptor does it primarily target?\n",
      "   answer: In the study, fentanyl acts as a selective micro-opioid receptor agonist used to promote peripheral antinociception in male Wistar rats. Its antinociceptive effect is dose-dependent and is measured using the paw pressure test.\n",
      "   text: Target-15665994\n",
      "   table: None\n",
      "\n",
      "3. question: What effect did carrageenan have on the responsiveness to noxious pressure in the study, and how was this measured?\n",
      "   answer: Carrageenan decreased the threshold of responsiveness to noxious pressure, resulting in mechanical hyperalgesia, which was measured by a reduction in delta of 188.1 +/- 5.3 g in the paw pressure test.\n",
      "   text: Target-15665994\n",
      "   table: None\n",
      "\n",
      "4. question: Which K+ channel blockers were tested in the study to observe their interactions with fentanyl's effects?\n",
      "   answer: The study tested several K+ channel blockers, including glibenclamide, tolbutamide, charybdotoxin (ChTX), apamin, tetraethylammonium chloride (TEA), 4-aminopyridine (4-AP), and cesium, to examine their interactions with fentanyl's antinociceptive effects.\n",
      "   text: Target-15665994\n",
      "   table: None\n",
      "\n",
      "5. question: What specific doses of fentanyl were used in the study, and what was the observed effect on mechanical hyperalgesia?\n",
      "   answer: The study used fentanyl doses of 0.5, 1.5, and 3 microg/paw, which reduced mechanical hyperalgesia in a dose-dependent manner with reductions of 17.3%, 45.3%, and 62.6%, respectively.\n",
      "   text: Target-15665994\n",
      "   table: None\n",
      "[{'question': 'How does glibenclamide affect the antinociceptive effect of fentanyl in the study?', 'answer': 'Glibenclamide, a selective blocker of ATP-sensitive K+ channels, dose-dependently antagonized the antinociception induced by fentanyl, as observed in the study with male Wistar rats.', 'text': 'Target-15665994', 'table': 'None'}, {'question': 'What is the role of fentanyl in the study, and what receptor does it primarily target?', 'answer': 'In the study, fentanyl acts as a selective micro-opioid receptor agonist used to promote peripheral antinociception in male Wistar rats. Its antinociceptive effect is dose-dependent and is measured using the paw pressure test.', 'text': 'Target-15665994', 'table': 'None'}, {'question': 'What effect did carrageenan have on the responsiveness to noxious pressure in the study, and how was this measured?', 'answer': 'Carrageenan decreased the threshold of responsiveness to noxious pressure, resulting in mechanical hyperalgesia, which was measured by a reduction in delta of 188.1 +/- 5.3 g in the paw pressure test.', 'text': 'Target-15665994', 'table': 'None'}, {'question': \"Which K+ channel blockers were tested in the study to observe their interactions with fentanyl's effects?\", 'answer': \"The study tested several K+ channel blockers, including glibenclamide, tolbutamide, charybdotoxin (ChTX), apamin, tetraethylammonium chloride (TEA), 4-aminopyridine (4-AP), and cesium, to examine their interactions with fentanyl's antinociceptive effects.\", 'text': 'Target-15665994', 'table': 'None'}, {'question': 'What specific doses of fentanyl were used in the study, and what was the observed effect on mechanical hyperalgesia?', 'answer': 'The study used fentanyl doses of 0.5, 1.5, and 3 microg/paw, which reduced mechanical hyperalgesia in a dose-dependent manner with reductions of 17.3%, 45.3%, and 62.6%, respectively.', 'text': 'Target-15665994', 'table': 'None'}]\n",
      "No table mapping found for passage Target-976190\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 39%|███▉      | 59/150 [04:09<06:01,  3.98s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What are the affinities of amoxapine and loxapine for serotoninergic 5-HT2 receptors, and how do these compare to other receptors?\n",
      "   answer: Amoxapine and loxapine both show high affinities for serotoninergic 5-HT2 receptors, with Ki values less than 10(-7) mol/L. This affinity is higher compared to their moderate affinity for alpha 2 receptors (Ki less than 10(-6) mol/L) and low affinities for Muscarinic and 5-HT1 receptors (Ki less than 10(-5) mol/L). Neither drug shows significant affinity for BZ and beta-adrenergic receptors.\n",
      "   text: Target-1966571\n",
      "   table: None\n",
      "\n",
      "2. question: How do the affinities of amoxapine and loxapine for dopaminergic D1 receptors differ, and what might this imply about their pharmacological effects?\n",
      "   answer: Loxapine has a moderate affinity for dopaminergic D1 receptors, which is nearly 20 times greater than that of amoxapine. This suggests that loxapine may have a stronger influence on D1 receptor-mediated pathways compared to amoxapine, potentially affecting their psychopharmacological profiles differently.\n",
      "   text: Target-1966571\n",
      "   table: None\n",
      "\n",
      "3. question: Which receptors do neither amoxapine nor loxapine show significant affinity for, and why is this relevant to their pharmacological profiles?\n",
      "   answer: Neither amoxapine nor loxapine show significant affinity for benzodiazepine (BZ) and beta-adrenergic receptors. This lack of affinity suggests that these drugs are less likely to influence pathways mediated by these receptors, which may influence their side effect profiles and therapeutic applications.\n",
      "   text: Target-1966571\n",
      "   table: None\n",
      "\n",
      "4. question: In terms of receptor affinity, how does amoxapine's inhibitory effect differ between serotonin and dopamine receptors?\n",
      "   answer: Amoxapine exhibits more potent inhibitory effects on serotonin receptors, particularly 5-HT2, compared to its weaker inhibitory effects on dopamine receptors. This indicates that amoxapine may exert stronger serotonergic effects, which could influence its antidepressant and antipsychotic effects.\n",
      "   text: Target-1966571\n",
      "   table: None\n",
      "[{'question': 'What are the affinities of amoxapine and loxapine for serotoninergic 5-HT2 receptors, and how do these compare to other receptors?', 'answer': 'Amoxapine and loxapine both show high affinities for serotoninergic 5-HT2 receptors, with Ki values less than 10(-7) mol/L. This affinity is higher compared to their moderate affinity for alpha 2 receptors (Ki less than 10(-6) mol/L) and low affinities for Muscarinic and 5-HT1 receptors (Ki less than 10(-5) mol/L). Neither drug shows significant affinity for BZ and beta-adrenergic receptors.', 'text': 'Target-1966571', 'table': 'None'}, {'question': 'How do the affinities of amoxapine and loxapine for dopaminergic D1 receptors differ, and what might this imply about their pharmacological effects?', 'answer': 'Loxapine has a moderate affinity for dopaminergic D1 receptors, which is nearly 20 times greater than that of amoxapine. This suggests that loxapine may have a stronger influence on D1 receptor-mediated pathways compared to amoxapine, potentially affecting their psychopharmacological profiles differently.', 'text': 'Target-1966571', 'table': 'None'}, {'question': 'Which receptors do neither amoxapine nor loxapine show significant affinity for, and why is this relevant to their pharmacological profiles?', 'answer': 'Neither amoxapine nor loxapine show significant affinity for benzodiazepine (BZ) and beta-adrenergic receptors. This lack of affinity suggests that these drugs are less likely to influence pathways mediated by these receptors, which may influence their side effect profiles and therapeutic applications.', 'text': 'Target-1966571', 'table': 'None'}, {'question': \"In terms of receptor affinity, how does amoxapine's inhibitory effect differ between serotonin and dopamine receptors?\", 'answer': 'Amoxapine exhibits more potent inhibitory effects on serotonin receptors, particularly 5-HT2, compared to its weaker inhibitory effects on dopamine receptors. This indicates that amoxapine may exert stronger serotonergic effects, which could influence its antidepressant and antipsychotic effects.', 'text': 'Target-1966571', 'table': 'None'}]\n",
      "No table mapping found for passage Target-7909721\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 41%|████      | 61/150 [04:24<07:46,  5.25s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Certainly! Here are some question-answer pairs based on the provided passage and tables:\n",
      "\n",
      "1. **Question:** What is the EC(50) of cabergoline for preventing neuronal death in the described oxidative stress model, and how does this relate to its mechanism?\n",
      "   - **Answer:** The EC(50) of cabergoline for preventing neuronal death in the oxidative stress model is 1.24 microM. This concentration indicates the effectiveness of cabergoline as a neuroprotective agent, acting in a concentration-dependent manner to prevent cell death. Cabergoline's mechanism involves acting as a dopamine D2 receptor agonist, which may contribute to its neuroprotective effects by increasing intracellular GSH levels and reducing lipid peroxidation.\n",
      "   - **Text:** Target-12464354\n",
      "   - **Table:** None\n",
      "\n",
      "2. **Question:** How does cabergoline's effect on neuronal death compare to its interaction with haloperidol, a known dopamine antagonist?\n",
      "   - **Answer:** Cabergoline's effect on preventing neuronal death was not antagonized by haloperidol, even at concentrations up to 10 microM. This suggests that cabergoline's neuroprotective effects are not inhibited by dopamine D2 receptor antagonism, indicating a possible distinct or additional mechanism of action beyond dopamine receptor interaction.\n",
      "   - **Text:** Target-12464354\n",
      "   - **Table:** None\n",
      "\n",
      "3. **Question:** In the context of the study, what changes in cellular biochemistry were observed with cabergoline treatment, and how might these changes contribute to its use in Parkinson's disease therapy?\n",
      "   - **Answer:** Cabergoline treatment led to a +30±11% increase in intracellular glutathione (GSH) levels and a -23±9% decrease in membrane lipid peroxidation. These changes suggest that cabergoline enhances cellular antioxidant capacity and reduces oxidative damage, which could be beneficial in neurodegenerative diseases like Parkinson's disease where oxidative stress is a contributing factor.\n",
      "   - **Text:** Target-12464354\n",
      "   - **Table:** None\n",
      "\n",
      "4. **Question:** What specific model and oxidative stressor were used in the study to test cabergoline's neuroprotective effects?\n",
      "   - **Answer:** The study used SH-SY5Y human neuroblastoma cells exposed to tert-butylhydroperoxide (t-BOOH) at a concentration of 500 microM to induce oxidative stress. This model helped in evaluating cabergoline's neuroprotective effects against oxidative stress-induced neuronal death.\n",
      "   - **Text:** Target-12464354\n",
      "   - **Table:** None\n",
      "[]\n",
      "No table mapping found for passage Target-8591723\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 42%|████▏     | 63/150 [04:28<06:03,  4.17s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How is etretinate primarily bound in human plasma, and what is its main carrier?\n",
      "   answer: Etretinate is primarily lipoprotein-bound in human plasma, accounting for 75% of plasma etretinate. Its main carrier is low density lipoprotein, which accounts for 48% of the total plasma-bound drug, with a binding constant of 40 x 10(6) M-1.\n",
      "   text: Target-1449542\n",
      "   table: None\n",
      "\n",
      "2. question: What percentage of acitretin is bound to albumin in plasma, and what is the binding constant?\n",
      "   answer: In plasma, 91% of acitretin is bound to albumin, with a binding constant of 0.7 x 10(6) M-1.\n",
      "   text: Target-1449542\n",
      "   table: None\n",
      "\n",
      "3. question: What are the total plasma binding percentages for etretinate and acitretin, and how do their erythrocyte associations compare?\n",
      "   answer: The total plasma binding for both etretinate and acitretin is greater than 99%. In blood, the fractions associated with erythrocytes are 14.5% for etretinate and 8.1% for acitretin.\n",
      "   text: Target-1449542\n",
      "   table: None\n",
      "[{'question': 'How is etretinate primarily bound in human plasma, and what is its main carrier?', 'answer': 'Etretinate is primarily lipoprotein-bound in human plasma, accounting for 75% of plasma etretinate. Its main carrier is low density lipoprotein, which accounts for 48% of the total plasma-bound drug, with a binding constant of 40 x 10(6) M-1.', 'text': 'Target-1449542', 'table': 'None'}, {'question': 'What percentage of acitretin is bound to albumin in plasma, and what is the binding constant?', 'answer': 'In plasma, 91% of acitretin is bound to albumin, with a binding constant of 0.7 x 10(6) M-1.', 'text': 'Target-1449542', 'table': 'None'}, {'question': 'What are the total plasma binding percentages for etretinate and acitretin, and how do their erythrocyte associations compare?', 'answer': 'The total plasma binding for both etretinate and acitretin is greater than 99%. In blood, the fractions associated with erythrocytes are 14.5% for etretinate and 8.1% for acitretin.', 'text': 'Target-1449542', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 43%|████▎     | 64/150 [04:32<05:47,  4.05s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the effect of glucocorticoid administration on memory performance in nonpsychiatric subjects?\n",
      "   answer: In nonpsychiatric subjects, acute glucocorticoid administration selectively impairs working and declarative memory performance.\n",
      "   text: Target-16891588\n",
      "   table: None\n",
      "\n",
      "2. question: What hypothesis was tested regarding subjects with PTSD and their memory impairments after glucocorticoid administration?\n",
      "   answer: It was hypothesized that subjects with PTSD, compared to nonpsychiatric controls, would show greater impairments in verbal declarative memory and working memory, but not attention, following exogenous glucocorticoid administration.\n",
      "   text: Target-16891588\n",
      "   table: None\n",
      "\n",
      "3. question: What procedures were part of the study involving subjects with PTSD to assess their response to glucocorticoids?\n",
      "   answer: Subjects underwent a 0.5-mg dexamethasone suppression test and measurement of basal cortisol, basal plasma lymphocyte glucocorticoid receptor number, and postdexamethasone cortisol on a separate day.\n",
      "   text: Target-16891588\n",
      "   table: None\n",
      "[{'question': 'What is the effect of glucocorticoid administration on memory performance in nonpsychiatric subjects?', 'answer': 'In nonpsychiatric subjects, acute glucocorticoid administration selectively impairs working and declarative memory performance.', 'text': 'Target-16891588', 'table': 'None'}, {'question': 'What hypothesis was tested regarding subjects with PTSD and their memory impairments after glucocorticoid administration?', 'answer': 'It was hypothesized that subjects with PTSD, compared to nonpsychiatric controls, would show greater impairments in verbal declarative memory and working memory, but not attention, following exogenous glucocorticoid administration.', 'text': 'Target-16891588', 'table': 'None'}, {'question': 'What procedures were part of the study involving subjects with PTSD to assess their response to glucocorticoids?', 'answer': 'Subjects underwent a 0.5-mg dexamethasone suppression test and measurement of basal cortisol, basal plasma lymphocyte glucocorticoid receptor number, and postdexamethasone cortisol on a separate day.', 'text': 'Target-16891588', 'table': 'None'}]\n",
      "No table mapping found for passage Target-15509185\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 44%|████▍     | 66/150 [04:40<05:49,  4.16s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the significance of acetylation in the binding affinity of 5-Fluorouracil to human serum albumin?\n",
      "   answer: Acetylation, specifically the acetylation of Lys199, results in a decreased apparent binding affinity constant (nK) for 5-Fluorouracil (FU) when interacting with human serum albumin. This modification can be induced under physiological conditions by aspirin, potentially affecting the drug's efficacy.\n",
      "   text: Target-8573632\n",
      "   table: None\n",
      "\n",
      "2. question: How does 5-Fluorouracil interact with human serum albumin, and what techniques are used to study this interaction?\n",
      "   answer: 5-Fluorouracil is carried in the serum by plasma proteins such as human serum albumin. Its binding interactions have been studied using various spectroscopic techniques, including difference circular dichroism, UV studies, and NMR spectroscopy. These studies revealed that FU has at least one secondary binding site in the coumarin binding area of human serum albumin but does not interact with the benzodiazepine binding area.\n",
      "   text: Target-8573632\n",
      "   table: None\n",
      "\n",
      "3. question: How does the interaction of 5-Fluorouracil with human serum albumin affect its NMR signals?\n",
      "   answer: The binding of 5-Fluorouracil to human serum albumin results in an increase in the 19F NMR signal of FU, which is a key indicator of its interaction. Difference 1H NMR was also used to investigate this binding, providing detailed insights into the molecular interactions involved.\n",
      "   text: Target-8573632\n",
      "   table: None\n",
      "\n",
      "4. question: What specific binding site on human serum albumin does 5-Fluorouracil utilize, and how was this determined?\n",
      "   answer: 5-Fluorouracil utilizes at least one secondary binding site in the coumarin binding area of human serum albumin. This was determined through displacement experiments that indicated FU does not interact with the benzodiazepine binding area.\n",
      "   text: Target-8573632\n",
      "   table: None\n",
      "\n",
      "5. question: What is the role of aspirin in the modification of the binding affinity of 5-Fluorouracil to human serum albumin?\n",
      "   answer: Aspirin induces chemical acetylation of Lys199 on human serum albumin under physiological conditions, which results in a decreased apparent binding affinity constant (nK) for 5-Fluorouracil. This suggests that aspirin could potentially modulate the efficacy of FU by altering its binding dynamics.\n",
      "   text: Target-8573632\n",
      "   table: None\n",
      "[{'question': 'What is the significance of acetylation in the binding affinity of 5-Fluorouracil to human serum albumin?', 'answer': \"Acetylation, specifically the acetylation of Lys199, results in a decreased apparent binding affinity constant (nK) for 5-Fluorouracil (FU) when interacting with human serum albumin. This modification can be induced under physiological conditions by aspirin, potentially affecting the drug's efficacy.\", 'text': 'Target-8573632', 'table': 'None'}, {'question': 'How does 5-Fluorouracil interact with human serum albumin, and what techniques are used to study this interaction?', 'answer': '5-Fluorouracil is carried in the serum by plasma proteins such as human serum albumin. Its binding interactions have been studied using various spectroscopic techniques, including difference circular dichroism, UV studies, and NMR spectroscopy. These studies revealed that FU has at least one secondary binding site in the coumarin binding area of human serum albumin but does not interact with the benzodiazepine binding area.', 'text': 'Target-8573632', 'table': 'None'}, {'question': 'How does the interaction of 5-Fluorouracil with human serum albumin affect its NMR signals?', 'answer': 'The binding of 5-Fluorouracil to human serum albumin results in an increase in the 19F NMR signal of FU, which is a key indicator of its interaction. Difference 1H NMR was also used to investigate this binding, providing detailed insights into the molecular interactions involved.', 'text': 'Target-8573632', 'table': 'None'}, {'question': 'What specific binding site on human serum albumin does 5-Fluorouracil utilize, and how was this determined?', 'answer': '5-Fluorouracil utilizes at least one secondary binding site in the coumarin binding area of human serum albumin. This was determined through displacement experiments that indicated FU does not interact with the benzodiazepine binding area.', 'text': 'Target-8573632', 'table': 'None'}, {'question': 'What is the role of aspirin in the modification of the binding affinity of 5-Fluorouracil to human serum albumin?', 'answer': 'Aspirin induces chemical acetylation of Lys199 on human serum albumin under physiological conditions, which results in a decreased apparent binding affinity constant (nK) for 5-Fluorouracil. This suggests that aspirin could potentially modulate the efficacy of FU by altering its binding dynamics.', 'text': 'Target-8573632', 'table': 'None'}]\n",
      "No table mapping found for passage Target-15094758\n",
      "No table mapping found for passage Target-8818569\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 46%|████▌     | 69/150 [04:49<04:48,  3.56s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does darunavir affect P-glycoprotein (P-gp) expression on lymphocytes compared to raltegravir?\n",
      "   answer: Darunavir exposure caused a moderate, dose-dependent increase in P-glycoprotein (P-gp) expression on total, T, and T helper lymphocytes, whereas raltegravir did not cause such an increase. This observation was supported by the relative frequency of P-gp+ cells and the amount of P-gp molecules present on the cell surface.\n",
      "   text: Target-23707228\n",
      "   table: None\n",
      "\n",
      "2. question: What is the known action of P-glycoprotein 1 in humans according to the drugbank-transporters table?\n",
      "   answer: The known action of P-glycoprotein 1 in humans is listed as \"unknown\" in the drugbank-transporters table. This table provides information about transporters like P-gp, which are relevant to the study of drug interactions and pharmacokinetics, such as those described in the passage regarding darunavir and raltegravir.\n",
      "   text: Target-23707228\n",
      "   table: drugbank-transporters\n",
      "\n",
      "3. question: What experimental method was used to study the functional activity of P-glycoprotein in the passage, and is there any related information in the tables about P-gp function?\n",
      "   answer: The rhodamine-123 efflux test was used to study the functional activity of P-glycoprotein (P-gp) in the passage. The drugbank-transporters table does not provide specific functional activity information for P-glycoprotein, listing its known action as \"unknown.\"\n",
      "   text: Target-23707228\n",
      "   table: drugbank-transporters\n",
      "\n",
      "4. question: Which antiretroviral drugs were tested for their effect on P-glycoprotein expression in the study, and what information is provided about these drugs in the drugbank-drug table?\n",
      "   answer: The antiretroviral drugs tested for their effect on P-glycoprotein expression were darunavir and raltegravir. The drugbank-drug table does not provide specific entries for these drugs but contains detailed entries on other drugs, indicating the type, description, and historical data about drug entries in the database.\n",
      "   text: Target-23707228\n",
      "   table: drugbank-drug\n",
      "[{'question': 'How does darunavir affect P-glycoprotein (P-gp) expression on lymphocytes compared to raltegravir?', 'answer': 'Darunavir exposure caused a moderate, dose-dependent increase in P-glycoprotein (P-gp) expression on total, T, and T helper lymphocytes, whereas raltegravir did not cause such an increase. This observation was supported by the relative frequency of P-gp+ cells and the amount of P-gp molecules present on the cell surface.', 'text': 'Target-23707228', 'table': 'None'}, {'question': 'What is the known action of P-glycoprotein 1 in humans according to the drugbank-transporters table?', 'answer': 'The known action of P-glycoprotein 1 in humans is listed as \"unknown\" in the drugbank-transporters table. This table provides information about transporters like P-gp, which are relevant to the study of drug interactions and pharmacokinetics, such as those described in the passage regarding darunavir and raltegravir.', 'text': 'Target-23707228', 'table': 'drugbank-transporters'}, {'question': 'What experimental method was used to study the functional activity of P-glycoprotein in the passage, and is there any related information in the tables about P-gp function?', 'answer': 'The rhodamine-123 efflux test was used to study the functional activity of P-glycoprotein (P-gp) in the passage. The drugbank-transporters table does not provide specific functional activity information for P-glycoprotein, listing its known action as \"unknown.\"', 'text': 'Target-23707228', 'table': 'drugbank-transporters'}, {'question': 'Which antiretroviral drugs were tested for their effect on P-glycoprotein expression in the study, and what information is provided about these drugs in the drugbank-drug table?', 'answer': 'The antiretroviral drugs tested for their effect on P-glycoprotein expression were darunavir and raltegravir. The drugbank-drug table does not provide specific entries for these drugs but contains detailed entries on other drugs, indicating the type, description, and historical data about drug entries in the database.', 'text': 'Target-23707228', 'table': 'drugbank-drug'}]\n",
      "No table mapping found for passage Target-19951121\n",
      "No table mapping found for passage Target-16192110\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 48%|████▊     | 72/150 [04:55<03:50,  2.95s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the main purpose of studying Memantine's brain uptake in Swiss Outbred mice?\n",
      "   answer: The main purpose of studying Memantine's brain uptake in Swiss Outbred mice is to characterize the mechanisms facilitating its transport across the blood-brain barrier and identify the putative transporter involved in Memantine's disposition into the brain. The study used an in situ transcardiac perfusion technique to conduct this research.\n",
      "   text: Target-24098999\n",
      "   table: None\n",
      "\n",
      "2. question: How does the brain uptake of Memantine demonstrate saturability, and what does this indicate?\n",
      "   answer: The brain uptake of Memantine was observed to be saturable following transcardiac perfusion with increasing concentrations. This indicates that there is a limited capacity or maximum rate at which Memantine can be transported across the blood-brain barrier, suggesting the involvement of specific transporters.\n",
      "   text: Target-24098999\n",
      "   table: None\n",
      "\n",
      "3. question: Which cationic transporter inhibitors were found to reduce Memantine brain uptake, and by what percentage?\n",
      "   answer: The cationic transporter inhibitors amantadine, quinine, tetraethylammonium, choline, and carnitine were found to reduce Memantine brain uptake by up to 55%. This indicates that Memantine's transport across the blood-brain barrier involves cationic transporters.\n",
      "   text: Target-24098999\n",
      "   table: None\n",
      "\n",
      "4. question: What role does extracellular pH play in the brain uptake of Memantine?\n",
      "   answer: The brain uptake of Memantine was found to be dependent on extracellular pH, suggesting that changes in pH levels can affect the efficiency and rate of Memantine transport across the blood-brain barrier.\n",
      "   text: Target-24098999\n",
      "   table: None\n",
      "\n",
      "5. question: Based on the passage, what potential issue is raised regarding Memantine's transport across the blood-brain barrier?\n",
      "   answer: The passage raises the potential issue of drug-drug interactions at the blood-brain barrier due to Memantine's transport mechanisms. Since Memantine is often prescribed with other Alzheimer's disease and non-Alzheimer's disease medications, understanding its transport across the BBB is crucial to identifying possible interactions.\n",
      "   text: Target-24098999\n",
      "   table: None\n",
      "[{'question': \"What is the main purpose of studying Memantine's brain uptake in Swiss Outbred mice?\", 'answer': \"The main purpose of studying Memantine's brain uptake in Swiss Outbred mice is to characterize the mechanisms facilitating its transport across the blood-brain barrier and identify the putative transporter involved in Memantine's disposition into the brain. The study used an in situ transcardiac perfusion technique to conduct this research.\", 'text': 'Target-24098999', 'table': 'None'}, {'question': 'How does the brain uptake of Memantine demonstrate saturability, and what does this indicate?', 'answer': 'The brain uptake of Memantine was observed to be saturable following transcardiac perfusion with increasing concentrations. This indicates that there is a limited capacity or maximum rate at which Memantine can be transported across the blood-brain barrier, suggesting the involvement of specific transporters.', 'text': 'Target-24098999', 'table': 'None'}, {'question': 'Which cationic transporter inhibitors were found to reduce Memantine brain uptake, and by what percentage?', 'answer': \"The cationic transporter inhibitors amantadine, quinine, tetraethylammonium, choline, and carnitine were found to reduce Memantine brain uptake by up to 55%. This indicates that Memantine's transport across the blood-brain barrier involves cationic transporters.\", 'text': 'Target-24098999', 'table': 'None'}, {'question': 'What role does extracellular pH play in the brain uptake of Memantine?', 'answer': 'The brain uptake of Memantine was found to be dependent on extracellular pH, suggesting that changes in pH levels can affect the efficiency and rate of Memantine transport across the blood-brain barrier.', 'text': 'Target-24098999', 'table': 'None'}, {'question': \"Based on the passage, what potential issue is raised regarding Memantine's transport across the blood-brain barrier?\", 'answer': \"The passage raises the potential issue of drug-drug interactions at the blood-brain barrier due to Memantine's transport mechanisms. Since Memantine is often prescribed with other Alzheimer's disease and non-Alzheimer's disease medications, understanding its transport across the BBB is crucial to identifying possible interactions.\", 'text': 'Target-24098999', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 49%|████▊     | 73/150 [05:01<04:27,  3.48s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What are some uses of nicotine besides its interaction with nicotinic acetylcholine receptors, and how has its significance changed over time?\n",
      "   answer: Nicotine has been used as an effective insecticide and its significance was increasingly recognized from toxicological, pharmacological, and environmental perspectives starting in the 1990s. This is due in part to new research on neuronal nicotinic acetylcholine receptors, especially with its potential use in treating Alzheimer's disease due to its impact on cholinergic activity.\n",
      "   text: Target-11006350\n",
      "   table: None\n",
      "\n",
      "2. question: How has nicotine's role evolved in the context of Alzheimer's disease treatment research?\n",
      "   answer: Due to Alzheimer's disease being associated with down-regulation of cholinergic activity in the brain, various nicotine derivatives are currently being tested and developed for treating the disease, highlighting nicotine's evolving role in pharmacological research.\n",
      "   text: Target-11006350\n",
      "   table: None\n",
      "\n",
      "3. question: What public concern regarding nicotine is highlighted in the passage, and why is it significant in pest-control?\n",
      "   answer: Public awareness of the adverse effects of nicotine has reached the highest level recently. Additionally, insect resistance to insecticides remains a critical issue in pest control, making the development of new insecticides that act on different mechanisms an urgent requirement.\n",
      "   text: Target-11006350\n",
      "   table: None\n",
      "[{'question': 'What are some uses of nicotine besides its interaction with nicotinic acetylcholine receptors, and how has its significance changed over time?', 'answer': \"Nicotine has been used as an effective insecticide and its significance was increasingly recognized from toxicological, pharmacological, and environmental perspectives starting in the 1990s. This is due in part to new research on neuronal nicotinic acetylcholine receptors, especially with its potential use in treating Alzheimer's disease due to its impact on cholinergic activity.\", 'text': 'Target-11006350', 'table': 'None'}, {'question': \"How has nicotine's role evolved in the context of Alzheimer's disease treatment research?\", 'answer': \"Due to Alzheimer's disease being associated with down-regulation of cholinergic activity in the brain, various nicotine derivatives are currently being tested and developed for treating the disease, highlighting nicotine's evolving role in pharmacological research.\", 'text': 'Target-11006350', 'table': 'None'}, {'question': 'What public concern regarding nicotine is highlighted in the passage, and why is it significant in pest-control?', 'answer': 'Public awareness of the adverse effects of nicotine has reached the highest level recently. Additionally, insect resistance to insecticides remains a critical issue in pest control, making the development of new insecticides that act on different mechanisms an urgent requirement.', 'text': 'Target-11006350', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 49%|████▉     | 74/150 [05:12<06:02,  4.78s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What are the primary concerns in the clinical use of local anesthetics, and how might this drive research into new anesthetics?\n",
      "   answer: The clinical use of local anesthetics is primarily limited by severe side effects, including arrhythmias and convulsions. These significant side effects make the search for new local anesthetics a high priority in medical research.\n",
      "   text: Target-18574460\n",
      "   table: None\n",
      "\n",
      "2. question: What are the IC(50) values for the block of resting sodium channels (Na(V)1.4) by the halogenated propofol analogues studied?\n",
      "   answer: The IC(50) values for the block of resting sodium channels (Na(V)1.4) are 2.3 microM for 4-iodopropofol, 3.9 microM for 4-bromopropofol, and 11.3 microM for 4-chloropropofol.\n",
      "   text: Target-18574460\n",
      "   table: None\n",
      "\n",
      "3. question: Which compound was tested on neuronal sodium channels (Na(V)1.2) and what was its IC(50) value?\n",
      "   answer: The compound 4-chloropropofol was tested on neuronal sodium channels (Na(V)1.2), and its IC(50) value was found to be 29.2 microM.\n",
      "   text: Target-18574460\n",
      "   table: None\n",
      "\n",
      "4. question: How do the effects of 4-chloropropofol on human skeletal muscle sodium channels compare to its effects on neuronal sodium channels?\n",
      "   answer: 4-Chloropropofol has an IC(50) of 11.3 microM on human skeletal muscle sodium channels (Na(V)1.4) and an IC(50) of 29.2 microM on neuronal sodium channels (Na(V)1.2), indicating it is more potent on the skeletal muscle sodium channels.\n",
      "   text: Target-18574460\n",
      "   table: None\n",
      "\n",
      "5. question: What is the focus of the experimental approach in the study discussed in the passage?\n",
      "   answer: The experimental approach focused on investigating the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound, 4-chloropropofol, on neuronal sodium channels (Na(V)1.2) expressed in a human embryonic kidney cell line.\n",
      "   text: Target-18574460\n",
      "   table: None\n",
      "[{'question': 'What are the primary concerns in the clinical use of local anesthetics, and how might this drive research into new anesthetics?', 'answer': 'The clinical use of local anesthetics is primarily limited by severe side effects, including arrhythmias and convulsions. These significant side effects make the search for new local anesthetics a high priority in medical research.', 'text': 'Target-18574460', 'table': 'None'}, {'question': 'What are the IC(50) values for the block of resting sodium channels (Na(V)1.4) by the halogenated propofol analogues studied?', 'answer': 'The IC(50) values for the block of resting sodium channels (Na(V)1.4) are 2.3 microM for 4-iodopropofol, 3.9 microM for 4-bromopropofol, and 11.3 microM for 4-chloropropofol.', 'text': 'Target-18574460', 'table': 'None'}, {'question': 'Which compound was tested on neuronal sodium channels (Na(V)1.2) and what was its IC(50) value?', 'answer': 'The compound 4-chloropropofol was tested on neuronal sodium channels (Na(V)1.2), and its IC(50) value was found to be 29.2 microM.', 'text': 'Target-18574460', 'table': 'None'}, {'question': 'How do the effects of 4-chloropropofol on human skeletal muscle sodium channels compare to its effects on neuronal sodium channels?', 'answer': '4-Chloropropofol has an IC(50) of 11.3 microM on human skeletal muscle sodium channels (Na(V)1.4) and an IC(50) of 29.2 microM on neuronal sodium channels (Na(V)1.2), indicating it is more potent on the skeletal muscle sodium channels.', 'text': 'Target-18574460', 'table': 'None'}, {'question': 'What is the focus of the experimental approach in the study discussed in the passage?', 'answer': 'The experimental approach focused on investigating the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound, 4-chloropropofol, on neuronal sodium channels (Na(V)1.2) expressed in a human embryonic kidney cell line.', 'text': 'Target-18574460', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 50%|█████     | 75/150 [05:18<06:27,  5.16s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the mechanism of action of Galantamine in the treatment of Alzheimer's disease as described in the passage?\n",
      "   answer: Galantamine has a dual mechanism of action in the treatment of Alzheimer's disease, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase.\n",
      "   text: Target-10971048\n",
      "   table: None\n",
      "\n",
      "2. question: How many patients were enrolled in the Phase III clinical trial programme for Galantamine as per the passage?\n",
      "   answer: Over 3,000 patients with mild-to-moderate Alzheimer's disease were enrolled in the Phase III clinical trial programme for Galantamine.\n",
      "   text: Target-10971048\n",
      "   table: None\n",
      "\n",
      "3. question: What were the findings of the Phase III clinical trials regarding the effectiveness of Galantamine at different doses?\n",
      "   answer: In the Phase III clinical trials, Galantamine was found to be significantly superior to placebo in all five studies at doses of 16, 24, and 32 mg/day, with Galantamine-treated patients maintaining their cognitive function, while placebo-treated patients experienced a significant deterioration in ADAS-cog scores. However, the 32-mg/day dose was not associated with any additional cognitive benefit.\n",
      "   text: Target-10971048\n",
      "   table: None\n",
      "\n",
      "4. question: What scale was used to assess cognitive function in the Galantamine clinical trials, and what was the result?\n",
      "   answer: The Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) was used to assess memory and other cognitive functions in the Galantamine clinical trials. Galantamine-treated patients maintained their cognitive function, whereas placebo-treated patients experienced significant deterioration in ADAS-cog scores.\n",
      "   text: Target-10971048\n",
      "   table: None\n",
      "\n",
      "5. question: Was there any additional cognitive benefit observed with the highest dose of Galantamine administered in the trials?\n",
      "   answer: No, the 32-mg/day dose of Galantamine was not associated with any additional cognitive benefit compared to the lower doses.\n",
      "   text: Target-10971048\n",
      "   table: None\n",
      "[{'question': \"What is the mechanism of action of Galantamine in the treatment of Alzheimer's disease as described in the passage?\", 'answer': \"Galantamine has a dual mechanism of action in the treatment of Alzheimer's disease, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase.\", 'text': 'Target-10971048', 'table': 'None'}, {'question': 'How many patients were enrolled in the Phase III clinical trial programme for Galantamine as per the passage?', 'answer': \"Over 3,000 patients with mild-to-moderate Alzheimer's disease were enrolled in the Phase III clinical trial programme for Galantamine.\", 'text': 'Target-10971048', 'table': 'None'}, {'question': 'What were the findings of the Phase III clinical trials regarding the effectiveness of Galantamine at different doses?', 'answer': 'In the Phase III clinical trials, Galantamine was found to be significantly superior to placebo in all five studies at doses of 16, 24, and 32 mg/day, with Galantamine-treated patients maintaining their cognitive function, while placebo-treated patients experienced a significant deterioration in ADAS-cog scores. However, the 32-mg/day dose was not associated with any additional cognitive benefit.', 'text': 'Target-10971048', 'table': 'None'}, {'question': 'What scale was used to assess cognitive function in the Galantamine clinical trials, and what was the result?', 'answer': \"The Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) was used to assess memory and other cognitive functions in the Galantamine clinical trials. Galantamine-treated patients maintained their cognitive function, whereas placebo-treated patients experienced significant deterioration in ADAS-cog scores.\", 'text': 'Target-10971048', 'table': 'None'}, {'question': 'Was there any additional cognitive benefit observed with the highest dose of Galantamine administered in the trials?', 'answer': 'No, the 32-mg/day dose of Galantamine was not associated with any additional cognitive benefit compared to the lower doses.', 'text': 'Target-10971048', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 51%|█████     | 76/150 [05:29<08:00,  6.50s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does human serum affect the antifungal action of terbinafine and what might be the underlying cause of this effect?\n",
      "   answer: Human serum antagonizes the inhibition of ergosterol biosynthesis by terbinafine in a dose-dependent non-saturable manner. The underlying cause appears to be the non-specific binding of the drug to major serum components, including albumin and lipoproteins such as LDL and HDL. This effect reduces the bioavailability of terbinafine.\n",
      "   text: Target-1287164\n",
      "   table: None\n",
      "\n",
      "2. question: What is the mechanism of action for the allylamine antimycotic terbinafine?\n",
      "   answer: Terbinafine acts by inhibiting ergosterol biosynthesis at the level of squalene epoxidase, which is a critical step in the cell membrane formation of fungi.\n",
      "   text: Target-1287164\n",
      "   table: None\n",
      "\n",
      "3. question: What is the correlation between the lipophilicity of allylamine compounds and their antagonism by serum?\n",
      "   answer: The extent of antagonism by serum correlates with the lipophilicity of the allylamine compounds. This means that more lipophilic compounds like naftifine and SDZ 87-469 experience a similar serum antagonism as terbinafine.\n",
      "   text: Target-1287164\n",
      "   table: None\n",
      "[{'question': 'How does human serum affect the antifungal action of terbinafine and what might be the underlying cause of this effect?', 'answer': 'Human serum antagonizes the inhibition of ergosterol biosynthesis by terbinafine in a dose-dependent non-saturable manner. The underlying cause appears to be the non-specific binding of the drug to major serum components, including albumin and lipoproteins such as LDL and HDL. This effect reduces the bioavailability of terbinafine.', 'text': 'Target-1287164', 'table': 'None'}, {'question': 'What is the mechanism of action for the allylamine antimycotic terbinafine?', 'answer': 'Terbinafine acts by inhibiting ergosterol biosynthesis at the level of squalene epoxidase, which is a critical step in the cell membrane formation of fungi.', 'text': 'Target-1287164', 'table': 'None'}, {'question': 'What is the correlation between the lipophilicity of allylamine compounds and their antagonism by serum?', 'answer': 'The extent of antagonism by serum correlates with the lipophilicity of the allylamine compounds. This means that more lipophilic compounds like naftifine and SDZ 87-469 experience a similar serum antagonism as terbinafine.', 'text': 'Target-1287164', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 51%|█████▏    | 77/150 [05:36<07:55,  6.51s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What experimental model system was used to study the transport of nucleoside analogues such as ribavirin, and which human transporters were expressed in it?\n",
      "   answer: The experimental model system used to study the transport of nucleoside analogues such as ribavirin involved the Xenopus laevis oocyte. This system expressed human concentrative nucleoside transporter 3 and human equilibrative transporter 1.\n",
      "   text: Target-20096989\n",
      "   table: None\n",
      "\n",
      "2. question: How do the two types of nucleoside transporters mentioned in the study differ in their function, and what example of an antiviral drug utilizes these transporters?\n",
      "   answer: The two types of nucleoside transporters are concentrative transporters and equilibrative transporters, which differ in their mechanisms of transporting nucleoside derivatives across cell membranes. An example of an antiviral drug that utilizes these transporters is ribavirin.\n",
      "   text: Target-20096989\n",
      "   table: None\n",
      "\n",
      "3. question: What counterintuitive result was observed in the study after inhibiting one of the nucleoside transporters, and what was the subsequent approach taken by the researchers?\n",
      "   answer: The study observed that the transport of ribavirin could be reduced by inhibiting one of the two types of transporters, which was counterintuitive. As a result, the researchers designed a simple mathematical model to study the dynamics of ribavirin uptake.\n",
      "   text: Target-20096989\n",
      "   table: None\n",
      "\n",
      "4. question: Why are cross-disciplinary approaches necessary in studying the transport of nucleoside analogues like ribavirin, according to the passage?\n",
      "   answer: Cross-disciplinary approaches are necessary in studying the transport of nucleoside analogues like ribavirin because the process of transport across the cell membrane is complex and involves both biological experiments and theoretical considerations.\n",
      "   text: Target-20096989\n",
      "   table: None\n",
      "\n",
      "5. question: What is the significance of using both biological experiments and theoretical models in the study of drug transport across cell membranes?\n",
      "   answer: The significance of using both biological experiments and theoretical models in the study of drug transport across cell membranes lies in the ability to comprehensively understand and analyze the complex processes involved in the transport of drugs like nucleoside analogues. This combined approach allows for a better understanding of how drugs are absorbed and utilized by the body.\n",
      "   text: Target-20096989\n",
      "   table: None\n",
      "[{'question': 'What experimental model system was used to study the transport of nucleoside analogues such as ribavirin, and which human transporters were expressed in it?', 'answer': 'The experimental model system used to study the transport of nucleoside analogues such as ribavirin involved the Xenopus laevis oocyte. This system expressed human concentrative nucleoside transporter 3 and human equilibrative transporter 1.', 'text': 'Target-20096989', 'table': 'None'}, {'question': 'How do the two types of nucleoside transporters mentioned in the study differ in their function, and what example of an antiviral drug utilizes these transporters?', 'answer': 'The two types of nucleoside transporters are concentrative transporters and equilibrative transporters, which differ in their mechanisms of transporting nucleoside derivatives across cell membranes. An example of an antiviral drug that utilizes these transporters is ribavirin.', 'text': 'Target-20096989', 'table': 'None'}, {'question': 'What counterintuitive result was observed in the study after inhibiting one of the nucleoside transporters, and what was the subsequent approach taken by the researchers?', 'answer': 'The study observed that the transport of ribavirin could be reduced by inhibiting one of the two types of transporters, which was counterintuitive. As a result, the researchers designed a simple mathematical model to study the dynamics of ribavirin uptake.', 'text': 'Target-20096989', 'table': 'None'}, {'question': 'Why are cross-disciplinary approaches necessary in studying the transport of nucleoside analogues like ribavirin, according to the passage?', 'answer': 'Cross-disciplinary approaches are necessary in studying the transport of nucleoside analogues like ribavirin because the process of transport across the cell membrane is complex and involves both biological experiments and theoretical considerations.', 'text': 'Target-20096989', 'table': 'None'}, {'question': 'What is the significance of using both biological experiments and theoretical models in the study of drug transport across cell membranes?', 'answer': 'The significance of using both biological experiments and theoretical models in the study of drug transport across cell membranes lies in the ability to comprehensively understand and analyze the complex processes involved in the transport of drugs like nucleoside analogues. This combined approach allows for a better understanding of how drugs are absorbed and utilized by the body.', 'text': 'Target-20096989', 'table': 'None'}]\n",
      "No table mapping found for passage Target-28697165\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 53%|█████▎    | 79/150 [05:48<07:33,  6.39s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the role of P-glycoprotein (P-gp) in drug distribution across the blood-brain barrier, and which psychotropic drugs are identified as substrates for P-gp?\n",
      "   answer: P-glycoprotein (P-gp) acts as a drug transporter, influencing drug distribution across the blood-brain barrier (BBB) by actively extruding drugs into neural capillaries. Several psychotropic drugs, including nortriptyline (NT) and risperidone (Risp), are identified as substrates for P-gp. The related table \"drugbank-transporters\" indicates that P-gp, also known as P-glycoprotein 1, is relevant to humans, but its known action is unknown in the table.\n",
      "   text: Target-16118767\n",
      "   table: drugbank-transporters\n",
      "\n",
      "2. question: How do the V(max)/K(m) ratios of risperidone and its major metabolite, 9-OH-Risperidone, compare, and what does this suggest about their interaction with P-glycoprotein?\n",
      "   answer: The V(max)/K(m) ratios determined by an in vitro ATPase assay for risperidone (Risp) and its major metabolite, 9-OH-Risperidone (OH-Risp), are 2.7 and 0.5, respectively. This suggests that risperidone is a better substrate for P-glycoprotein (P-gp) compared to OH-Risp. The information on P-glycoprotein can be cross-referenced with its listing in the \"drugbank-transporters\" table, where it is identified as P-glycoprotein 1 for humans.\n",
      "   text: Target-16118767\n",
      "   table: drugbank-transporters\n",
      "\n",
      "3. question: What were the effects observed on the brain-serum ratios of risperidone and 9-OH-Risperidone in P-gp knock-out mice compared to control mice?\n",
      "   answer: In Mdr1a (-/-) knock-out mice, the brain-serum ratios of both risperidone (Risp) and 9-OH-Risperidone (OH-Risp) were more than ten times those observed in control mice, with ratios of 14 and 11, respectively. This indicates a significant impact on the distribution of these drugs across the blood-brain barrier due to the absence of P-glycoprotein function. The \"drugbank-transporters\" table lists P-glycoprotein 1, confirming its relevance to drug transport in humans.\n",
      "   text: Target-16118767\n",
      "   table: drugbank-transporters\n",
      "[{'question': 'What is the role of P-glycoprotein (P-gp) in drug distribution across the blood-brain barrier, and which psychotropic drugs are identified as substrates for P-gp?', 'answer': 'P-glycoprotein (P-gp) acts as a drug transporter, influencing drug distribution across the blood-brain barrier (BBB) by actively extruding drugs into neural capillaries. Several psychotropic drugs, including nortriptyline (NT) and risperidone (Risp), are identified as substrates for P-gp. The related table \"drugbank-transporters\" indicates that P-gp, also known as P-glycoprotein 1, is relevant to humans, but its known action is unknown in the table.', 'text': 'Target-16118767', 'table': 'drugbank-transporters'}, {'question': 'How do the V(max)/K(m) ratios of risperidone and its major metabolite, 9-OH-Risperidone, compare, and what does this suggest about their interaction with P-glycoprotein?', 'answer': 'The V(max)/K(m) ratios determined by an in vitro ATPase assay for risperidone (Risp) and its major metabolite, 9-OH-Risperidone (OH-Risp), are 2.7 and 0.5, respectively. This suggests that risperidone is a better substrate for P-glycoprotein (P-gp) compared to OH-Risp. The information on P-glycoprotein can be cross-referenced with its listing in the \"drugbank-transporters\" table, where it is identified as P-glycoprotein 1 for humans.', 'text': 'Target-16118767', 'table': 'drugbank-transporters'}, {'question': 'What were the effects observed on the brain-serum ratios of risperidone and 9-OH-Risperidone in P-gp knock-out mice compared to control mice?', 'answer': 'In Mdr1a (-/-) knock-out mice, the brain-serum ratios of both risperidone (Risp) and 9-OH-Risperidone (OH-Risp) were more than ten times those observed in control mice, with ratios of 14 and 11, respectively. This indicates a significant impact on the distribution of these drugs across the blood-brain barrier due to the absence of P-glycoprotein function. The \"drugbank-transporters\" table lists P-glycoprotein 1, confirming its relevance to drug transport in humans.', 'text': 'Target-16118767', 'table': 'drugbank-transporters'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 53%|█████▎    | 80/150 [05:55<07:32,  6.47s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What are the primary chelators mentioned in the review assessing chelation therapy for cardiovascular disease?\n",
      "   answer: The primary chelators mentioned in the review are ethylenediaminetetraacetic acid (EDTA), deferoxamine, and dexrazoxane (ICRF-187). The majority of the literature focused on these three chelators.\n",
      "   text: Target-9549639\n",
      "   table: None\n",
      "\n",
      "2. question: What is the FDA-approved use of dexrazoxane, and for which patient population is it specifically approved?\n",
      "   answer: Dexrazoxane is approved for parenteral use to reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer.\n",
      "   text: Target-9549639\n",
      "   table: None\n",
      "\n",
      "3. question: How does the review describe the research context of deferoxamine in cardiovascular disease?\n",
      "   answer: The review indicates that studies of deferoxamine are more recent but are mostly limited to animals and ex vivo models, suggesting limited clinical application data for cardiovascular disease.\n",
      "   text: Target-9549639\n",
      "   table: None\n",
      "\n",
      "4. question: What challenge is associated with the mechanism of action of EDTA in the context of cardiovascular disease according to the review?\n",
      "   answer: The review highlights that the mechanism of action of EDTA is poorly understood despite much being written about its beneficial effects historically. There are few controlled studies to support a clear understanding.\n",
      "   text: Target-9549639\n",
      "   table: None\n",
      "[{'question': 'What are the primary chelators mentioned in the review assessing chelation therapy for cardiovascular disease?', 'answer': 'The primary chelators mentioned in the review are ethylenediaminetetraacetic acid (EDTA), deferoxamine, and dexrazoxane (ICRF-187). The majority of the literature focused on these three chelators.', 'text': 'Target-9549639', 'table': 'None'}, {'question': 'What is the FDA-approved use of dexrazoxane, and for which patient population is it specifically approved?', 'answer': 'Dexrazoxane is approved for parenteral use to reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer.', 'text': 'Target-9549639', 'table': 'None'}, {'question': 'How does the review describe the research context of deferoxamine in cardiovascular disease?', 'answer': 'The review indicates that studies of deferoxamine are more recent but are mostly limited to animals and ex vivo models, suggesting limited clinical application data for cardiovascular disease.', 'text': 'Target-9549639', 'table': 'None'}, {'question': 'What challenge is associated with the mechanism of action of EDTA in the context of cardiovascular disease according to the review?', 'answer': 'The review highlights that the mechanism of action of EDTA is poorly understood despite much being written about its beneficial effects historically. There are few controlled studies to support a clear understanding.', 'text': 'Target-9549639', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 54%|█████▍    | 81/150 [06:08<09:10,  7.98s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does bumetanide interact with hepatic bile acid transport systems, and is it associated with any known drugbank transporters?\n",
      "   answer: Bumetanide is suggested to be a substrate for a multispecific bile acid transport system in liver parenchymal cells, but when expressed in Xenopus laevis oocytes, it was not taken up by the cloned bile acid transporters Ntcp and oatp. Instead, it is taken up by a different organic anion transport system. The passage does not directly link bumetanide to any specific drugbank transporters, as information about bumetanide's association with specific transporters is not provided in the tables.\n",
      "   text: Target-8652636\n",
      "   table: drugbank-transporters\n",
      "\n",
      "2. question: What experimental model was used to assess the uptake of bumetanide by hepatic bile acid transporters, and what were the findings?\n",
      "   answer: The experimental model used was the expression of in vitro transcripts of two cloned hepatic bile acid uptake carriers, Ntcp and oatp, in Xenopus laevis oocytes. The findings were that [3H]bumetanide uptake was not increased in this model, although bile acid uptake was stimulated, indicating bumetanide is taken up by a different organic anion transport system.\n",
      "   text: Target-8652636\n",
      "   table: None\n",
      "\n",
      "3. question: What is the role of the Na+/taurocholate cotransporting polypeptide (Ntcp) in the study, and how does it relate to bumetanide's transport?\n",
      "   answer: In the study, Ntcp is one of the hepatic bile acid uptake carriers expressed in Xenopus laevis oocytes to evaluate its role in bumetanide uptake. The result showed that while bile acid uptake was stimulated, bumetanide's uptake was not increased, indicating that Ntcp does not facilitate bumetanide transport, suggesting its uptake is mediated by a different transport system.\n",
      "   text: Target-8652636\n",
      "   table: None\n",
      "\n",
      "4. question: Which non-human organism was used for expressing hepatic bile acid uptake carriers in the study, and what was the purpose?\n",
      "   answer: Xenopus laevis oocytes were used for expressing hepatic bile acid uptake carriers (Ntcp and oatp) in the study. The purpose was to assess whether these carriers could facilitate the uptake of bumetanide, which was not observed, indicating bumetanide is taken up by a different organic anion transport system.\n",
      "   text: Target-8652636\n",
      "   table: None\n",
      "\n",
      "5. question: What conclusion can be drawn about bumetanide's uptake mechanism based on the study's findings?\n",
      "   answer: The study concludes that bumetanide is taken up by a third organic anion transport system, distinct from the cloned hepatic bile acid transporters Ntcp and oatp, as bumetanide uptake was not increased in the Xenopus laevis oocyte model despite the stimulation of bile acid uptake.\n",
      "   text: Target-8652636\n",
      "   table: None\n",
      "[{'question': 'How does bumetanide interact with hepatic bile acid transport systems, and is it associated with any known drugbank transporters?', 'answer': \"Bumetanide is suggested to be a substrate for a multispecific bile acid transport system in liver parenchymal cells, but when expressed in Xenopus laevis oocytes, it was not taken up by the cloned bile acid transporters Ntcp and oatp. Instead, it is taken up by a different organic anion transport system. The passage does not directly link bumetanide to any specific drugbank transporters, as information about bumetanide's association with specific transporters is not provided in the tables.\", 'text': 'Target-8652636', 'table': 'drugbank-transporters'}, {'question': 'What experimental model was used to assess the uptake of bumetanide by hepatic bile acid transporters, and what were the findings?', 'answer': 'The experimental model used was the expression of in vitro transcripts of two cloned hepatic bile acid uptake carriers, Ntcp and oatp, in Xenopus laevis oocytes. The findings were that [3H]bumetanide uptake was not increased in this model, although bile acid uptake was stimulated, indicating bumetanide is taken up by a different organic anion transport system.', 'text': 'Target-8652636', 'table': 'None'}, {'question': \"What is the role of the Na+/taurocholate cotransporting polypeptide (Ntcp) in the study, and how does it relate to bumetanide's transport?\", 'answer': \"In the study, Ntcp is one of the hepatic bile acid uptake carriers expressed in Xenopus laevis oocytes to evaluate its role in bumetanide uptake. The result showed that while bile acid uptake was stimulated, bumetanide's uptake was not increased, indicating that Ntcp does not facilitate bumetanide transport, suggesting its uptake is mediated by a different transport system.\", 'text': 'Target-8652636', 'table': 'None'}, {'question': 'Which non-human organism was used for expressing hepatic bile acid uptake carriers in the study, and what was the purpose?', 'answer': 'Xenopus laevis oocytes were used for expressing hepatic bile acid uptake carriers (Ntcp and oatp) in the study. The purpose was to assess whether these carriers could facilitate the uptake of bumetanide, which was not observed, indicating bumetanide is taken up by a different organic anion transport system.', 'text': 'Target-8652636', 'table': 'None'}, {'question': \"What conclusion can be drawn about bumetanide's uptake mechanism based on the study's findings?\", 'answer': 'The study concludes that bumetanide is taken up by a third organic anion transport system, distinct from the cloned hepatic bile acid transporters Ntcp and oatp, as bumetanide uptake was not increased in the Xenopus laevis oocyte model despite the stimulation of bile acid uptake.', 'text': 'Target-8652636', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 55%|█████▍    | 82/150 [06:15<08:50,  7.80s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What chemotherapy drugs were involved in the development of therapy-related acute myeloblastic leukemia (t-AML) in a 59-year-old female patient?\n",
      "   answer: The chemotherapy drugs involved in the development of therapy-related acute myeloblastic leukemia (t-AML) in the patient were DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, as well as an alkylating agent, cyclophosphamide. The cumulative dose of etoposide was 5500 mg, with 1500 mg administered intravenously and 4000 mg orally.\n",
      "   text: Target-9631585\n",
      "   table: None\n",
      "\n",
      "2. question: What specific genetic abnormalities were identified in the bone marrow cells of the patient who developed AML of FAB M2?\n",
      "   answer: The cytogenetic analysis of the patient's bone marrow cells revealed a deletion of 7q and a rare translocation, t(16;21)(q24;q22). Additionally, fluorescence in situ hybridization (FISH) analysis showed a translocational splitting between chromosome 21 involving the AML1 gene and chromosome 16.\n",
      "   text: Target-9631585\n",
      "   table: None\n",
      "\n",
      "3. question: Was there any detected rearrangement of the AML1 gene in the bone marrow cells of the patient through Southern blot analysis?\n",
      "   answer: No, the Southern blot analysis of the bone marrow cells did not detect any rearrangement of the AML1 gene in the patient.\n",
      "   text: Target-9631585\n",
      "   table: None\n",
      "\n",
      "4. question: What was the method used to confirm the translocational splitting involving the AML1 gene in the patient's bone marrow cells?\n",
      "   answer: The translocational splitting involving the AML1 gene in the patient's bone marrow cells was confirmed using fluorescence in situ hybridization (FISH) analysis at interphase and metaphase.\n",
      "   text: Target-9631585\n",
      "   table: None\n",
      "[{'question': 'What chemotherapy drugs were involved in the development of therapy-related acute myeloblastic leukemia (t-AML) in a 59-year-old female patient?', 'answer': 'The chemotherapy drugs involved in the development of therapy-related acute myeloblastic leukemia (t-AML) in the patient were DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, as well as an alkylating agent, cyclophosphamide. The cumulative dose of etoposide was 5500 mg, with 1500 mg administered intravenously and 4000 mg orally.', 'text': 'Target-9631585', 'table': 'None'}, {'question': 'What specific genetic abnormalities were identified in the bone marrow cells of the patient who developed AML of FAB M2?', 'answer': \"The cytogenetic analysis of the patient's bone marrow cells revealed a deletion of 7q and a rare translocation, t(16;21)(q24;q22). Additionally, fluorescence in situ hybridization (FISH) analysis showed a translocational splitting between chromosome 21 involving the AML1 gene and chromosome 16.\", 'text': 'Target-9631585', 'table': 'None'}, {'question': 'Was there any detected rearrangement of the AML1 gene in the bone marrow cells of the patient through Southern blot analysis?', 'answer': 'No, the Southern blot analysis of the bone marrow cells did not detect any rearrangement of the AML1 gene in the patient.', 'text': 'Target-9631585', 'table': 'None'}, {'question': \"What was the method used to confirm the translocational splitting involving the AML1 gene in the patient's bone marrow cells?\", 'answer': \"The translocational splitting involving the AML1 gene in the patient's bone marrow cells was confirmed using fluorescence in situ hybridization (FISH) analysis at interphase and metaphase.\", 'text': 'Target-9631585', 'table': 'None'}]\n",
      "No table mapping found for passage Target-20706860\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 56%|█████▌    | 84/150 [06:21<06:16,  5.70s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the bioavailability range of hydroxychloroquine and chloroquine when administered orally, and how does malnutrition affect this?\n",
      "   answer: Hydroxychloroquine (HCQ) and chloroquine (CQ) have a bioavailability range of 0.7-0.8 when taken orally. Severe malnutrition, such as kwashiorkor, affects their absorption, but diarrhea does not have an effect.\n",
      "   text: Target-8803904\n",
      "   table: None\n",
      "\n",
      "2. question: How do the half-lives and blood clearance rates of hydroxychloroquine and chloroquine compare, and what variability exists in blood concentrations after dosing?\n",
      "   answer: Both hydroxychloroquine (HCQ) and chloroquine (CQ) have prolonged half-lives of 40 to 50 days and low blood clearance, with hydroxychloroquine having a clearance rate of 96 ml/min. There is significant variability in blood concentrations, with an eleven-fold range observed after similar doses in rheumatoid arthritis (RA) patients.\n",
      "   text: Target-8803904\n",
      "   table: None\n",
      "\n",
      "3. question: What is the percentage of hydroxychloroquine and chloroquine that is excreted unchanged, and what is the primary route of excretion?\n",
      "   answer: Between 21 and 47% of hydroxychloroquine and chloroquine is excreted unchanged, with 40-50% being excreted renally.\n",
      "   text: Target-8803904\n",
      "   table: None\n",
      "\n",
      "4. question: How do hydroxychloroquine and chloroquine interact with proteins in the blood, and what tissues do they bind strongly to?\n",
      "   answer: Hydroxychloroquine (HCQ) and chloroquine (CQ) have protein binding that ranges between 30 and 40%, with binding occurring to both albumin and alpha glycoprotein. They bind strongly to pigmented tissues and also bind to mononuclear cells and muscles.\n",
      "   text: Target-8803904\n",
      "   table: None\n",
      "[{'question': 'What is the bioavailability range of hydroxychloroquine and chloroquine when administered orally, and how does malnutrition affect this?', 'answer': 'Hydroxychloroquine (HCQ) and chloroquine (CQ) have a bioavailability range of 0.7-0.8 when taken orally. Severe malnutrition, such as kwashiorkor, affects their absorption, but diarrhea does not have an effect.', 'text': 'Target-8803904', 'table': 'None'}, {'question': 'How do the half-lives and blood clearance rates of hydroxychloroquine and chloroquine compare, and what variability exists in blood concentrations after dosing?', 'answer': 'Both hydroxychloroquine (HCQ) and chloroquine (CQ) have prolonged half-lives of 40 to 50 days and low blood clearance, with hydroxychloroquine having a clearance rate of 96 ml/min. There is significant variability in blood concentrations, with an eleven-fold range observed after similar doses in rheumatoid arthritis (RA) patients.', 'text': 'Target-8803904', 'table': 'None'}, {'question': 'What is the percentage of hydroxychloroquine and chloroquine that is excreted unchanged, and what is the primary route of excretion?', 'answer': 'Between 21 and 47% of hydroxychloroquine and chloroquine is excreted unchanged, with 40-50% being excreted renally.', 'text': 'Target-8803904', 'table': 'None'}, {'question': 'How do hydroxychloroquine and chloroquine interact with proteins in the blood, and what tissues do they bind strongly to?', 'answer': 'Hydroxychloroquine (HCQ) and chloroquine (CQ) have protein binding that ranges between 30 and 40%, with binding occurring to both albumin and alpha glycoprotein. They bind strongly to pigmented tissues and also bind to mononuclear cells and muscles.', 'text': 'Target-8803904', 'table': 'None'}]\n",
      "No table mapping found for passage Target-8312688\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 57%|█████▋    | 86/150 [06:28<05:09,  4.84s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the main mechanism of digoxin elimination in the human body?\n",
      "   answer: Digoxin is primarily eliminated from the circulation by the kidney, and P-glycoprotein acts as a digoxin pump at the apical membrane of the nephron.\n",
      "   text: Target-14993604\n",
      "   table: drugbank-transporters\n",
      "\n",
      "2. question: Which transporter is known to mediate the transport of digoxin in humans, and how is it characterized?\n",
      "   answer: P-glycoprotein 1 is known to mediate the transport of digoxin in humans, and its action is characterized as unknown in the provided table.\n",
      "   text: Target-14993604\n",
      "   table: drugbank-transporters\n",
      "\n",
      "3. question: What role does the organic anion transporter OATP4C1 play in the human kidney?\n",
      "   answer: The organic anion transporter OATP4C1, which is the first member of the OATP family expressed in the human kidney, is responsible for transporting cardiac glycosides like digoxin, thyroid hormone, cAMP, and methotrexate in a sodium-independent manner.\n",
      "   text: Target-14993604\n",
      "   table: None\n",
      "\n",
      "4. question: What is the significance of the OATP4C1 transporter's genomic organization?\n",
      "   answer: The genomic organization of the OATP4C1 transporter consists of 13 exons located on chromosome 5q21, indicating its specific genetic structure and location in the human genome.\n",
      "   text: Target-14993604\n",
      "   table: None\n",
      "\n",
      "5. question: How does the transport capability of the rat Oatp4c1 compare to the human OATP4C1?\n",
      "   answer: The rat Oatp4c1 transporter, similar to the human OATP4C1, can also transport cardiac glycosides and other compounds, indicating a functional similarity between the human and rat transporters.\n",
      "   text: Target-14993604\n",
      "   table: None\n",
      "[{'question': 'What is the main mechanism of digoxin elimination in the human body?', 'answer': 'Digoxin is primarily eliminated from the circulation by the kidney, and P-glycoprotein acts as a digoxin pump at the apical membrane of the nephron.', 'text': 'Target-14993604', 'table': 'drugbank-transporters'}, {'question': 'Which transporter is known to mediate the transport of digoxin in humans, and how is it characterized?', 'answer': 'P-glycoprotein 1 is known to mediate the transport of digoxin in humans, and its action is characterized as unknown in the provided table.', 'text': 'Target-14993604', 'table': 'drugbank-transporters'}, {'question': 'What role does the organic anion transporter OATP4C1 play in the human kidney?', 'answer': 'The organic anion transporter OATP4C1, which is the first member of the OATP family expressed in the human kidney, is responsible for transporting cardiac glycosides like digoxin, thyroid hormone, cAMP, and methotrexate in a sodium-independent manner.', 'text': 'Target-14993604', 'table': 'None'}, {'question': \"What is the significance of the OATP4C1 transporter's genomic organization?\", 'answer': 'The genomic organization of the OATP4C1 transporter consists of 13 exons located on chromosome 5q21, indicating its specific genetic structure and location in the human genome.', 'text': 'Target-14993604', 'table': 'None'}, {'question': 'How does the transport capability of the rat Oatp4c1 compare to the human OATP4C1?', 'answer': 'The rat Oatp4c1 transporter, similar to the human OATP4C1, can also transport cardiac glycosides and other compounds, indicating a functional similarity between the human and rat transporters.', 'text': 'Target-14993604', 'table': 'None'}]\n",
      "No table mapping found for passage Target-20552178\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 59%|█████▊    | 88/150 [06:32<04:04,  3.95s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What are the neuraminidase inhibitors introduced into clinical practice between 1999 and 2002, and what is their significance?\n",
      "   answer: The neuraminidase inhibitors introduced into clinical practice between 1999 and 2002 are zanamivir and oseltamivir. These drugs are significant as they were introduced to treat influenza and are monitored for resistance development through the Neuraminidase Inhibitor Susceptibility Network, which tests clinical isolates collected by the World Health Organization influenza surveillance network. \n",
      "   text: Target-12821478\n",
      "   table: None\n",
      "\n",
      "2. question: What methods were used to determine the susceptibilities of clinical influenza isolates to NA inhibitors before and after their introduction into clinical practice?\n",
      "   answer: The susceptibilities of clinical influenza isolates to NA inhibitors were determined using enzyme inhibition assays with chemiluminescent or fluorescent substrates. Known NA inhibitor-resistant viruses were used as controls to establish baseline susceptibilities prior to and shortly after the introduction of the NA inhibitors.\n",
      "   text: Target-12821478\n",
      "   table: None\n",
      "\n",
      "3. question: Which network was established to coordinate the testing of clinical isolates for resistance to NA inhibitors, and how is it related to the WHO?\n",
      "   answer: The Neuraminidase Inhibitor Susceptibility Network was established to coordinate the testing of clinical isolates for resistance to NA inhibitors. It is related to the World Health Organization as it collects clinical isolates through the WHO influenza surveillance network from different regions of the world.\n",
      "   text: Target-12821478\n",
      "   table: None\n",
      "[{'question': 'What are the neuraminidase inhibitors introduced into clinical practice between 1999 and 2002, and what is their significance?', 'answer': 'The neuraminidase inhibitors introduced into clinical practice between 1999 and 2002 are zanamivir and oseltamivir. These drugs are significant as they were introduced to treat influenza and are monitored for resistance development through the Neuraminidase Inhibitor Susceptibility Network, which tests clinical isolates collected by the World Health Organization influenza surveillance network.', 'text': 'Target-12821478', 'table': 'None'}, {'question': 'What methods were used to determine the susceptibilities of clinical influenza isolates to NA inhibitors before and after their introduction into clinical practice?', 'answer': 'The susceptibilities of clinical influenza isolates to NA inhibitors were determined using enzyme inhibition assays with chemiluminescent or fluorescent substrates. Known NA inhibitor-resistant viruses were used as controls to establish baseline susceptibilities prior to and shortly after the introduction of the NA inhibitors.', 'text': 'Target-12821478', 'table': 'None'}, {'question': 'Which network was established to coordinate the testing of clinical isolates for resistance to NA inhibitors, and how is it related to the WHO?', 'answer': 'The Neuraminidase Inhibitor Susceptibility Network was established to coordinate the testing of clinical isolates for resistance to NA inhibitors. It is related to the World Health Organization as it collects clinical isolates through the WHO influenza surveillance network from different regions of the world.', 'text': 'Target-12821478', 'table': 'None'}]\n",
      "No table mapping found for passage Target-22909231\n",
      "No table mapping found for passage Target-15258107\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 61%|██████    | 91/150 [06:38<03:02,  3.09s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What are the functions of chlorhexidine and alexidine in relation to bacterial components and TLR activation?\n",
      "   answer: Chlorhexidine and alexidine are amphipathic bisbiguanides that can neutralize bacterial membrane components such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA), which are stimulators of Toll-like receptors (TLRs). Their binding to LPS and LTA was determined using fluorescence displacement assay and isothermal calorimetric titration. These compounds help prevent inflammation by neutralizing the biological effects of LPS and LTA on TLR-activated cellular activation.\n",
      "   text: Target-18635521\n",
      "   table: None\n",
      "\n",
      "2. question: How do chlorhexidine and alexidine affect NF-kappaB activation and NO production in the presence of bacterial components?\n",
      "   answer: Chlorhexidine and alexidine neutralize the biological effects of LPS and LTA, which are known to activate Toll-like receptors (TLRs). This neutralization was assessed by observing NF-kappaB reporter luciferase activation on cells transfected with specific TLRs, as well as the production of nitric oxide (NO) by murine macrophages in the presence of isolated agonists and antibiotic-treated bacteria.\n",
      "   text: Target-18635521\n",
      "   table: None\n",
      "\n",
      "3. question: What methods were used to determine the binding affinity of chlorhexidine and alexidine to bacterial components?\n",
      "   answer: The binding of chlorhexidine and alexidine to bacterial components such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA) was determined using fluorescence displacement assay and isothermal calorimetric titration. These methods helped assess their potential to neutralize these components and prevent inflammation.\n",
      "   text: Target-18635521\n",
      "   table: None\n",
      "[{'question': 'What are the functions of chlorhexidine and alexidine in relation to bacterial components and TLR activation?', 'answer': 'Chlorhexidine and alexidine are amphipathic bisbiguanides that can neutralize bacterial membrane components such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA), which are stimulators of Toll-like receptors (TLRs). Their binding to LPS and LTA was determined using fluorescence displacement assay and isothermal calorimetric titration. These compounds help prevent inflammation by neutralizing the biological effects of LPS and LTA on TLR-activated cellular activation.', 'text': 'Target-18635521', 'table': 'None'}, {'question': 'How do chlorhexidine and alexidine affect NF-kappaB activation and NO production in the presence of bacterial components?', 'answer': 'Chlorhexidine and alexidine neutralize the biological effects of LPS and LTA, which are known to activate Toll-like receptors (TLRs). This neutralization was assessed by observing NF-kappaB reporter luciferase activation on cells transfected with specific TLRs, as well as the production of nitric oxide (NO) by murine macrophages in the presence of isolated agonists and antibiotic-treated bacteria.', 'text': 'Target-18635521', 'table': 'None'}, {'question': 'What methods were used to determine the binding affinity of chlorhexidine and alexidine to bacterial components?', 'answer': 'The binding of chlorhexidine and alexidine to bacterial components such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA) was determined using fluorescence displacement assay and isothermal calorimetric titration. These methods helped assess their potential to neutralize these components and prevent inflammation.', 'text': 'Target-18635521', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 61%|██████▏   | 92/150 [06:44<03:30,  3.64s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does omeprazole treatment affect MRP3 expression in human livers?\n",
      "   answer: Omeprazole treatment significantly increases MRP3 expression in human livers. Patients treated with omeprazole showed a 4.8-fold higher MRP3 protein expression compared to those not receiving the treatment. This indicates that omeprazole is a factor that up-regulates MRP3 expression.\n",
      "   text: Target-12538803\n",
      "   table: None\n",
      "\n",
      "2. question: What is the primary function of MRP3 in hepatocytes and enterocytes?\n",
      "   answer: MRP3 (Multidrug resistance protein 3) primarily functions to transport bile salts and conjugated xenobiotics from hepatocytes and enterocytes into the blood. This transport mechanism is crucial for the detoxification processes in the liver and intestines.\n",
      "   text: Target-12538803\n",
      "   table: None\n",
      "\n",
      "3. question: In the context of cholestasis, how does MRP3 expression change, and what role does omeprazole play in this change?\n",
      "   answer: During cholestasis, hepatic MRP3 expression is markedly up-regulated compared to normal conditions. Omeprazole treatment further increases MRP3 expression, as evidenced by the 4.8-fold higher protein expression in human livers of patients treated with this drug.\n",
      "   text: Target-12538803\n",
      "   table: None\n",
      "\n",
      "4. question: How does omeprazole affect MRP3 expression in HepG2 cells in terms of mRNA and protein levels?\n",
      "   answer: In HepG2 cells, omeprazole treatment induces MRP3 mRNA and protein levels by 2.4-fold and 1.8-fold, respectively. This demonstrates omeprazole's role in enhancing both the transcription and translation of MRP3 in these liver cells.\n",
      "   text: Target-12538803\n",
      "   table: None\n",
      "\n",
      "5. question: What are the known functions of MRP3 in bile salt transport, and how might this be relevant in drug formulations recognized in drugbank-drugs_links?\n",
      "   answer: MRP3 is responsible for transporting bile salts and conjugated xenobiotics from cells into the blood, a critical process for detoxification and bile acid homeostasis. This transporter function is relevant in drug formulations where modulation of bile salt transport could affect drug absorption and efficacy, as might be considered in drugbank-drugs_links when assessing drug interactions and formulations.\n",
      "   text: Target-12538803\n",
      "   table: None\n",
      "[{'question': 'How does omeprazole treatment affect MRP3 expression in human livers?', 'answer': 'Omeprazole treatment significantly increases MRP3 expression in human livers. Patients treated with omeprazole showed a 4.8-fold higher MRP3 protein expression compared to those not receiving the treatment. This indicates that omeprazole is a factor that up-regulates MRP3 expression.', 'text': 'Target-12538803', 'table': 'None'}, {'question': 'What is the primary function of MRP3 in hepatocytes and enterocytes?', 'answer': 'MRP3 (Multidrug resistance protein 3) primarily functions to transport bile salts and conjugated xenobiotics from hepatocytes and enterocytes into the blood. This transport mechanism is crucial for the detoxification processes in the liver and intestines.', 'text': 'Target-12538803', 'table': 'None'}, {'question': 'In the context of cholestasis, how does MRP3 expression change, and what role does omeprazole play in this change?', 'answer': 'During cholestasis, hepatic MRP3 expression is markedly up-regulated compared to normal conditions. Omeprazole treatment further increases MRP3 expression, as evidenced by the 4.8-fold higher protein expression in human livers of patients treated with this drug.', 'text': 'Target-12538803', 'table': 'None'}, {'question': 'How does omeprazole affect MRP3 expression in HepG2 cells in terms of mRNA and protein levels?', 'answer': \"In HepG2 cells, omeprazole treatment induces MRP3 mRNA and protein levels by 2.4-fold and 1.8-fold, respectively. This demonstrates omeprazole's role in enhancing both the transcription and translation of MRP3 in these liver cells.\", 'text': 'Target-12538803', 'table': 'None'}, {'question': 'What are the known functions of MRP3 in bile salt transport, and how might this be relevant in drug formulations recognized in drugbank-drugs_links?', 'answer': 'MRP3 is responsible for transporting bile salts and conjugated xenobiotics from cells into the blood, a critical process for detoxification and bile acid homeostasis. This transporter function is relevant in drug formulations where modulation of bile salt transport could affect drug absorption and efficacy, as might be considered in drugbank-drugs_links when assessing drug interactions and formulations.', 'text': 'Target-12538803', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 62%|██████▏   | 93/150 [06:49<03:35,  3.78s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the role of large-conductance calcium-activated potassium channel beta subunits in the context of thiazide-like diuretics used for treating arterial hypertension?\n",
      "   answer: The large-conductance calcium-activated potassium channel beta subunits are implicated in the mechanism of action of thiazide-like diuretics, which are commonly used to treat arterial hypertension. These diuretics are effective due to their chronic vasodilatory effect, and studies suggest that their efficacy is linked to the activation of these potassium channels.\n",
      "   text: Target-29188803\n",
      "   table: None\n",
      "\n",
      "2. question: How does hydrochlorothiazide contribute to the treatment of arterial hypertension?\n",
      "   answer: Hydrochlorothiazide, a thiazide-like diuretic, is used to treat arterial hypertension by exerting a chronic vasodilatory effect. This effect is suggested to be due to the activation of large conductance calcium-activated potassium channels, which contribute to its efficacy in managing high blood pressure.\n",
      "   text: Target-29188803\n",
      "   table: None\n",
      "\n",
      "3. question: What is the relationship between membrane potentials and the efficacy of thiazide-like diuretics in treating hypertension?\n",
      "   answer: The efficacy of thiazide-like diuretics in treating arterial hypertension is linked to their chronic vasodilatory effect, which involves changes in membrane potentials. These drugs are thought to activate large conductance calcium-activated potassium channels, which play a role in regulating membrane potentials and contributing to their blood pressure-lowering effects.\n",
      "   text: Target-29188803\n",
      "   table: None\n",
      "[{'question': 'What is the role of large-conductance calcium-activated potassium channel beta subunits in the context of thiazide-like diuretics used for treating arterial hypertension?', 'answer': 'The large-conductance calcium-activated potassium channel beta subunits are implicated in the mechanism of action of thiazide-like diuretics, which are commonly used to treat arterial hypertension. These diuretics are effective due to their chronic vasodilatory effect, and studies suggest that their efficacy is linked to the activation of these potassium channels.', 'text': 'Target-29188803', 'table': 'None'}, {'question': 'How does hydrochlorothiazide contribute to the treatment of arterial hypertension?', 'answer': 'Hydrochlorothiazide, a thiazide-like diuretic, is used to treat arterial hypertension by exerting a chronic vasodilatory effect. This effect is suggested to be due to the activation of large conductance calcium-activated potassium channels, which contribute to its efficacy in managing high blood pressure.', 'text': 'Target-29188803', 'table': 'None'}, {'question': 'What is the relationship between membrane potentials and the efficacy of thiazide-like diuretics in treating hypertension?', 'answer': 'The efficacy of thiazide-like diuretics in treating arterial hypertension is linked to their chronic vasodilatory effect, which involves changes in membrane potentials. These drugs are thought to activate large conductance calcium-activated potassium channels, which play a role in regulating membrane potentials and contributing to their blood pressure-lowering effects.', 'text': 'Target-29188803', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 63%|██████▎   | 94/150 [06:57<04:26,  4.75s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What effect does dopamine have on alveolar fluid clearance when administered to rats, and which receptor does it target?\n",
      "   answer: Dopamine, which is a beta-1 adrenergic agonist, had no effect on alveolar fluid clearance when administered either intra-alveolar or intravenously in anesthetized, ventilated rats. It specifically targets the beta-1 receptor.\n",
      "   text: Target-9279221\n",
      "   table: None\n",
      "\n",
      "2. question: How does dobutamine affect alveolar fluid clearance, and what is its receptor profile?\n",
      "   answer: Dobutamine increases alveolar liquid clearance when administered both intra-alveolar and intravenously in anesthetized, ventilated rats. It acts as an agonist for both beta-1 and beta-2 adrenergic receptors.\n",
      "   text: Target-9279221\n",
      "   table: None\n",
      "\n",
      "3. question: What methodology was used to measure alveolar fluid clearance in the study, and what was the role of 125I-albumin?\n",
      "   answer: Alveolar fluid clearance was measured by quantifying the concentrations of labeled and unlabeled albumin after instilling an isosmolar 5% albumin solution in Ringer's lactate with 3 microCi 125I-albumin into the lungs of anesthetized, ventilated rats. The 125I-albumin served as a tracer to facilitate the measurement of liquid clearance.\n",
      "   text: Target-9279221\n",
      "   table: None\n",
      "\n",
      "4. question: Describe the main purpose of the study conducted on beta-adrenergic agonists in the passage.\n",
      "   answer: The main purpose of the study was to determine whether the beta-1 or beta-2 receptor mediates the effect of beta-adrenergic agonist stimulation on increasing alveolar epithelial sodium and fluid transport. This was investigated using dopamine and dobutamine, which are clinically relevant beta-adrenergic agonists.\n",
      "   text: Target-9279221\n",
      "   table: None\n",
      "[{'question': 'What effect does dopamine have on alveolar fluid clearance when administered to rats, and which receptor does it target?', 'answer': 'Dopamine, which is a beta-1 adrenergic agonist, had no effect on alveolar fluid clearance when administered either intra-alveolar or intravenously in anesthetized, ventilated rats. It specifically targets the beta-1 receptor.', 'text': 'Target-9279221', 'table': 'None'}, {'question': 'How does dobutamine affect alveolar fluid clearance, and what is its receptor profile?', 'answer': 'Dobutamine increases alveolar liquid clearance when administered both intra-alveolar and intravenously in anesthetized, ventilated rats. It acts as an agonist for both beta-1 and beta-2 adrenergic receptors.', 'text': 'Target-9279221', 'table': 'None'}, {'question': 'What methodology was used to measure alveolar fluid clearance in the study, and what was the role of 125I-albumin?', 'answer': \"Alveolar fluid clearance was measured by quantifying the concentrations of labeled and unlabeled albumin after instilling an isosmolar 5% albumin solution in Ringer's lactate with 3 microCi 125I-albumin into the lungs of anesthetized, ventilated rats. The 125I-albumin served as a tracer to facilitate the measurement of liquid clearance.\", 'text': 'Target-9279221', 'table': 'None'}, {'question': 'Describe the main purpose of the study conducted on beta-adrenergic agonists in the passage.', 'answer': 'The main purpose of the study was to determine whether the beta-1 or beta-2 receptor mediates the effect of beta-adrenergic agonist stimulation on increasing alveolar epithelial sodium and fluid transport. This was investigated using dopamine and dobutamine, which are clinically relevant beta-adrenergic agonists.', 'text': 'Target-9279221', 'table': 'None'}]\n",
      "No table mapping found for passage Target-14642738\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 64%|██████▍   | 96/150 [07:03<03:37,  4.03s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the method used to identify the structural determinants of steroid binding in the absence of crystallographic data for CATI?\n",
      "   answer: The structural determinants of steroid binding in the absence of crystallographic data for CATI were identified through the construction in vitro of genes encoding chimeric enzymes containing segments of CATI and the related type III variant (CATIII), and site-directed mutagenesis of the gene encoding CATIII, followed by kinetic characterization of the substituted variants.\n",
      "   text: Target-7500366\n",
      "   table: None\n",
      "\n",
      "2. question: Which residues of CATIII were replaced to yield an enzyme variant susceptible to fusidate inhibition, and what was the Ki value for fusidate?\n",
      "   answer: The residues of CATIII that were replaced to yield an enzyme variant susceptible to fusidate inhibition were Gln92, Asn146, Tyr168, and Ile172. The Ki value for fusidate with respect to chloramphenicol was 5.4 microM.\n",
      "   text: Target-7500366\n",
      "   table: None\n",
      "\n",
      "3. question: How is the inhibitory action of fusidate on CATI characterized in the passage?\n",
      "   answer: The inhibitory action of fusidate on CATI is characterized as a competitive inhibition with respect to chloramphenicol.\n",
      "   text: Target-7500366\n",
      "   table: None\n",
      "\n",
      "4. question: What technique was used to determine the structure of the complex of fusidate and the enzyme variant at 2.2 A resolution?\n",
      "   answer: X-ray crystallography was used to determine the structure of the complex of fusidate and the enzyme variant at 2.2 A resolution.\n",
      "   text: Target-7500366\n",
      "   table: None\n",
      "\n",
      "5. question: What is the relationship between fusidic acid and the type I variant of chloramphenicol acetyltransferase (CATI)?\n",
      "   answer: Fusidic acid and certain closely related steroidal compounds are potent competitive inhibitors of the type I variant of chloramphenicol acetyltransferase (CATI).\n",
      "   text: Target-7500366\n",
      "   table: None\n",
      "[{'question': 'What is the method used to identify the structural determinants of steroid binding in the absence of crystallographic data for CATI?', 'answer': 'The structural determinants of steroid binding in the absence of crystallographic data for CATI were identified through the construction in vitro of genes encoding chimeric enzymes containing segments of CATI and the related type III variant (CATIII), and site-directed mutagenesis of the gene encoding CATIII, followed by kinetic characterization of the substituted variants.', 'text': 'Target-7500366', 'table': 'None'}, {'question': 'Which residues of CATIII were replaced to yield an enzyme variant susceptible to fusidate inhibition, and what was the Ki value for fusidate?', 'answer': 'The residues of CATIII that were replaced to yield an enzyme variant susceptible to fusidate inhibition were Gln92, Asn146, Tyr168, and Ile172. The Ki value for fusidate with respect to chloramphenicol was 5.4 microM.', 'text': 'Target-7500366', 'table': 'None'}, {'question': 'How is the inhibitory action of fusidate on CATI characterized in the passage?', 'answer': 'The inhibitory action of fusidate on CATI is characterized as a competitive inhibition with respect to chloramphenicol.', 'text': 'Target-7500366', 'table': 'None'}, {'question': 'What technique was used to determine the structure of the complex of fusidate and the enzyme variant at 2.2 A resolution?', 'answer': 'X-ray crystallography was used to determine the structure of the complex of fusidate and the enzyme variant at 2.2 A resolution.', 'text': 'Target-7500366', 'table': 'None'}, {'question': 'What is the relationship between fusidic acid and the type I variant of chloramphenicol acetyltransferase (CATI)?', 'answer': 'Fusidic acid and certain closely related steroidal compounds are potent competitive inhibitors of the type I variant of chloramphenicol acetyltransferase (CATI).', 'text': 'Target-7500366', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 65%|██████▍   | 97/150 [07:08<03:53,  4.40s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the target organism for the antiretroviral nucleoside analog didanosine and what is the method used for its biosynthetic pathway construction?\n",
      "   answer: The target organism for didanosine is humans, as it is used as an antiretroviral treatment. The biosynthetic pathway for didanosine was constructed using 'bioretrosynthesis', which applies the retrograde evolution hypothesis. This method involved engineering a pathway starting with a retro-extension from an engineered purine nucleoside phosphorylase and evolving enzymes like 1,5-phosphopentomutase and ribokinase for improved substrate selectivity and nucleoside production.\n",
      "   text: Target-24657930\n",
      "   table: None\n",
      "\n",
      "2. question: How was the enzyme 1,5-phosphopentomutase modified to enhance the synthesis of didanosine, and what was the extent of this enhancement?\n",
      "   answer: The enzyme 1,5-phosphopentomutase was evolved to accept the substrate 2,3-dideoxyribose 5-phosphate, resulting in a 700-fold change in substrate selectivity and a threefold increase in turnover in cell lysate, contributing to the synthesis of didanosine.\n",
      "   text: Target-24657930\n",
      "   table: None\n",
      "\n",
      "3. question: Describe the role and modification of ribokinase in the engineered pathway for didanosine production.\n",
      "   answer: Ribokinase was engineered as part of a subsequent retrograde pathway extension, which led to a didanosine pathway with a significant enhancement in production metrics. This engineering resulted in a 9,500-fold change in nucleoside production selectivity and a 50-fold increase in overall production, showcasing its critical role in the bioretrosynthesis approach.\n",
      "   text: Target-24657930\n",
      "   table: None\n",
      "[{'question': 'What is the target organism for the antiretroviral nucleoside analog didanosine and what is the method used for its biosynthetic pathway construction?', 'answer': \"The target organism for didanosine is humans, as it is used as an antiretroviral treatment. The biosynthetic pathway for didanosine was constructed using 'bioretrosynthesis', which applies the retrograde evolution hypothesis. This method involved engineering a pathway starting with a retro-extension from an engineered purine nucleoside phosphorylase and evolving enzymes like 1,5-phosphopentomutase and ribokinase for improved substrate selectivity and nucleoside production.\", 'text': 'Target-24657930', 'table': 'None'}, {'question': 'How was the enzyme 1,5-phosphopentomutase modified to enhance the synthesis of didanosine, and what was the extent of this enhancement?', 'answer': 'The enzyme 1,5-phosphopentomutase was evolved to accept the substrate 2,3-dideoxyribose 5-phosphate, resulting in a 700-fold change in substrate selectivity and a threefold increase in turnover in cell lysate, contributing to the synthesis of didanosine.', 'text': 'Target-24657930', 'table': 'None'}, {'question': 'Describe the role and modification of ribokinase in the engineered pathway for didanosine production.', 'answer': 'Ribokinase was engineered as part of a subsequent retrograde pathway extension, which led to a didanosine pathway with a significant enhancement in production metrics. This engineering resulted in a 9,500-fold change in nucleoside production selectivity and a 50-fold increase in overall production, showcasing its critical role in the bioretrosynthesis approach.', 'text': 'Target-24657930', 'table': 'None'}]\n",
      "No table mapping found for passage Target-12920163\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 66%|██████▌   | 99/150 [07:14<03:10,  3.73s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the effect of glyburide on mitochondrial KATP channels when the channels are in an open state induced by Mg2+, ATP, and a pharmacological opener like diazoxide?\n",
      "   answer: Glyburide inhibits the mitochondrial KATP channels when they are in an open state induced by Mg2+, ATP, and a pharmacological opener such as diazoxide, with K1/2 values ranging from 1-6 microM. This suggests that under these conditions, the mitoKATP channel becomes highly sensitive to glyburide.\n",
      "   text: Target-9593694\n",
      "   table: None\n",
      "\n",
      "2. question: How does 5-hydroxydecanoate (5-HD) affect mitochondrial KATP channels under different experimental conditions?\n",
      "   answer: 5-hydroxydecanoate (5-HD) does not affect mitochondrial KATP channels when the channels are in an open state induced by the absence of ATP and Mg2+. However, 5-HD inhibits the channels when they are in an open state induced by Mg2+, ATP, and a physiological or pharmacological opener, such as GTP or diazoxide, with K1/2 values ranging from 45-75 microM.\n",
      "   text: Target-9593694\n",
      "   table: None\n",
      "\n",
      "3. question: In the context of cardioprotective effects, what is the role of the mitochondrial KATP channel with respect to K+ channel openers (KCO) and glyburide?\n",
      "   answer: The mitochondrial KATP channel is believed to be the receptor mediating the cardioprotective effects of K+ channel openers (KCO). It is also involved in the blocking of cardioprotection by glyburide. However, under certain experimental conditions, the mitoKATP channel shows insensitivity to glyburide unless the open state is induced by factors such as Mg2+, ATP, and diazoxide.\n",
      "   text: Target-9593694\n",
      "   table: None\n",
      "[{'question': 'What is the effect of glyburide on mitochondrial KATP channels when the channels are in an open state induced by Mg2+, ATP, and a pharmacological opener like diazoxide?', 'answer': 'Glyburide inhibits the mitochondrial KATP channels when they are in an open state induced by Mg2+, ATP, and a pharmacological opener such as diazoxide, with K1/2 values ranging from 1-6 microM. This suggests that under these conditions, the mitoKATP channel becomes highly sensitive to glyburide.', 'text': 'Target-9593694', 'table': 'None'}, {'question': 'How does 5-hydroxydecanoate (5-HD) affect mitochondrial KATP channels under different experimental conditions?', 'answer': '5-hydroxydecanoate (5-HD) does not affect mitochondrial KATP channels when the channels are in an open state induced by the absence of ATP and Mg2+. However, 5-HD inhibits the channels when they are in an open state induced by Mg2+, ATP, and a physiological or pharmacological opener, such as GTP or diazoxide, with K1/2 values ranging from 45-75 microM.', 'text': 'Target-9593694', 'table': 'None'}, {'question': 'In the context of cardioprotective effects, what is the role of the mitochondrial KATP channel with respect to K+ channel openers (KCO) and glyburide?', 'answer': 'The mitochondrial KATP channel is believed to be the receptor mediating the cardioprotective effects of K+ channel openers (KCO). It is also involved in the blocking of cardioprotection by glyburide. However, under certain experimental conditions, the mitoKATP channel shows insensitivity to glyburide unless the open state is induced by factors such as Mg2+, ATP, and diazoxide.', 'text': 'Target-9593694', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 67%|██████▋   | 100/150 [07:23<04:01,  4.84s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does the presence of CYP2D6 allelic variants impact the clinical outcome of patients receiving tamoxifen?\n",
      "   answer: The presence of CYP2D6 allelic variants is significantly associated with shorter recurrence-free survival in patients receiving tamoxifen. This suggests that genetic polymorphisms in the CYP2D6 enzyme can influence the drug's efficacy in treating hormone receptor-positive, invasive breast cancer.\n",
      "   text: Target-20124171\n",
      "   table: None\n",
      "\n",
      "2. question: Which transporter genes were studied for their polymorphisms in relation to tamoxifen treatment outcomes?\n",
      "   answer: The study investigated polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 in relation to tamoxifen treatment outcomes. These polymorphisms, along with CYP2D6 variants, were analyzed for their effects on recurrence-free survival in patients receiving tamoxifen.\n",
      "   text: Target-20124171\n",
      "   table: None\n",
      "\n",
      "3. question: What is the known action of P-glycoprotein 1 as a transporter, and how does this relate to the study on tamoxifen?\n",
      "   answer: The known action of P-glycoprotein 1 as a transporter is listed as \"unknown\" in the drugbank-transporters table. In the study on tamoxifen, polymorphisms in transporter genes like ABCB1, which encodes for P-glycoprotein 1, were investigated to understand their potential impact on the drug's metabolism and efficacy, despite the unknown action of P-glycoprotein 1.\n",
      "   text: Target-20124171\n",
      "   table: drugbank-transporters\n",
      "\n",
      "4. question: How was recurrence-free survival measured in the study of tamoxifen's efficacy, and which statistical methods were used?\n",
      "   answer: Recurrence-free survival in the study of tamoxifen's efficacy was measured using the Kaplan-Meier method and Cox regression analysis. These statistical methods were employed to investigate the effects of genetic polymorphisms on the clinical outcomes of tamoxifen treatment in breast cancer patients.\n",
      "   text: Target-20124171\n",
      "   table: None\n",
      "[{'question': 'How does the presence of CYP2D6 allelic variants impact the clinical outcome of patients receiving tamoxifen?', 'answer': \"The presence of CYP2D6 allelic variants is significantly associated with shorter recurrence-free survival in patients receiving tamoxifen. This suggests that genetic polymorphisms in the CYP2D6 enzyme can influence the drug's efficacy in treating hormone receptor-positive, invasive breast cancer.\", 'text': 'Target-20124171', 'table': 'None'}, {'question': 'Which transporter genes were studied for their polymorphisms in relation to tamoxifen treatment outcomes?', 'answer': 'The study investigated polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 in relation to tamoxifen treatment outcomes. These polymorphisms, along with CYP2D6 variants, were analyzed for their effects on recurrence-free survival in patients receiving tamoxifen.', 'text': 'Target-20124171', 'table': 'None'}, {'question': 'What is the known action of P-glycoprotein 1 as a transporter, and how does this relate to the study on tamoxifen?', 'answer': 'The known action of P-glycoprotein 1 as a transporter is listed as \"unknown\" in the drugbank-transporters table. In the study on tamoxifen, polymorphisms in transporter genes like ABCB1, which encodes for P-glycoprotein 1, were investigated to understand their potential impact on the drug\\'s metabolism and efficacy, despite the unknown action of P-glycoprotein 1.', 'text': 'Target-20124171', 'table': 'drugbank-transporters'}, {'question': \"How was recurrence-free survival measured in the study of tamoxifen's efficacy, and which statistical methods were used?\", 'answer': \"Recurrence-free survival in the study of tamoxifen's efficacy was measured using the Kaplan-Meier method and Cox regression analysis. These statistical methods were employed to investigate the effects of genetic polymorphisms on the clinical outcomes of tamoxifen treatment in breast cancer patients.\", 'text': 'Target-20124171', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 67%|██████▋   | 101/150 [07:33<05:01,  6.14s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does the use of levonorgestrel-releasing IUS affect endometrial proliferation and apoptosis, and what implications does this have for the management of menorrhagic women with uterine myomas?\n",
      "   answer: The use of levonorgestrel-releasing intrauterine system (IUS) results in a remarkable decrease in endometrial proliferation and a significant increase in apoptosis in the endometrium. This makes it effective for the long-term management of menorrhagic women with uterine myomas due to the striking reduction in menorrhagia.\n",
      "   text: Target-17531625\n",
      "   table: None\n",
      "\n",
      "2. question: What effect does progesterone (P(4)) have on uterine leiomyoma cells compared to normal myometrial cells, and what molecular changes does it induce?\n",
      "   answer: Progesterone (P(4)) stimulates the proliferative activity in uterine leiomyoma cells but does not affect normal myometrial cells. It increases EGF expression and augments EGF-R expression in leiomyoma cells, indicating a combined effect with E(2) in stimulating cell growth. Additionally, P(4) increases Bcl-2 expression and decreases TNF-alpha expression.\n",
      "   text: Target-17531625\n",
      "   table: None\n",
      "\n",
      "3. question: What is the role of epidermal growth factor receptor (EGF-R) in the growth of leiomyoma cells, and how is it influenced by other factors in the study?\n",
      "   answer: In the study, EGF-R expression in leiomyoma cells is augmented by E(2), and this receptor plays a role in cell growth stimulation when combined with P(4), which increases EGF expression. This indicates that both E(2) and P(4) work together to promote leiomyoma cell growth through EGF-R.\n",
      "   text: Target-17531625\n",
      "   table: None\n",
      "[{'question': 'How does the use of levonorgestrel-releasing IUS affect endometrial proliferation and apoptosis, and what implications does this have for the management of menorrhagic women with uterine myomas?', 'answer': 'The use of levonorgestrel-releasing intrauterine system (IUS) results in a remarkable decrease in endometrial proliferation and a significant increase in apoptosis in the endometrium. This makes it effective for the long-term management of menorrhagic women with uterine myomas due to the striking reduction in menorrhagia.', 'text': 'Target-17531625', 'table': 'None'}, {'question': 'What effect does progesterone (P(4)) have on uterine leiomyoma cells compared to normal myometrial cells, and what molecular changes does it induce?', 'answer': 'Progesterone (P(4)) stimulates the proliferative activity in uterine leiomyoma cells but does not affect normal myometrial cells. It increases EGF expression and augments EGF-R expression in leiomyoma cells, indicating a combined effect with E(2) in stimulating cell growth. Additionally, P(4) increases Bcl-2 expression and decreases TNF-alpha expression.', 'text': 'Target-17531625', 'table': 'None'}, {'question': 'What is the role of epidermal growth factor receptor (EGF-R) in the growth of leiomyoma cells, and how is it influenced by other factors in the study?', 'answer': 'In the study, EGF-R expression in leiomyoma cells is augmented by E(2), and this receptor plays a role in cell growth stimulation when combined with P(4), which increases EGF expression. This indicates that both E(2) and P(4) work together to promote leiomyoma cell growth through EGF-R.', 'text': 'Target-17531625', 'table': 'None'}]\n",
      "No table mapping found for passage Target-2828440\n",
      "No table mapping found for passage Target-21175441\n",
      "No table mapping found for passage Target-22205779\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 70%|███████   | 105/150 [07:42<02:55,  3.90s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does the 5-HT (2C/2B) receptor antagonist SB 206553 affect imipramine-induced hyperglycemia in mice?\n",
      "   answer: The 5-HT (2C/2B) receptor antagonist SB 206553 augments or enhances the hyperglycemia induced by imipramine in mice, according to the study. The passage describes the effects of imipramine and mentions that it induces dose-dependent hyperglycemia, which is further enhanced by SB 206553.\n",
      "   text: Target-14517765\n",
      "   table: None\n",
      "\n",
      "2. question: What is the role of the 5-HT (2C/2B) receptor agonist 1-(3-chlorophenyl)piperazine (mCPP) in imipramine-induced hyperglycemia?\n",
      "   answer: The 5-HT (2C/2B) receptor agonist 1-(3-chlorophenyl)piperazine (mCPP) antagonizes or reduces the hyperglycemia induced by imipramine in mice. The passage indicates that mCPP has an antagonizing effect on the hyperglycemic response caused by imipramine.\n",
      "   text: Target-14517765\n",
      "   table: None\n",
      "\n",
      "3. question: What effect does adrenalectomy have on hyperglycemia induced by central injection of imipramine in mice?\n",
      "   answer: Adrenalectomy abolishes the hyperglycemia elicited by the central injection of imipramine in mice. This suggests that the adrenal glands play a significant role in the hyperglycemic response to imipramine.\n",
      "   text: Target-14517765\n",
      "   table: None\n",
      "\n",
      "4. question: Which 5-HT receptor antagonists were found to have no effect on imipramine-induced hyperglycemia?\n",
      "   answer: The 5-HT (1A) and 5-HT (1B) receptor antagonist (-)-propranolol, the 5-HT (2A) receptor antagonist ketanserin, and the 5-HT (3/4) receptor antagonist tropisetron each had no effect on imipramine-induced hyperglycemia in mice. These findings are detailed in the passage, showing that not all 5-HT receptor antagonists influence the hyperglycemic effect of imipramine.\n",
      "   text: Target-14517765\n",
      "   table: None\n",
      "\n",
      "5. question: How does the 5-HT (2B) receptor agonist BW 723C86 affect imipramine-induced hyperglycemia?\n",
      "   answer: The 5-HT (2B) receptor agonist BW 723C86 has no effect on the hyperglycemia induced by imipramine in mice. The passage clearly states that unlike 1-(3-chlorophenyl)piperazine (mCPP), BW 723C86 does not alter the hyperglycemic response to imipramine.\n",
      "   text: Target-14517765\n",
      "   table: None\n",
      "[{'question': 'How does the 5-HT (2C/2B) receptor antagonist SB 206553 affect imipramine-induced hyperglycemia in mice?', 'answer': 'The 5-HT (2C/2B) receptor antagonist SB 206553 augments or enhances the hyperglycemia induced by imipramine in mice, according to the study. The passage describes the effects of imipramine and mentions that it induces dose-dependent hyperglycemia, which is further enhanced by SB 206553.', 'text': 'Target-14517765', 'table': 'None'}, {'question': 'What is the role of the 5-HT (2C/2B) receptor agonist 1-(3-chlorophenyl)piperazine (mCPP) in imipramine-induced hyperglycemia?', 'answer': 'The 5-HT (2C/2B) receptor agonist 1-(3-chlorophenyl)piperazine (mCPP) antagonizes or reduces the hyperglycemia induced by imipramine in mice. The passage indicates that mCPP has an antagonizing effect on the hyperglycemic response caused by imipramine.', 'text': 'Target-14517765', 'table': 'None'}, {'question': 'What effect does adrenalectomy have on hyperglycemia induced by central injection of imipramine in mice?', 'answer': 'Adrenalectomy abolishes the hyperglycemia elicited by the central injection of imipramine in mice. This suggests that the adrenal glands play a significant role in the hyperglycemic response to imipramine.', 'text': 'Target-14517765', 'table': 'None'}, {'question': 'Which 5-HT receptor antagonists were found to have no effect on imipramine-induced hyperglycemia?', 'answer': 'The 5-HT (1A) and 5-HT (1B) receptor antagonist (-)-propranolol, the 5-HT (2A) receptor antagonist ketanserin, and the 5-HT (3/4) receptor antagonist tropisetron each had no effect on imipramine-induced hyperglycemia in mice. These findings are detailed in the passage, showing that not all 5-HT receptor antagonists influence the hyperglycemic effect of imipramine.', 'text': 'Target-14517765', 'table': 'None'}, {'question': 'How does the 5-HT (2B) receptor agonist BW 723C86 affect imipramine-induced hyperglycemia?', 'answer': 'The 5-HT (2B) receptor agonist BW 723C86 has no effect on the hyperglycemia induced by imipramine in mice. The passage clearly states that unlike 1-(3-chlorophenyl)piperazine (mCPP), BW 723C86 does not alter the hyperglycemic response to imipramine.', 'text': 'Target-14517765', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 71%|███████   | 106/150 [07:50<03:25,  4.66s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does the genetic polymorphism in the human nicotinic alpha4beta2 receptor affect the auditory and visual event-related potentials?\n",
      "   answer: The genetic polymorphism c.1629T-C (Ser543Ser) in the human nicotinic alpha4beta2 receptor preferentially modulates early components of the cognitive event-related potentials in both auditory and visual modalities. Specifically, the auditory N1 component amplitude is higher in individuals who are T allele homozygotes compared to C allele carriers. In the visual modality, the P1 component shows significant polymorphic modulation, while the later N1 amplitude differences are marginally significant.\n",
      "   text: Target-17590520\n",
      "   table: None\n",
      "\n",
      "2. question: What is the significance of the thymine-to-cytosine polymorphism (c.1629T-C) in terms of top-down modulation of sensory processing?\n",
      "   answer: The thymine-to-cytosine polymorphism (c.1629T-C) in the nicotinic alpha4beta2 receptor appears to modulate early latency modality-specific event-related potential (ERP) components in both vision and audition. This parallel modulation suggests that the CHRNA4 polymorphism affects factors that are common to the top-down modulation of sensory processing across different sensory modalities.\n",
      "   text: Target-17590520\n",
      "   table: None\n",
      "\n",
      "3. question: What can be inferred about the interactions between genotype and task factors in relation to the CHRNA4 polymorphism?\n",
      "   answer: The study found no reliable indication of interactions between genotype and task factors concerning the CHRNA4 polymorphism. This suggests that the polymorphism's influence on cognitive event-related potentials is consistent across different tasks, implying a general rather than task-specific effect.\n",
      "   text: Target-17590520\n",
      "   table: None\n",
      "[{'question': 'How does the genetic polymorphism in the human nicotinic alpha4beta2 receptor affect the auditory and visual event-related potentials?', 'answer': 'The genetic polymorphism c.1629T-C (Ser543Ser) in the human nicotinic alpha4beta2 receptor preferentially modulates early components of the cognitive event-related potentials in both auditory and visual modalities. Specifically, the auditory N1 component amplitude is higher in individuals who are T allele homozygotes compared to C allele carriers. In the visual modality, the P1 component shows significant polymorphic modulation, while the later N1 amplitude differences are marginally significant.', 'text': 'Target-17590520', 'table': 'None'}, {'question': 'What is the significance of the thymine-to-cytosine polymorphism (c.1629T-C) in terms of top-down modulation of sensory processing?', 'answer': 'The thymine-to-cytosine polymorphism (c.1629T-C) in the nicotinic alpha4beta2 receptor appears to modulate early latency modality-specific event-related potential (ERP) components in both vision and audition. This parallel modulation suggests that the CHRNA4 polymorphism affects factors that are common to the top-down modulation of sensory processing across different sensory modalities.', 'text': 'Target-17590520', 'table': 'None'}, {'question': 'What can be inferred about the interactions between genotype and task factors in relation to the CHRNA4 polymorphism?', 'answer': \"The study found no reliable indication of interactions between genotype and task factors concerning the CHRNA4 polymorphism. This suggests that the polymorphism's influence on cognitive event-related potentials is consistent across different tasks, implying a general rather than task-specific effect.\", 'text': 'Target-17590520', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 71%|███████▏  | 107/150 [08:07<04:58,  6.94s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the role of the inactivated channel conformation in the mechanism of Ca(2+) channel block by 1,4-dihydropyridine (DHP) drugs, specifically (+)-isradipine?\n",
      "   answer: The inactivated channel conformation plays a crucial role in the molecular mechanism of Ca(2+) channel block by the 1,4-dihydropyridine (DHP) drug (+)-isradipine. The analysis was conducted using L-type channel constructs and a DHP-sensitive class A Ca(2+) channel mutant. These constructs carry high affinity determinants of the DHP receptor site but inactivate at different rates, indicating the significance of inactivation in the blocking process.\n",
      "   text: Target-10766758\n",
      "   table: None\n",
      "\n",
      "2. question: How was Ca(2+) channel inactivation modulated in the study of (+)-isradipine's effect, and what were the specific mutations used?\n",
      "   answer: In the study of (+)-isradipine's effect, Ca(2+) channel inactivation was modulated by coexpressing the alpha(1A-DHP)- or alpha(1Lc)-subunits in Xenopus oocytes with either the beta(2a)- or the beta(1a)-subunit. Additionally, amino acid substitutions in the L-type segment IVS6, specifically I1497A, I1498A, and V1504A, were utilized to study the effect on channel inactivation.\n",
      "   text: Target-10766758\n",
      "   table: None\n",
      "\n",
      "3. question: What type of drug is (+)-isradipine, and what is its mechanism of action related to Ca(2+) channels?\n",
      "   answer: (+)-isradipine is a 1,4-dihydropyridine (DHP) drug that acts as a blocker of Ca(2+) channels. Its mechanism of action involves binding to the inactivated conformation of the channel, which is crucial for its blocking effect. This was studied in specific L-type channel constructs and DHP-sensitive class A Ca(2+) channel mutants.\n",
      "   text: Target-10766758\n",
      "   table: None\n",
      "\n",
      "4. question: What organisms were used in the expression studies for Ca(2+) channel inactivation involving (+)-isradipine?\n",
      "   answer: Xenopus oocytes were used in the expression studies to investigate Ca(2+) channel inactivation involving (+)-isradipine. These oocytes were coexpressed with alpha(1A-DHP)- or alpha(1Lc)-subunits and either the beta(2a)- or the beta(1a)-subunit.\n",
      "   text: Target-10766758\n",
      "   table: None\n",
      "\n",
      "5. question: What are the specific amino acid substitutions mentioned in the passage that are used to study the effect of (+)-isradipine on Ca(2+) channels?\n",
      "   answer: The specific amino acid substitutions mentioned in the passage to study the effect of (+)-isradipine on Ca(2+) channels are I1497A, I1498A, and V1504A. These mutations were introduced in the L-type segment IVS6.\n",
      "   text: Target-10766758\n",
      "   table: None\n",
      "[{'question': 'What is the role of the inactivated channel conformation in the mechanism of Ca(2+) channel block by 1,4-dihydropyridine (DHP) drugs, specifically (+)-isradipine?', 'answer': 'The inactivated channel conformation plays a crucial role in the molecular mechanism of Ca(2+) channel block by the 1,4-dihydropyridine (DHP) drug (+)-isradipine. The analysis was conducted using L-type channel constructs and a DHP-sensitive class A Ca(2+) channel mutant. These constructs carry high affinity determinants of the DHP receptor site but inactivate at different rates, indicating the significance of inactivation in the blocking process.', 'text': 'Target-10766758', 'table': 'None'}, {'question': \"How was Ca(2+) channel inactivation modulated in the study of (+)-isradipine's effect, and what were the specific mutations used?\", 'answer': \"In the study of (+)-isradipine's effect, Ca(2+) channel inactivation was modulated by coexpressing the alpha(1A-DHP)- or alpha(1Lc)-subunits in Xenopus oocytes with either the beta(2a)- or the beta(1a)-subunit. Additionally, amino acid substitutions in the L-type segment IVS6, specifically I1497A, I1498A, and V1504A, were utilized to study the effect on channel inactivation.\", 'text': 'Target-10766758', 'table': 'None'}, {'question': 'What type of drug is (+)-isradipine, and what is its mechanism of action related to Ca(2+) channels?', 'answer': '(+)-isradipine is a 1,4-dihydropyridine (DHP) drug that acts as a blocker of Ca(2+) channels. Its mechanism of action involves binding to the inactivated conformation of the channel, which is crucial for its blocking effect. This was studied in specific L-type channel constructs and DHP-sensitive class A Ca(2+) channel mutants.', 'text': 'Target-10766758', 'table': 'None'}, {'question': 'What organisms were used in the expression studies for Ca(2+) channel inactivation involving (+)-isradipine?', 'answer': 'Xenopus oocytes were used in the expression studies to investigate Ca(2+) channel inactivation involving (+)-isradipine. These oocytes were coexpressed with alpha(1A-DHP)- or alpha(1Lc)-subunits and either the beta(2a)- or the beta(1a)-subunit.', 'text': 'Target-10766758', 'table': 'None'}, {'question': 'What are the specific amino acid substitutions mentioned in the passage that are used to study the effect of (+)-isradipine on Ca(2+) channels?', 'answer': 'The specific amino acid substitutions mentioned in the passage to study the effect of (+)-isradipine on Ca(2+) channels are I1497A, I1498A, and V1504A. These mutations were introduced in the L-type segment IVS6.', 'text': 'Target-10766758', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 72%|███████▏  | 108/150 [08:13<04:43,  6.74s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What were the treatment groups in the study on Jingui Shenqi Pill (JSP) and what were their respective effective rates?\n",
      "   answer: The study on Jingui Shenqi Pill (JSP) divided thirty bullous pemphigoid (BP) patients into two treatment groups: the treatment group, which received JSP plus prednisone, and the prednisone group, which received prednisone alone. The total effective rate was 93.33% in the treatment group and 73.33% in the prednisone group. This indicates that the treatment group had a significantly higher effective rate than the prednisone group (P < 0.05).\n",
      "   text: Target-17121036\n",
      "   table: None\n",
      "\n",
      "2. question: What was the effect of Jingui Shenqi Pill (JSP) on glucocorticoid receptor expressions in the study?\n",
      "   answer: The study found that Jingui Shenqi Pill (JSP) increased the expression of GR-alpha in the skin lesions of bullous pemphigoid (BP) patients in the treatment group compared to the other groups (P < 0.01). Additionally, GR-beta expression in the treatment group was lower than that in the prednisone group (P < 0.01), suggesting a differential effect on glucocorticoid receptor expressions by JSP.\n",
      "   text: Target-17121036\n",
      "   table: None\n",
      "\n",
      "3. question: How did the treatment with Jingui Shenqi Pill (JSP) compare to prednisone alone in terms of glucocorticoid receptor (GR) expression?\n",
      "   answer: In the study, the treatment group that received Jingui Shenqi Pill (JSP) plus prednisone exhibited higher GR-alpha expression and lower GR-beta expression compared to the group that received prednisone alone. This suggests that JSP may modulate glucocorticoid receptor expressions more effectively than prednisone alone.\n",
      "   text: Target-17121036\n",
      "   table: None\n",
      "[{'question': 'What were the treatment groups in the study on Jingui Shenqi Pill (JSP) and what were their respective effective rates?', 'answer': 'The study on Jingui Shenqi Pill (JSP) divided thirty bullous pemphigoid (BP) patients into two treatment groups: the treatment group, which received JSP plus prednisone, and the prednisone group, which received prednisone alone. The total effective rate was 93.33% in the treatment group and 73.33% in the prednisone group. This indicates that the treatment group had a significantly higher effective rate than the prednisone group (P < 0.05).', 'text': 'Target-17121036', 'table': 'None'}, {'question': 'What was the effect of Jingui Shenqi Pill (JSP) on glucocorticoid receptor expressions in the study?', 'answer': 'The study found that Jingui Shenqi Pill (JSP) increased the expression of GR-alpha in the skin lesions of bullous pemphigoid (BP) patients in the treatment group compared to the other groups (P < 0.01). Additionally, GR-beta expression in the treatment group was lower than that in the prednisone group (P < 0.01), suggesting a differential effect on glucocorticoid receptor expressions by JSP.', 'text': 'Target-17121036', 'table': 'None'}, {'question': 'How did the treatment with Jingui Shenqi Pill (JSP) compare to prednisone alone in terms of glucocorticoid receptor (GR) expression?', 'answer': 'In the study, the treatment group that received Jingui Shenqi Pill (JSP) plus prednisone exhibited higher GR-alpha expression and lower GR-beta expression compared to the group that received prednisone alone. This suggests that JSP may modulate glucocorticoid receptor expressions more effectively than prednisone alone.', 'text': 'Target-17121036', 'table': 'None'}]\n",
      "No table mapping found for passage Target-15039299\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 73%|███████▎  | 110/150 [08:22<03:58,  5.95s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What type of drug is bethanechol and what is its intended therapeutic use for patients with ineffective esophageal motility (IEM)?\n",
      "   answer: Bethanechol is a direct-acting muscarinic receptor agonist. It is intended for use to improve smooth muscle contractility and bolus transit in patients with ineffective esophageal motility (IEM). In the study, it was shown to increase peristaltic amplitude in the distal esophagus of healthy volunteers.\n",
      "   text: Target-17413603\n",
      "   table: None\n",
      "\n",
      "2. question: How was ineffective esophageal motility (IEM) defined in the study involving bethanechol?\n",
      "   answer: Ineffective esophageal motility (IEM) was defined using criteria of greater than or equal to 50% saline swallows with contraction amplitude <30 mm Hg either 5 and/or 10 cm above the lower esophageal sphincter (LES).\n",
      "   text: Target-17413603\n",
      "   table: None\n",
      "\n",
      "3. question: What methodology was used to assess the effects of bethanechol on patients with severe IEM in the study?\n",
      "   answer: The study involved seven patients diagnosed with severe IEM, and the methodology included evaluating patients in the supine position with 10 swallows of 5 mL of normal saline followed by 10 swallows of a viscous solution, each 20 to 30 seconds apart, to assess the effects of bethanechol.\n",
      "   text: Target-17413603\n",
      "   table: None\n",
      "[{'question': 'What type of drug is bethanechol and what is its intended therapeutic use for patients with ineffective esophageal motility (IEM)?', 'answer': 'Bethanechol is a direct-acting muscarinic receptor agonist. It is intended for use to improve smooth muscle contractility and bolus transit in patients with ineffective esophageal motility (IEM). In the study, it was shown to increase peristaltic amplitude in the distal esophagus of healthy volunteers.', 'text': 'Target-17413603', 'table': 'None'}, {'question': 'How was ineffective esophageal motility (IEM) defined in the study involving bethanechol?', 'answer': 'Ineffective esophageal motility (IEM) was defined using criteria of greater than or equal to 50% saline swallows with contraction amplitude <30 mm Hg either 5 and/or 10 cm above the lower esophageal sphincter (LES).', 'text': 'Target-17413603', 'table': 'None'}, {'question': 'What methodology was used to assess the effects of bethanechol on patients with severe IEM in the study?', 'answer': 'The study involved seven patients diagnosed with severe IEM, and the methodology included evaluating patients in the supine position with 10 swallows of 5 mL of normal saline followed by 10 swallows of a viscous solution, each 20 to 30 seconds apart, to assess the effects of bethanechol.', 'text': 'Target-17413603', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 74%|███████▍  | 111/150 [08:33<04:33,  7.01s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the role of anti-digoxin antiserum in protecting myocardium during hypoxia-reoxygenation, and which drug from the related table could be investigated for similar protective effects?\n",
      "   answer: The anti-digoxin antiserum plays a protective role by antagonizing the effect of endoxin, which is the molecular biological basis of myocardial damage during hypoxia-reoxygenation. It helps to resume ATPase activity in the cell membrane in a concentration-dependent manner. Although none of the drugs in the related table are directly related to this mechanism, Etanercept (DB00005) is involved in modulating immune responses and could potentially be investigated for similar protective effects since immune modulation can influence inflammatory pathways involved in myocardial injury.\n",
      "   text: Target-11324464\n",
      "   table: drugbank-drug\n",
      "\n",
      "2. question: How does the anti-digoxin antiserum affect ATPase activity in hypoxia-reoxygenation injury, and is there a drug in the table that involves calcium-transporting ATPases?\n",
      "   answer: The anti-digoxin antiserum helps resume ATPase activity in a concentration-dependent manner, which is beneficial in hypoxia-reoxygenation injury as ATPase activities are remarkably lower in such conditions. There is no specific drug in the table directly involving calcium-transporting ATPases, which are crucial for cellular ion balance and could relate to ATPase function.\n",
      "   text: Target-11324464\n",
      "   table: None\n",
      "\n",
      "3. question: According to the passage, what is the molecular biological basis of myocardial damage during hypoxia-reoxygenation, and does the passage or tables suggest any specific target for this condition?\n",
      "   answer: The rise of endoxin is identified as the molecular biological basis of myocardial damage during myocardial hypoxia-reoxygenation. While the passage itself does not suggest specific targets, the table includes \"Calcium-Transporting ATPases\" as a category, indicating that these enzymes could be potential targets to explore further in relation to ATPase activity and myocardial protection.\n",
      "   text: Target-11324464\n",
      "   table: None\n",
      "\n",
      "4. question: In the context of myocardial hypoxia-reoxygenation injury, what is the effect of the anti-digoxin antiserum on endoxin levels, and is there a comparable therapeutic agent in the provided tables?\n",
      "   answer: The anti-digoxin antiserum lessens myocardial injury by antagonizing the effect of endoxin, which is elevated during hypoxia-reoxygenation injury. The tables do not provide a directly comparable therapeutic agent that targets endoxin or has a similar mechanism of action.\n",
      "   text: Target-11324464\n",
      "   table: None\n",
      "[{'question': 'What is the role of anti-digoxin antiserum in protecting myocardium during hypoxia-reoxygenation, and which drug from the related table could be investigated for similar protective effects?', 'answer': 'The anti-digoxin antiserum plays a protective role by antagonizing the effect of endoxin, which is the molecular biological basis of myocardial damage during hypoxia-reoxygenation. It helps to resume ATPase activity in the cell membrane in a concentration-dependent manner. Although none of the drugs in the related table are directly related to this mechanism, Etanercept (DB00005) is involved in modulating immune responses and could potentially be investigated for similar protective effects since immune modulation can influence inflammatory pathways involved in myocardial injury.', 'text': 'Target-11324464', 'table': 'drugbank-drug'}, {'question': 'How does the anti-digoxin antiserum affect ATPase activity in hypoxia-reoxygenation injury, and is there a drug in the table that involves calcium-transporting ATPases?', 'answer': 'The anti-digoxin antiserum helps resume ATPase activity in a concentration-dependent manner, which is beneficial in hypoxia-reoxygenation injury as ATPase activities are remarkably lower in such conditions. There is no specific drug in the table directly involving calcium-transporting ATPases, which are crucial for cellular ion balance and could relate to ATPase function.', 'text': 'Target-11324464', 'table': 'None'}, {'question': 'According to the passage, what is the molecular biological basis of myocardial damage during hypoxia-reoxygenation, and does the passage or tables suggest any specific target for this condition?', 'answer': 'The rise of endoxin is identified as the molecular biological basis of myocardial damage during myocardial hypoxia-reoxygenation. While the passage itself does not suggest specific targets, the table includes \"Calcium-Transporting ATPases\" as a category, indicating that these enzymes could be potential targets to explore further in relation to ATPase activity and myocardial protection.', 'text': 'Target-11324464', 'table': 'None'}, {'question': 'In the context of myocardial hypoxia-reoxygenation injury, what is the effect of the anti-digoxin antiserum on endoxin levels, and is there a comparable therapeutic agent in the provided tables?', 'answer': 'The anti-digoxin antiserum lessens myocardial injury by antagonizing the effect of endoxin, which is elevated during hypoxia-reoxygenation injury. The tables do not provide a directly comparable therapeutic agent that targets endoxin or has a similar mechanism of action.', 'text': 'Target-11324464', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 75%|███████▍  | 112/150 [08:40<04:26,  7.01s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the primary therapeutic indication for voriconazole as mentioned in the passage, and is there a corresponding entry for it in the drugbank tables?\n",
      "   answer: Voriconazole is primarily indicated as a therapy to target Aspergillus spp., and it is also effective against both yeasts and molds for treating other mycoses. However, the DrugBank tables provided do not list voriconazole, so there is no corresponding entry for it.\n",
      "   text: Target-19947892\n",
      "   table: None\n",
      "\n",
      "2. question: How does the passage describe the pharmacokinetics and pharmacodynamics of voriconazole, and are there any synthesis references for similar antifungal agents in the drugbank tables?\n",
      "   answer: The passage mentions that voriconazole's pharmacodynamics and pharmacokinetics are discussed in terms of its broad spectrum of activity and unique side effect profile. There are no synthesis references for voriconazole in the DrugBank tables, and the tables provided focus on other drugs such as Etanercept, which has a synthesis reference listed.\n",
      "   text: Target-19947892\n",
      "   table: drugbank-drug\n",
      "\n",
      "3. question: According to the passage, what are some of the unique advantages of using voriconazole over other antifungal agents, and does the DrugBank contain any entries related to antifungal agents that might offer similar benefits?\n",
      "   answer: The passage states that voriconazole offers distinct advantages over several other antifungal agents, primarily due to its unique side effect profile and broad spectrum of activity. The DrugBank tables do not contain entries related to antifungal agents similar to voriconazole, as the examples provided in the tables are focused on biotech drugs unrelated to antifungal treatments.\n",
      "   text: Target-19947892\n",
      "   table: None\n",
      "[{'question': 'What is the primary therapeutic indication for voriconazole as mentioned in the passage, and is there a corresponding entry for it in the drugbank tables?', 'answer': 'Voriconazole is primarily indicated as a therapy to target Aspergillus spp., and it is also effective against both yeasts and molds for treating other mycoses. However, the DrugBank tables provided do not list voriconazole, so there is no corresponding entry for it.', 'text': 'Target-19947892', 'table': 'None'}, {'question': 'How does the passage describe the pharmacokinetics and pharmacodynamics of voriconazole, and are there any synthesis references for similar antifungal agents in the drugbank tables?', 'answer': \"The passage mentions that voriconazole's pharmacodynamics and pharmacokinetics are discussed in terms of its broad spectrum of activity and unique side effect profile. There are no synthesis references for voriconazole in the DrugBank tables, and the tables provided focus on other drugs such as Etanercept, which has a synthesis reference listed.\", 'text': 'Target-19947892', 'table': 'drugbank-drug'}, {'question': 'According to the passage, what are some of the unique advantages of using voriconazole over other antifungal agents, and does the DrugBank contain any entries related to antifungal agents that might offer similar benefits?', 'answer': 'The passage states that voriconazole offers distinct advantages over several other antifungal agents, primarily due to its unique side effect profile and broad spectrum of activity. The DrugBank tables do not contain entries related to antifungal agents similar to voriconazole, as the examples provided in the tables are focused on biotech drugs unrelated to antifungal treatments.', 'text': 'Target-19947892', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 75%|███████▌  | 113/150 [08:45<04:02,  6.56s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does verapamil influence the pharmacokinetics of oxcarbazepine and its metabolite MHD?\n",
      "   answer: Verapamil, a P-glycoprotein (P-gp) inhibitor, affects the disposition of oxcarbazepine and its active metabolite, 10-hydroxycarbazepine (MHD), as both are P-gp substrates. The presence of verapamil alters the concentration-time profiles of the MHD enantiomers.\n",
      "   text: Target-28528287\n",
      "   table: \"drugbank-transporters\"\n",
      "\n",
      "2. question: What is the role of P-glycoprotein in the treatment involving oxcarbazepine?\n",
      "   answer: P-glycoprotein acts as a transporter that influences the pharmacokinetics of oxcarbazepine and its metabolite MHD, as both are substrates of P-gp. The modulation of P-gp activity by inhibitors like verapamil can alter the disposition of these drugs.\n",
      "   text: Target-28528287\n",
      "   table: \"drugbank-transporters\"\n",
      "\n",
      "3. question: What model was used to describe the pharmacokinetics of oxcarbazepine in the study?\n",
      "   answer: The pharmacokinetics of oxcarbazepine was described using a two-compartment model with absorption transit compartments and first-order elimination. This model was developed through nonlinear mixed effects modeling.\n",
      "   text: Target-28528287\n",
      "   table: None\n",
      "\n",
      "4. question: How are blood samples used in the study of oxcarbazepine's pharmacokinetics?\n",
      "   answer: Blood samples, totaling 185, were collected over a 12-hour period post oxcarbazepine dose to analyze the concentration-time profiles of oxcarbazepine and its metabolites, contributing to the pharmacokinetic modeling.\n",
      "   text: Target-28528287\n",
      "   table: None\n",
      "[{'question': 'How does verapamil influence the pharmacokinetics of oxcarbazepine and its metabolite MHD?', 'answer': 'Verapamil, a P-glycoprotein (P-gp) inhibitor, affects the disposition of oxcarbazepine and its active metabolite, 10-hydroxycarbazepine (MHD), as both are P-gp substrates. The presence of verapamil alters the concentration-time profiles of the MHD enantiomers.', 'text': 'Target-28528287', 'table': '\"drugbank-transporters\"'}, {'question': 'What is the role of P-glycoprotein in the treatment involving oxcarbazepine?', 'answer': 'P-glycoprotein acts as a transporter that influences the pharmacokinetics of oxcarbazepine and its metabolite MHD, as both are substrates of P-gp. The modulation of P-gp activity by inhibitors like verapamil can alter the disposition of these drugs.', 'text': 'Target-28528287', 'table': '\"drugbank-transporters\"'}, {'question': 'What model was used to describe the pharmacokinetics of oxcarbazepine in the study?', 'answer': 'The pharmacokinetics of oxcarbazepine was described using a two-compartment model with absorption transit compartments and first-order elimination. This model was developed through nonlinear mixed effects modeling.', 'text': 'Target-28528287', 'table': 'None'}, {'question': \"How are blood samples used in the study of oxcarbazepine's pharmacokinetics?\", 'answer': 'Blood samples, totaling 185, were collected over a 12-hour period post oxcarbazepine dose to analyze the concentration-time profiles of oxcarbazepine and its metabolites, contributing to the pharmacokinetic modeling.', 'text': 'Target-28528287', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 76%|███████▌  | 114/150 [08:51<03:47,  6.32s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the proposed mechanism by which Gabapentin (GBP) affects voltage-gated calcium channels?\n",
      "   answer: Gabapentin (GBP) is hypothesized to impair the ability of alpha(2)delta subunits to enhance the plasma membrane density of voltage-gated Ca(2+) channels through an effect on trafficking. It does so by binding to the alpha(2)delta-1 and alpha(2)delta-2 auxiliary subunits, although acute inhibition of calcium currents by GBP is minimal or absent. The effect becomes significant when GBP is applied chronically, suggesting that GBP acts primarily at an intracellular location, necessitating uptake into cells.\n",
      "   text: Target-18299583\n",
      "   table: None\n",
      "\n",
      "2. question: How does the application duration of Gabapentin influence its effects on calcium currents?\n",
      "   answer: The effect of Gabapentin on calcium currents is significant only when applied chronically, mimicking a lack of alpha(2)delta subunits in both heterologous expression systems and dorsal root-ganglion neurons. In contrast, acute application of Gabapentin does not significantly inhibit calcium currents.\n",
      "   text: Target-18299583\n",
      "   table: None\n",
      "\n",
      "3. question: What is the role of the system-L neutral amino acid transporters in the action of Gabapentin?\n",
      "   answer: The system-L neutral amino acid transporters play a role in the uptake of Gabapentin into cells. The chronic effect of GBP on inhibiting calcium currents is blocked by an inhibitor of these transporters, indicating that Gabapentin needs to be taken up by cells to exert its effect.\n",
      "   text: Target-18299583\n",
      "   table: None\n",
      "[{'question': 'What is the proposed mechanism by which Gabapentin (GBP) affects voltage-gated calcium channels?', 'answer': 'Gabapentin (GBP) is hypothesized to impair the ability of alpha(2)delta subunits to enhance the plasma membrane density of voltage-gated Ca(2+) channels through an effect on trafficking. It does so by binding to the alpha(2)delta-1 and alpha(2)delta-2 auxiliary subunits, although acute inhibition of calcium currents by GBP is minimal or absent. The effect becomes significant when GBP is applied chronically, suggesting that GBP acts primarily at an intracellular location, necessitating uptake into cells.', 'text': 'Target-18299583', 'table': 'None'}, {'question': 'How does the application duration of Gabapentin influence its effects on calcium currents?', 'answer': 'The effect of Gabapentin on calcium currents is significant only when applied chronically, mimicking a lack of alpha(2)delta subunits in both heterologous expression systems and dorsal root-ganglion neurons. In contrast, acute application of Gabapentin does not significantly inhibit calcium currents.', 'text': 'Target-18299583', 'table': 'None'}, {'question': 'What is the role of the system-L neutral amino acid transporters in the action of Gabapentin?', 'answer': 'The system-L neutral amino acid transporters play a role in the uptake of Gabapentin into cells. The chronic effect of GBP on inhibiting calcium currents is blocked by an inhibitor of these transporters, indicating that Gabapentin needs to be taken up by cells to exert its effect.', 'text': 'Target-18299583', 'table': 'None'}]\n",
      "No table mapping found for passage Target-9660842\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 77%|███████▋  | 116/150 [08:58<02:57,  5.23s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the primary reason rofecoxib was withdrawn from the market, and how does this relate to its effects on the thoracic aorta in rats?\n",
      "   answer: Rofecoxib was withdrawn from the market due to an increased risk of cardiovascular events. In studies with rats, oral administration of [14C]rofecoxib showed considerable radioactivity retained by and accumulated in the thoracic aorta, indicating a potential mechanism for its cardiovascular risks, as the radioactivity was largely covalently bound to elastin in the aorta.\n",
      "   text: Target-16679386\n",
      "   table: None\n",
      "\n",
      "2. question: How does the tissue distribution of radioactivity compare among [14C]rofecoxib, [14C]celecoxib, and [14C]CS-706 in rats?\n",
      "   answer: The distribution profile of radioactivity in rats showed that [14C]rofecoxib resulted in significant retention and accumulation of radioactivity in the thoracic aorta, unlike [14C]celecoxib and [14C]CS-706, which did not exhibit similar accumulation.\n",
      "   text: Target-16679386\n",
      "   table: None\n",
      "\n",
      "3. question: What was discovered about the binding nature of radioactivity from rofecoxib in the thoracic aorta?\n",
      "   answer: The radioactivity from [14C]rofecoxib in the thoracic aorta was found to be covalently bound to elastin, as demonstrated by acid, organic solvent, and proteolytic enzyme treatments.\n",
      "   text: Target-16679386\n",
      "   table: None\n",
      "\n",
      "4. question: What are the chemical characteristics of the novel COX-2 inhibitor compared with rofecoxib, and what does this imply about their different effects on the aorta?\n",
      "   answer: The novel COX-2 inhibitor, [14C]CS-706, is described as 2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1H-pyrrole. Unlike rofecoxib, [14C]CS-706 did not show significant radioactivity accumulation in the thoracic aorta, suggesting a different interaction or binding characteristic compared to rofecoxib.\n",
      "   text: Target-16679386\n",
      "   table: None\n",
      "\n",
      "5. question: What role does elastin play in the retention of radioactivity from rofecoxib in the rat thoracic aorta?\n",
      "   answer: The study found that most of the radioactivity from [14C]rofecoxib was covalently bound to elastin in the thoracic aorta, indicating that elastin may play a significant role in the retention and potential cardiovascular effects of rofecoxib.\n",
      "   text: Target-16679386\n",
      "   table: None\n",
      "[{'question': 'What is the primary reason rofecoxib was withdrawn from the market, and how does this relate to its effects on the thoracic aorta in rats?', 'answer': 'Rofecoxib was withdrawn from the market due to an increased risk of cardiovascular events. In studies with rats, oral administration of [14C]rofecoxib showed considerable radioactivity retained by and accumulated in the thoracic aorta, indicating a potential mechanism for its cardiovascular risks, as the radioactivity was largely covalently bound to elastin in the aorta.', 'text': 'Target-16679386', 'table': 'None'}, {'question': 'How does the tissue distribution of radioactivity compare among [14C]rofecoxib, [14C]celecoxib, and [14C]CS-706 in rats?', 'answer': 'The distribution profile of radioactivity in rats showed that [14C]rofecoxib resulted in significant retention and accumulation of radioactivity in the thoracic aorta, unlike [14C]celecoxib and [14C]CS-706, which did not exhibit similar accumulation.', 'text': 'Target-16679386', 'table': 'None'}, {'question': 'What was discovered about the binding nature of radioactivity from rofecoxib in the thoracic aorta?', 'answer': 'The radioactivity from [14C]rofecoxib in the thoracic aorta was found to be covalently bound to elastin, as demonstrated by acid, organic solvent, and proteolytic enzyme treatments.', 'text': 'Target-16679386', 'table': 'None'}, {'question': 'What are the chemical characteristics of the novel COX-2 inhibitor compared with rofecoxib, and what does this imply about their different effects on the aorta?', 'answer': 'The novel COX-2 inhibitor, [14C]CS-706, is described as 2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1H-pyrrole. Unlike rofecoxib, [14C]CS-706 did not show significant radioactivity accumulation in the thoracic aorta, suggesting a different interaction or binding characteristic compared to rofecoxib.', 'text': 'Target-16679386', 'table': 'None'}, {'question': 'What role does elastin play in the retention of radioactivity from rofecoxib in the rat thoracic aorta?', 'answer': 'The study found that most of the radioactivity from [14C]rofecoxib was covalently bound to elastin in the thoracic aorta, indicating that elastin may play a significant role in the retention and potential cardiovascular effects of rofecoxib.', 'text': 'Target-16679386', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 78%|███████▊  | 117/150 [09:04<02:59,  5.45s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the relative potency of naloxone compared to naltrindole in antagonizing the effects of butorphanol?\n",
      "   answer: Naloxone, a mu-selective opioid antagonist, is considerably more potent than the delta-selective opioid antagonist naltrindole in antagonizing the effects of butorphanol. This conclusion is based on the discriminative stimulus effects observed in the study involving pigeons.\n",
      "   text: Target-8968334\n",
      "   table: None\n",
      "\n",
      "2. question: Which mu opioid agonists completely substituted for the butorphanol stimulus in the study with pigeons?\n",
      "   answer: In the study, the mu opioid agonists morphine, l-methadone, and fentanyl, along with buprenorphine, (-)-pentazocine, nalbuphine, (-)-metazocine, and nalorphine, completely substituted for the butorphanol stimulus in each of the training dose groups.\n",
      "   text: Target-8968334\n",
      "   table: None\n",
      "\n",
      "3. question: What was the outcome for (-)-N-allylnormetazocine (NANM) and levallorphan in the low-dose group of the butorphanol discrimination study?\n",
      "   answer: In the low-dose group of the butorphanol discrimination study, (-)-N-allylnormetazocine (NANM) and levallorphan substituted completely for the butorphanol stimulus, indicating their effectiveness as substitutes at this dose level.\n",
      "   text: Target-8968334\n",
      "   table: None\n",
      "\n",
      "4. question: What is the similarity in the rank order of potency for the compounds tested in the butorphanol stimulus study?\n",
      "   answer: The rank order of potency for the compounds that substituted for the butorphanol stimulus was similar across training dose groups and also similar to those reported in studies using fentanyl or morphine as training stimuli, demonstrating consistent patterns of potency among these compounds.\n",
      "   text: Target-8968334\n",
      "   table: None\n",
      "[{'question': 'What is the relative potency of naloxone compared to naltrindole in antagonizing the effects of butorphanol?', 'answer': 'Naloxone, a mu-selective opioid antagonist, is considerably more potent than the delta-selective opioid antagonist naltrindole in antagonizing the effects of butorphanol. This conclusion is based on the discriminative stimulus effects observed in the study involving pigeons.', 'text': 'Target-8968334', 'table': 'None'}, {'question': 'Which mu opioid agonists completely substituted for the butorphanol stimulus in the study with pigeons?', 'answer': 'In the study, the mu opioid agonists morphine, l-methadone, and fentanyl, along with buprenorphine, (-)-pentazocine, nalbuphine, (-)-metazocine, and nalorphine, completely substituted for the butorphanol stimulus in each of the training dose groups.', 'text': 'Target-8968334', 'table': 'None'}, {'question': 'What was the outcome for (-)-N-allylnormetazocine (NANM) and levallorphan in the low-dose group of the butorphanol discrimination study?', 'answer': 'In the low-dose group of the butorphanol discrimination study, (-)-N-allylnormetazocine (NANM) and levallorphan substituted completely for the butorphanol stimulus, indicating their effectiveness as substitutes at this dose level.', 'text': 'Target-8968334', 'table': 'None'}, {'question': 'What is the similarity in the rank order of potency for the compounds tested in the butorphanol stimulus study?', 'answer': 'The rank order of potency for the compounds that substituted for the butorphanol stimulus was similar across training dose groups and also similar to those reported in studies using fentanyl or morphine as training stimuli, demonstrating consistent patterns of potency among these compounds.', 'text': 'Target-8968334', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 79%|███████▊  | 118/150 [09:10<02:54,  5.47s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is telbivudine, and what is its primary use in medical treatment?\n",
      "   answer: Telbivudine is an L-nucleoside that is structurally related to lamivudine, recently approved for use in patients with chronic hepatitis B virus (HBV) infection. It is highly selective for HBV DNA and inhibits viral DNA synthesis without affecting human DNA or other viruses.\n",
      "   text: Target-19225726\n",
      "   table: None\n",
      "\n",
      "2. question: How was telbivudine's therapeutic efficacy and safety evaluated, according to the passage?\n",
      "   answer: The therapeutic efficacy and safety of telbivudine were evaluated through phase 3 clinical studies, as indicated in the passage.\n",
      "   text: Target-19225726\n",
      "   table: None\n",
      "\n",
      "3. question: What makes telbivudine distinct in its action against viruses, according to the passage?\n",
      "   answer: Telbivudine is distinct because it is highly selective for HBV DNA and inhibits viral DNA synthesis without affecting human DNA or other viruses, making it a targeted antiviral agent for chronic HBV infection.\n",
      "   text: Target-19225726\n",
      "   table: None\n",
      "\n",
      "4. question: How was the data on telbivudine's pharmacology and safety gathered according to the passage?\n",
      "   answer: The data on telbivudine's pharmacology and safety were gathered by identifying relevant publications from searches of Medline and PubMed between 2000 and 2008, using specific search terms related to hepatitis B, telbivudine, pharmacokinetics, safety, adverse events, and resistance.\n",
      "   text: Target-19225726\n",
      "   table: None\n",
      "\n",
      "5. question: In what ways has the treatment of chronic HBV been revolutionized over the past decade, based on the passage?\n",
      "   answer: The treatment of chronic HBV has been revolutionized by the increased availability of effective antiviral agents, such as telbivudine, which are specifically designed to target HBV DNA synthesis without affecting human DNA or other viruses.\n",
      "   text: Target-19225726\n",
      "   table: None\n",
      "[{'question': 'What is telbivudine, and what is its primary use in medical treatment?', 'answer': 'Telbivudine is an L-nucleoside that is structurally related to lamivudine, recently approved for use in patients with chronic hepatitis B virus (HBV) infection. It is highly selective for HBV DNA and inhibits viral DNA synthesis without affecting human DNA or other viruses.', 'text': 'Target-19225726', 'table': 'None'}, {'question': \"How was telbivudine's therapeutic efficacy and safety evaluated, according to the passage?\", 'answer': 'The therapeutic efficacy and safety of telbivudine were evaluated through phase 3 clinical studies, as indicated in the passage.', 'text': 'Target-19225726', 'table': 'None'}, {'question': 'What makes telbivudine distinct in its action against viruses, according to the passage?', 'answer': 'Telbivudine is distinct because it is highly selective for HBV DNA and inhibits viral DNA synthesis without affecting human DNA or other viruses, making it a targeted antiviral agent for chronic HBV infection.', 'text': 'Target-19225726', 'table': 'None'}, {'question': \"How was the data on telbivudine's pharmacology and safety gathered according to the passage?\", 'answer': \"The data on telbivudine's pharmacology and safety were gathered by identifying relevant publications from searches of Medline and PubMed between 2000 and 2008, using specific search terms related to hepatitis B, telbivudine, pharmacokinetics, safety, adverse events, and resistance.\", 'text': 'Target-19225726', 'table': 'None'}, {'question': 'In what ways has the treatment of chronic HBV been revolutionized over the past decade, based on the passage?', 'answer': 'The treatment of chronic HBV has been revolutionized by the increased availability of effective antiviral agents, such as telbivudine, which are specifically designed to target HBV DNA synthesis without affecting human DNA or other viruses.', 'text': 'Target-19225726', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 79%|███████▉  | 119/150 [09:17<02:59,  5.78s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What role does the G-protein coupled receptor HM74A play in the context of niacin's anti-lipolytic effects?\n",
      "   answer: The G-protein coupled receptor HM74A, but not HM74, binds niacin with high affinity and mediates Gi signaling events in human embryonic kidney HEK293 cells and 3T3L1 adipocytes expressing HM74A. This receptor is sufficient to mediate the anti-lipolytic effect of niacin in adipose tissue.\n",
      "   text: Target-16018973\n",
      "   table: None\n",
      "\n",
      "2. question: How was the receptor HM74A identified to have a specific role in mediating niacin's effects compared to HM74?\n",
      "   answer: The receptor HM74A was identified to have a specific role in mediating niacin's effects by demonstrating that it binds niacin at high affinities and effectively mediates Gi signaling events, unlike HM74. This was shown in both human embryonic kidney HEK293 cells and 3T3L1 adipocytes expressing HM74A, where it mediated the inhibition of lipolysis by niacin.\n",
      "   text: Target-16018973\n",
      "   table: None\n",
      "\n",
      "3. question: In which cell lines did HM74A demonstrate its ability to mediate the anti-lipolytic effect of niacin?\n",
      "   answer: HM74A demonstrated its ability to mediate the anti-lipolytic effect of niacin in human embryonic kidney HEK293 cells and 3T3L1 adipocytes expressing HM74A.\n",
      "   text: Target-16018973\n",
      "   table: None\n",
      "\n",
      "4. question: What evidence supports the sufficiency of HM74A in mediating niacin's anti-lipolytic effects in adipose tissue?\n",
      "   answer: The evidence supporting the sufficiency of HM74A in mediating niacin's anti-lipolytic effects in adipose tissue includes the observation that HM74A, but not HM74, binds niacin at high affinities and effectively mediates Gi signaling events, leading to the inhibition of lipolysis in 3T3L1 adipocytes expressing HM74A.\n",
      "   text: Target-16018973\n",
      "   table: None\n",
      "[{'question': \"What role does the G-protein coupled receptor HM74A play in the context of niacin's anti-lipolytic effects?\", 'answer': 'The G-protein coupled receptor HM74A, but not HM74, binds niacin with high affinity and mediates Gi signaling events in human embryonic kidney HEK293 cells and 3T3L1 adipocytes expressing HM74A. This receptor is sufficient to mediate the anti-lipolytic effect of niacin in adipose tissue.', 'text': 'Target-16018973', 'table': 'None'}, {'question': \"How was the receptor HM74A identified to have a specific role in mediating niacin's effects compared to HM74?\", 'answer': \"The receptor HM74A was identified to have a specific role in mediating niacin's effects by demonstrating that it binds niacin at high affinities and effectively mediates Gi signaling events, unlike HM74. This was shown in both human embryonic kidney HEK293 cells and 3T3L1 adipocytes expressing HM74A, where it mediated the inhibition of lipolysis by niacin.\", 'text': 'Target-16018973', 'table': 'None'}, {'question': 'In which cell lines did HM74A demonstrate its ability to mediate the anti-lipolytic effect of niacin?', 'answer': 'HM74A demonstrated its ability to mediate the anti-lipolytic effect of niacin in human embryonic kidney HEK293 cells and 3T3L1 adipocytes expressing HM74A.', 'text': 'Target-16018973', 'table': 'None'}, {'question': \"What evidence supports the sufficiency of HM74A in mediating niacin's anti-lipolytic effects in adipose tissue?\", 'answer': \"The evidence supporting the sufficiency of HM74A in mediating niacin's anti-lipolytic effects in adipose tissue includes the observation that HM74A, but not HM74, binds niacin at high affinities and effectively mediates Gi signaling events, leading to the inhibition of lipolysis in 3T3L1 adipocytes expressing HM74A.\", 'text': 'Target-16018973', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 80%|████████  | 120/150 [09:22<02:52,  5.74s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: Which ATP-binding cassette transporters are known to be involved in the efflux transport of quinolone antibacterial agents?\n",
      "   answer: The passage mentions that several ATP-binding cassette transporters are involved in the efflux transport of quinolone antibacterial agents, although it does not specify which ones. The table contains examples of transporters, such as P-glycoprotein 1 and the bile salt export pump, which are ATP-binding cassette transporters in humans with unknown specific actions related to quinolones.\n",
      "   text: Target-17274666\n",
      "   table: drugbank-transporters\n",
      "\n",
      "2. question: What is the role of organic anion transporting polypeptide 1A2 (OATP1A2) in the transport of levofloxacin?\n",
      "   answer: The passage identifies organic anion transporting polypeptide 1A2 (OATP1A2) as the transporter responsible for the influx of levofloxacin. The research indicated a correlation between the expression level of OATP1A2 and levofloxacin transport activity in Caco-2 subclones.\n",
      "   text: Target-17274666\n",
      "   table: None\n",
      "\n",
      "3. question: How does the expression of OATP1A2 affect the transport of levofloxacin in Xenopus oocytes?\n",
      "   answer: The passage states that when OATP1A2 is expressed in Xenopus oocytes, the transport of levofloxacin is essentially pH-independent, indicating that OATP1A2 facilitates the influx of levofloxacin into cells.\n",
      "   text: Target-17274666\n",
      "   table: None\n",
      "\n",
      "4. question: Are there any identified influx transporters for quinolone antibiotics other than OATP1A2?\n",
      "   answer: As per the passage, no other influx transporters besides OATP1A2 have been molecularly identified for quinolone antibiotics, indicating that current research has primarily focused on OATP1A2 for the influx of these agents.\n",
      "   text: Target-17274666\n",
      "   table: None\n",
      "\n",
      "5. question: What experimental model was used to identify OATP1A2 as the transporter for levofloxacin?\n",
      "   answer: The passage describes the use of Caco-2 cell subclones and Xenopus oocytes as experimental models. Caco-2 cell subclones were utilized to identify differential uptake activities for levofloxacin, and expression in Xenopus oocytes was used to confirm pH-independent transport by OATP1A2.\n",
      "   text: Target-17274666\n",
      "   table: None\n",
      "[{'question': 'Which ATP-binding cassette transporters are known to be involved in the efflux transport of quinolone antibacterial agents?', 'answer': 'The passage mentions that several ATP-binding cassette transporters are involved in the efflux transport of quinolone antibacterial agents, although it does not specify which ones. The table contains examples of transporters, such as P-glycoprotein 1 and the bile salt export pump, which are ATP-binding cassette transporters in humans with unknown specific actions related to quinolones.', 'text': 'Target-17274666', 'table': 'drugbank-transporters'}, {'question': 'What is the role of organic anion transporting polypeptide 1A2 (OATP1A2) in the transport of levofloxacin?', 'answer': 'The passage identifies organic anion transporting polypeptide 1A2 (OATP1A2) as the transporter responsible for the influx of levofloxacin. The research indicated a correlation between the expression level of OATP1A2 and levofloxacin transport activity in Caco-2 subclones.', 'text': 'Target-17274666', 'table': 'None'}, {'question': 'How does the expression of OATP1A2 affect the transport of levofloxacin in Xenopus oocytes?', 'answer': 'The passage states that when OATP1A2 is expressed in Xenopus oocytes, the transport of levofloxacin is essentially pH-independent, indicating that OATP1A2 facilitates the influx of levofloxacin into cells.', 'text': 'Target-17274666', 'table': 'None'}, {'question': 'Are there any identified influx transporters for quinolone antibiotics other than OATP1A2?', 'answer': 'As per the passage, no other influx transporters besides OATP1A2 have been molecularly identified for quinolone antibiotics, indicating that current research has primarily focused on OATP1A2 for the influx of these agents.', 'text': 'Target-17274666', 'table': 'None'}, {'question': 'What experimental model was used to identify OATP1A2 as the transporter for levofloxacin?', 'answer': 'The passage describes the use of Caco-2 cell subclones and Xenopus oocytes as experimental models. Caco-2 cell subclones were utilized to identify differential uptake activities for levofloxacin, and expression in Xenopus oocytes was used to confirm pH-independent transport by OATP1A2.', 'text': 'Target-17274666', 'table': 'None'}]\n",
      "No table mapping found for passage Target-11602530\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 81%|████████▏ | 122/150 [09:31<02:26,  5.23s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What are the IC50 values of miconazole (MIZ) and econazole (ECZ) for C. albicans, and how do they compare to other drugs listed in the tables?\n",
      "   answer: The IC50 values of miconazole (MIZ) and econazole (ECZ) for C. albicans are 19.72 μmol L(-1) and 29.90 μmol L(-1), respectively. While the tables do not provide IC50 values for the other drugs, they detail different types of drugs and their uses, such as Lepirudin for anticoagulation and Cetuximab for cancer treatment, which are not directly comparable in terms of IC50 for C. albicans.\n",
      "   text: Target-25376919\n",
      "   table: drugbank-drug\n",
      "\n",
      "2. question: What are the binding constants of MIZ and ECZ with human serum albumin (HSA), and how do these values relate to the drugs described in the tables?\n",
      "   answer: The binding constants of MIZ and ECZ with human serum albumin (HSA) are 2.36 × 10(4) L mol(-1) and 3.73 × 10(4) L mol(-1), respectively. The drugs listed in the tables, such as Etanercept and Dornase alfa, are biotech drugs and do not have specified binding constants with HSA in the provided data, as they are used for different mechanisms of action.\n",
      "   text: Target-25376919\n",
      "   table: drugbank-drug\n",
      "\n",
      "3. question: How do the peak currents of C. albicans react to different concentrations of MIZ and ECZ, and how is this information relevant compared to other drugs or mixtures in the tables?\n",
      "   answer: After adding MIZ solution of 12 and 40 μmol L(-1), the peak currents increased to 4.887 and 6.024 μA. The peak currents of C. albicans in the presence of 20 and 48 μmol L(-1) ECZ were 4.701 and... The tables provide information on various drugs and mixtures, such as Refludan (Lepirudin) and Erbitux (Cetuximab), which do not have comparable peak current data but are used in different therapeutic areas.\n",
      "   text: Target-25376919\n",
      "   table: drugbank-drug_mixtures\n",
      "[{'question': 'What are the IC50 values of miconazole (MIZ) and econazole (ECZ) for C. albicans, and how do they compare to other drugs listed in the tables?', 'answer': 'The IC50 values of miconazole (MIZ) and econazole (ECZ) for C. albicans are 19.72 μmol\\u2009L(-1) and 29.90 μmol\\u2009L(-1), respectively. While the tables do not provide IC50 values for the other drugs, they detail different types of drugs and their uses, such as Lepirudin for anticoagulation and Cetuximab for cancer treatment, which are not directly comparable in terms of IC50 for C. albicans.', 'text': 'Target-25376919', 'table': 'drugbank-drug'}, {'question': 'What are the binding constants of MIZ and ECZ with human serum albumin (HSA), and how do these values relate to the drugs described in the tables?', 'answer': 'The binding constants of MIZ and ECZ with human serum albumin (HSA) are 2.36\\u2009×\\u200910(4) L\\u2009mol(-1) and 3.73\\u2009×\\u200910(4) L\\u2009mol(-1), respectively. The drugs listed in the tables, such as Etanercept and Dornase alfa, are biotech drugs and do not have specified binding constants with HSA in the provided data, as they are used for different mechanisms of action.', 'text': 'Target-25376919', 'table': 'drugbank-drug'}, {'question': 'How do the peak currents of C. albicans react to different concentrations of MIZ and ECZ, and how is this information relevant compared to other drugs or mixtures in the tables?', 'answer': 'After adding MIZ solution of 12 and 40\\u2009μmol\\u2009L(-1), the peak currents increased to 4.887 and 6.024\\u2009μA. The peak currents of C. albicans in the presence of 20 and 48\\u2009μmol\\u2009L(-1) ECZ were 4.701 and... The tables provide information on various drugs and mixtures, such as Refludan (Lepirudin) and Erbitux (Cetuximab), which do not have comparable peak current data but are used in different therapeutic areas.', 'text': 'Target-25376919', 'table': 'drugbank-drug_mixtures'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 82%|████████▏ | 123/150 [09:42<02:55,  6.49s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: Which antimalarial drugs were found to inhibit the formation of beta-haematin according to the study?\n",
      "   answer: The antimalarial drugs quinidine, halofantrine, desbutylhalofantrine, and mefloquine were found to inhibit the formation of beta-haematin.\n",
      "   text: Target-10212997\n",
      "   table: None\n",
      "\n",
      "2. question: What is the log K value for the complex formation between quinidine and ferriprotoporphyrin IX, and how does it compare to chloroquine under the same conditions?\n",
      "   answer: The log K value for the complex formation between quinidine and ferriprotoporphyrin IX is 5.02 +/- 0.03. This is stronger than chloroquine, which has a log K value of 4.56 +/- 0.02 under the same conditions.\n",
      "   text: Target-10212997\n",
      "   table: None\n",
      "\n",
      "3. question: How do the log K values for halofantrine and desbutylhalofantrine compare to those of quinidine and chloroquine when forming a complex with ferriprotoporphyrin IX?\n",
      "   answer: The log K values for halofantrine and desbutylhalofantrine are 5.29 +/- 0.02 and 5.15 +/- 0.02 respectively, which are stronger than both quinidine (log K = 5.02 +/- 0.03) and chloroquine (log K = 4.56 +/- 0.02) when forming a complex with ferriprotoporphyrin IX.\n",
      "   text: Target-10212997\n",
      "   table: None\n",
      "\n",
      "4. question: What conditions were used to achieve the formation of beta-haematin, and how does this relate to the inhibition effect of antimalarial drugs?\n",
      "   answer: Beta-haematin was formed by reacting haematin in 4.5 M acetate at pH 4.5 and 60 degrees C for 30 minutes, which was shown to be identical to beta-haematin prepared in 4.5 M acetic acid at 70 degrees C overnight at pH 2.6. The antimalarial drugs quinidine, halofantrine, desbutylhalofantrine, and mefloquine were found to inhibit this formation process.\n",
      "   text: Target-10212997\n",
      "   table: None\n",
      "[{'question': 'Which antimalarial drugs were found to inhibit the formation of beta-haematin according to the study?', 'answer': 'The antimalarial drugs quinidine, halofantrine, desbutylhalofantrine, and mefloquine were found to inhibit the formation of beta-haematin.', 'text': 'Target-10212997', 'table': 'None'}, {'question': 'What is the log K value for the complex formation between quinidine and ferriprotoporphyrin IX, and how does it compare to chloroquine under the same conditions?', 'answer': 'The log K value for the complex formation between quinidine and ferriprotoporphyrin IX is 5.02 +/- 0.03. This is stronger than chloroquine, which has a log K value of 4.56 +/- 0.02 under the same conditions.', 'text': 'Target-10212997', 'table': 'None'}, {'question': 'How do the log K values for halofantrine and desbutylhalofantrine compare to those of quinidine and chloroquine when forming a complex with ferriprotoporphyrin IX?', 'answer': 'The log K values for halofantrine and desbutylhalofantrine are 5.29 +/- 0.02 and 5.15 +/- 0.02 respectively, which are stronger than both quinidine (log K = 5.02 +/- 0.03) and chloroquine (log K = 4.56 +/- 0.02) when forming a complex with ferriprotoporphyrin IX.', 'text': 'Target-10212997', 'table': 'None'}, {'question': 'What conditions were used to achieve the formation of beta-haematin, and how does this relate to the inhibition effect of antimalarial drugs?', 'answer': 'Beta-haematin was formed by reacting haematin in 4.5 M acetate at pH 4.5 and 60 degrees C for 30 minutes, which was shown to be identical to beta-haematin prepared in 4.5 M acetic acid at 70 degrees C overnight at pH 2.6. The antimalarial drugs quinidine, halofantrine, desbutylhalofantrine, and mefloquine were found to inhibit this formation process.', 'text': 'Target-10212997', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 83%|████████▎ | 124/150 [10:08<04:59, 11.51s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does morphine's antinociceptive effect differ in mu opioid receptor knockout mice compared to wild type mice?\n",
      "   answer: Morphine produces a dose-dependent antinociceptive effect in mu opioid receptor knockout mice, but higher doses are needed to achieve this effect compared to wild type mice. This suggests that the mu opioid receptor plays a significant role in morphine's analgesic action.\n",
      "   text: Target-16530171\n",
      "   table: None\n",
      "\n",
      "2. question: Which opioid receptor antagonist completely blocks the antinociceptive effect of morphine in knockout mice?\n",
      "   answer: The antinociceptive effect of morphine in knockout mice is completely blocked by naloxone, a non-selective opioid antagonist, and nor-binaltorphimine (nor-BNI), a selective kappa-opioid receptor antagonist.\n",
      "   text: Target-16530171\n",
      "   table: None\n",
      "\n",
      "3. question: What evidence suggests that the mu opioid receptor is crucial for morphine's analgesic action?\n",
      "   answer: Previous studies, as well as the passage, indicate that mu opioid receptor knockout mice show a virtual lack of analgesia after systemic administration of morphine, suggesting that the mu opioid receptor is crucial for morphine's analgesic action.\n",
      "   text: Target-16530171\n",
      "   table: None\n",
      "\n",
      "4. question: How does the ability of morphine to bind to different opioid receptors in vitro relate to its analgesic action?\n",
      "   answer: Although morphine can bind to mu, kappa, and delta opioid receptors in vitro, its analgesic actions are primarily produced via the mu opioid receptor, as demonstrated by the lack of analgesic effect in mu opioid receptor knockout mice.\n",
      "   text: Target-16530171\n",
      "   table: None\n",
      "\n",
      "5. question: What is the role of nor-binaltorphimine (nor-BNI) in the study of morphine's antinociceptive effect?\n",
      "   answer: Nor-binaltorphimine (nor-BNI), a selective kappa-opioid receptor antagonist, was used in the study to completely block the antinociceptive effect of morphine in mu opioid receptor knockout mice, indicating the involvement of kappa receptors in morphine's action in the absence of mu receptors.\n",
      "   text: Target-16530171\n",
      "   table: None\n",
      "[{'question': \"How does morphine's antinociceptive effect differ in mu opioid receptor knockout mice compared to wild type mice?\", 'answer': \"Morphine produces a dose-dependent antinociceptive effect in mu opioid receptor knockout mice, but higher doses are needed to achieve this effect compared to wild type mice. This suggests that the mu opioid receptor plays a significant role in morphine's analgesic action.\", 'text': 'Target-16530171', 'table': 'None'}, {'question': 'Which opioid receptor antagonist completely blocks the antinociceptive effect of morphine in knockout mice?', 'answer': 'The antinociceptive effect of morphine in knockout mice is completely blocked by naloxone, a non-selective opioid antagonist, and nor-binaltorphimine (nor-BNI), a selective kappa-opioid receptor antagonist.', 'text': 'Target-16530171', 'table': 'None'}, {'question': \"What evidence suggests that the mu opioid receptor is crucial for morphine's analgesic action?\", 'answer': \"Previous studies, as well as the passage, indicate that mu opioid receptor knockout mice show a virtual lack of analgesia after systemic administration of morphine, suggesting that the mu opioid receptor is crucial for morphine's analgesic action.\", 'text': 'Target-16530171', 'table': 'None'}, {'question': 'How does the ability of morphine to bind to different opioid receptors in vitro relate to its analgesic action?', 'answer': 'Although morphine can bind to mu, kappa, and delta opioid receptors in vitro, its analgesic actions are primarily produced via the mu opioid receptor, as demonstrated by the lack of analgesic effect in mu opioid receptor knockout mice.', 'text': 'Target-16530171', 'table': 'None'}, {'question': \"What is the role of nor-binaltorphimine (nor-BNI) in the study of morphine's antinociceptive effect?\", 'answer': \"Nor-binaltorphimine (nor-BNI), a selective kappa-opioid receptor antagonist, was used in the study to completely block the antinociceptive effect of morphine in mu opioid receptor knockout mice, indicating the involvement of kappa receptors in morphine's action in the absence of mu receptors.\", 'text': 'Target-16530171', 'table': 'None'}]\n",
      "No table mapping found for passage Target-7879937\n",
      "No table mapping found for passage Target-12360109\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 85%|████████▍ | 127/150 [10:13<02:27,  6.41s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: Which drugs mentioned in the passage are known to be displaced from serum albumin by anionic drugs?\n",
      "   answer: The drugs mentioned in the passage that are displaced from serum albumin by anionic drugs are tolbutamide, glibencalmide (also known as glyburide), and chlorpropamide.\n",
      "   text: Target-820348\n",
      "   table: None\n",
      "\n",
      "2. question: What is the common pharmaceutical action that phenylbutazone and salicylates have on serum albumin?\n",
      "   answer: Both phenylbutazone and salicylates are anionic drugs that can displace other drugs from serum albumin, affecting their protein binding.\n",
      "   text: Target-820348\n",
      "   table: None\n",
      "\n",
      "3. question: How is bovine serum albumin relevant to the study of drug displacement as mentioned in the passage?\n",
      "   answer: Bovine serum albumin is used as a model in the study of drug displacement from serum albumin, which is crucial for understanding the interaction of drugs like tolbutamide, glibencalmide, and chlorpropamide with anionic drugs.\n",
      "   text: Target-820348\n",
      "   table: None\n",
      "\n",
      "4. question: According to the passage, which non-steroidal anti-inflammatory drug (NSAID) is involved in the displacement of other drugs from serum albumin?\n",
      "   answer: Phenylbutazone, a non-steroidal anti-inflammatory drug (NSAID), is involved in the displacement of other drugs from serum albumin.\n",
      "   text: Target-820348\n",
      "   table: None\n",
      "\n",
      "5. question: In the context of the passage, what role does dialysis play in the study of drug interactions with serum albumin?\n",
      "   answer: Dialysis is likely used as a method to study the extent of drug displacement and binding to serum albumin by anionic drugs, allowing researchers to examine these interactions in a controlled environment.\n",
      "   text: Target-820348\n",
      "   table: None\n",
      "[{'question': 'Which drugs mentioned in the passage are known to be displaced from serum albumin by anionic drugs?', 'answer': 'The drugs mentioned in the passage that are displaced from serum albumin by anionic drugs are tolbutamide, glibencalmide (also known as glyburide), and chlorpropamide.', 'text': 'Target-820348', 'table': 'None'}, {'question': 'What is the common pharmaceutical action that phenylbutazone and salicylates have on serum albumin?', 'answer': 'Both phenylbutazone and salicylates are anionic drugs that can displace other drugs from serum albumin, affecting their protein binding.', 'text': 'Target-820348', 'table': 'None'}, {'question': 'How is bovine serum albumin relevant to the study of drug displacement as mentioned in the passage?', 'answer': 'Bovine serum albumin is used as a model in the study of drug displacement from serum albumin, which is crucial for understanding the interaction of drugs like tolbutamide, glibencalmide, and chlorpropamide with anionic drugs.', 'text': 'Target-820348', 'table': 'None'}, {'question': 'According to the passage, which non-steroidal anti-inflammatory drug (NSAID) is involved in the displacement of other drugs from serum albumin?', 'answer': 'Phenylbutazone, a non-steroidal anti-inflammatory drug (NSAID), is involved in the displacement of other drugs from serum albumin.', 'text': 'Target-820348', 'table': 'None'}, {'question': 'In the context of the passage, what role does dialysis play in the study of drug interactions with serum albumin?', 'answer': 'Dialysis is likely used as a method to study the extent of drug displacement and binding to serum albumin by anionic drugs, allowing researchers to examine these interactions in a controlled environment.', 'text': 'Target-820348', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 85%|████████▌ | 128/150 [10:17<02:06,  5.77s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does lovastatin affect the interaction of LFA-1 with its counter-receptor, and what is its primary clinical use?\n",
      "   answer: Lovastatin inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1 by binding to a highly conserved domain of the LFA-1 alpha-chain called the I-domain. Its primary clinical use is for lowering cholesterol levels.\n",
      "   text: Target-10493852\n",
      "   table: None\n",
      "\n",
      "2. question: What structural techniques were used to reveal the atomic details of lovastatin's inhibition of LFA-1?\n",
      "   answer: Nuclear magnetic resonance spectroscopy and X-ray crystallography were used to reveal the atomic details of lovastatin's inhibition of LFA-1.\n",
      "   text: Target-10493852\n",
      "   table: None\n",
      "\n",
      "3. question: What potential drug development avenues does the study of lovastatin's interaction with LFA-1 suggest?\n",
      "   answer: The study of lovastatin's interaction with LFA-1 suggests avenues for designing novel anti-adhesive and immunosuppressive drugs by providing insights into the mechanisms of LFA-1 mediated signaling.\n",
      "   text: Target-10493852\n",
      "   table: None\n",
      "[{'question': 'How does lovastatin affect the interaction of LFA-1 with its counter-receptor, and what is its primary clinical use?', 'answer': 'Lovastatin inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1 by binding to a highly conserved domain of the LFA-1 alpha-chain called the I-domain. Its primary clinical use is for lowering cholesterol levels.', 'text': 'Target-10493852', 'table': 'None'}, {'question': \"What structural techniques were used to reveal the atomic details of lovastatin's inhibition of LFA-1?\", 'answer': \"Nuclear magnetic resonance spectroscopy and X-ray crystallography were used to reveal the atomic details of lovastatin's inhibition of LFA-1.\", 'text': 'Target-10493852', 'table': 'None'}, {'question': \"What potential drug development avenues does the study of lovastatin's interaction with LFA-1 suggest?\", 'answer': \"The study of lovastatin's interaction with LFA-1 suggests avenues for designing novel anti-adhesive and immunosuppressive drugs by providing insights into the mechanisms of LFA-1 mediated signaling.\", 'text': 'Target-10493852', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 86%|████████▌ | 129/150 [10:22<01:59,  5.70s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What are the side effects of dopamine receptor antagonists when used to counter opioid effects, and how does aripiprazole compare?\n",
      "   answer: Dopamine receptor antagonists are used to counter adverse effects of opioids such as hallucinations, delusions, and emesis, but they can cause side effects like extrapyramidal symptoms. Aripiprazole, a dopamine system stabilizer, was shown to reduce morphine-induced dopamine-related actions without causing catalepsy, even at higher doses, unlike prochlorperazine, which caused catalepsy at high doses.\n",
      "   text: Target-18955042\n",
      "   table: None\n",
      "\n",
      "2. question: How does aripiprazole affect morphine-induced hyperlocomotion and reward in mice?\n",
      "   answer: Aripiprazole significantly suppresses morphine-induced hyperlocomotion and reward in mice, suggesting its potential to mitigate the dopamine-related side effects of morphine.\n",
      "   text: Target-18955042\n",
      "   table: None\n",
      "\n",
      "3. question: What is the observed effect of aripiprazole on the dialysate dopamine level in the nucleus accumbens when stimulated by morphine?\n",
      "   answer: Aripiprazole significantly decreases the increased level of dialysate dopamine in the nucleus accumbens that is stimulated by morphine, indicating its effectiveness in modulating dopamine system activity.\n",
      "   text: Target-18955042\n",
      "   table: None\n",
      "[{'question': 'What are the side effects of dopamine receptor antagonists when used to counter opioid effects, and how does aripiprazole compare?', 'answer': 'Dopamine receptor antagonists are used to counter adverse effects of opioids such as hallucinations, delusions, and emesis, but they can cause side effects like extrapyramidal symptoms. Aripiprazole, a dopamine system stabilizer, was shown to reduce morphine-induced dopamine-related actions without causing catalepsy, even at higher doses, unlike prochlorperazine, which caused catalepsy at high doses.', 'text': 'Target-18955042', 'table': 'None'}, {'question': 'How does aripiprazole affect morphine-induced hyperlocomotion and reward in mice?', 'answer': 'Aripiprazole significantly suppresses morphine-induced hyperlocomotion and reward in mice, suggesting its potential to mitigate the dopamine-related side effects of morphine.', 'text': 'Target-18955042', 'table': 'None'}, {'question': 'What is the observed effect of aripiprazole on the dialysate dopamine level in the nucleus accumbens when stimulated by morphine?', 'answer': 'Aripiprazole significantly decreases the increased level of dialysate dopamine in the nucleus accumbens that is stimulated by morphine, indicating its effectiveness in modulating dopamine system activity.', 'text': 'Target-18955042', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-drug_mixtures.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 87%|████████▋ | 130/150 [10:33<02:19,  6.96s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the affinity of cefoperazone for binding to human serum albumin, and which cephalosporin shows the lowest affinity?\n",
      "   answer: Cefoperazone has an affinity value of 5.6 x 10^4 M^-1 for binding to human serum albumin. Among the cephalosporins studied, cefsulodin shows the lowest affinity with a value of 3.8 x 10^2 M^-1.\n",
      "   text: Target-8950041\n",
      "   table: None\n",
      "\n",
      "2. question: Which cephalosporins have the capacity to bind to the fatty acids binding site on albumin, and which type of protein state is associated with the drug Cetuximab?\n",
      "   answer: Ceftriaxone and cefoperazone have the capacity to bind to the fatty acids binding site on albumin. The drug Cetuximab is associated with a liquid protein state.\n",
      "   text: Target-8950041\n",
      "   table: drugbank-drug\n",
      "\n",
      "3. question: How many types of binding sites does albumin show for ceftriaxone, and what is the primary key of the drug Cetuximab?\n",
      "   answer: Albumin shows two types of binding sites for ceftriaxone. The primary key of the drug Cetuximab is DB00002.\n",
      "   text: Target-8950041\n",
      "   table: drugbank-drug\n",
      "\n",
      "4. question: Which cephalosporin is identified to interact only slightly with site I on serum albumin, and what is the associated drug mixture for Etanercept?\n",
      "   answer: Cefoperazone is identified to interact only slightly with site I on serum albumin. The drug mixture associated with Etanercept is not specified in the provided tables.\n",
      "   text: Target-8950041\n",
      "   table: drugbank-drug_mixtures\n",
      "\n",
      "5. question: Where can the FDA label for the drug Dornase alfa be accessed, and how does its mechanism differ from the cephalosporins in terms of binding to human serum albumin?\n",
      "   answer: The FDA label for the drug Dornase alfa can be accessed via the link: \"//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00003.pdf?1410715221\". Unlike cephalosporins which bind to specific sites on human serum albumin, Dornase alfa cleaves extracellular DNA without affecting intracellular DNA.\n",
      "   text: Target-8950041\n",
      "   table: drugbank-drug\n",
      "[{'question': 'What is the affinity of cefoperazone for binding to human serum albumin, and which cephalosporin shows the lowest affinity?', 'answer': 'Cefoperazone has an affinity value of 5.6 x 10^4 M^-1 for binding to human serum albumin. Among the cephalosporins studied, cefsulodin shows the lowest affinity with a value of 3.8 x 10^2 M^-1.', 'text': 'Target-8950041', 'table': 'None'}, {'question': 'Which cephalosporins have the capacity to bind to the fatty acids binding site on albumin, and which type of protein state is associated with the drug Cetuximab?', 'answer': 'Ceftriaxone and cefoperazone have the capacity to bind to the fatty acids binding site on albumin. The drug Cetuximab is associated with a liquid protein state.', 'text': 'Target-8950041', 'table': 'drugbank-drug'}, {'question': 'How many types of binding sites does albumin show for ceftriaxone, and what is the primary key of the drug Cetuximab?', 'answer': 'Albumin shows two types of binding sites for ceftriaxone. The primary key of the drug Cetuximab is DB00002.', 'text': 'Target-8950041', 'table': 'drugbank-drug'}, {'question': 'Which cephalosporin is identified to interact only slightly with site I on serum albumin, and what is the associated drug mixture for Etanercept?', 'answer': 'Cefoperazone is identified to interact only slightly with site I on serum albumin. The drug mixture associated with Etanercept is not specified in the provided tables.', 'text': 'Target-8950041', 'table': 'drugbank-drug_mixtures'}, {'question': 'Where can the FDA label for the drug Dornase alfa be accessed, and how does its mechanism differ from the cephalosporins in terms of binding to human serum albumin?', 'answer': 'The FDA label for the drug Dornase alfa can be accessed via the link: \"//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00003.pdf?1410715221\". Unlike cephalosporins which bind to specific sites on human serum albumin, Dornase alfa cleaves extracellular DNA without affecting intracellular DNA.', 'text': 'Target-8950041', 'table': 'drugbank-drug'}]\n",
      "No table mapping found for passage Target-26064350\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 88%|████████▊ | 132/150 [10:38<01:33,  5.22s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does chloroquine affect TNF-alpha production in mononuclear phagocytes, and what method was used to measure TNF-alpha production?\n",
      "   answer: Chloroquine inhibits TNF-alpha production in mononuclear phagocytes. The production of TNF-alpha was measured using ELISA in the study.\n",
      "   text: Target-16418198\n",
      "   table: None\n",
      "\n",
      "2. question: What are the primary cytokines involved in the pathogenesis of rheumatoid arthritis that chloroquine targets?\n",
      "   answer: The primary cytokines involved in the pathogenesis of rheumatoid arthritis that chloroquine targets are TNF-alpha, IL-1, and IL-6.\n",
      "   text: Target-16418198\n",
      "   table: None\n",
      "\n",
      "3. question: What experimental techniques were employed to analyze mRNA levels and TNF-alpha synthesis in the study?\n",
      "   answer: The study employed northern blotting and reverse transcription-polymerase chain reaction to measure mRNA levels and used metabolic labelling and immunoprecipitation analysis to analyze the synthesis of the 26-kDa TNF-alpha precursor.\n",
      "   text: Target-16418198\n",
      "   table: None\n",
      "\n",
      "4. question: What types of cells were used in the study to investigate the effects of chloroquine on cytokine production?\n",
      "   answer: The study used human peripheral blood mononuclear cells, monocytes/macrophages, and monocytic U-937 and THP-1 cells to investigate the effects of chloroquine on cytokine production.\n",
      "   text: Target-16418198\n",
      "   table: None\n",
      "\n",
      "5. question: What is the significance of TNF-alpha, IL-1, and IL-6 in inflammatory diseases, and how does chloroquine's mechanism of action relate to these cytokines?\n",
      "   answer: TNF-alpha, IL-1, and IL-6 play primary roles in the pathogenesis of rheumatoid arthritis and other inflammatory diseases. Chloroquine's mechanism of action involves inhibiting the production of these cytokines from mononuclear phagocytes.\n",
      "   text: Target-16418198\n",
      "   table: None\n",
      "[{'question': 'How does chloroquine affect TNF-alpha production in mononuclear phagocytes, and what method was used to measure TNF-alpha production?', 'answer': 'Chloroquine inhibits TNF-alpha production in mononuclear phagocytes. The production of TNF-alpha was measured using ELISA in the study.', 'text': 'Target-16418198', 'table': 'None'}, {'question': 'What are the primary cytokines involved in the pathogenesis of rheumatoid arthritis that chloroquine targets?', 'answer': 'The primary cytokines involved in the pathogenesis of rheumatoid arthritis that chloroquine targets are TNF-alpha, IL-1, and IL-6.', 'text': 'Target-16418198', 'table': 'None'}, {'question': 'What experimental techniques were employed to analyze mRNA levels and TNF-alpha synthesis in the study?', 'answer': 'The study employed northern blotting and reverse transcription-polymerase chain reaction to measure mRNA levels and used metabolic labelling and immunoprecipitation analysis to analyze the synthesis of the 26-kDa TNF-alpha precursor.', 'text': 'Target-16418198', 'table': 'None'}, {'question': 'What types of cells were used in the study to investigate the effects of chloroquine on cytokine production?', 'answer': 'The study used human peripheral blood mononuclear cells, monocytes/macrophages, and monocytic U-937 and THP-1 cells to investigate the effects of chloroquine on cytokine production.', 'text': 'Target-16418198', 'table': 'None'}, {'question': \"What is the significance of TNF-alpha, IL-1, and IL-6 in inflammatory diseases, and how does chloroquine's mechanism of action relate to these cytokines?\", 'answer': \"TNF-alpha, IL-1, and IL-6 play primary roles in the pathogenesis of rheumatoid arthritis and other inflammatory diseases. Chloroquine's mechanism of action involves inhibiting the production of these cytokines from mononuclear phagocytes.\", 'text': 'Target-16418198', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 89%|████████▊ | 133/150 [10:45<01:33,  5.53s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the mechanism by which KN-62 suppresses interleukin-18 release in the context of inflammatory conditions like sepsis?\n",
      "   answer: KN-62 suppresses interleukin-18 release by inhibiting ATP-mediated cellular activation via the purinoreceptor subtype P(2x7). This pharmacological interference with cytokine secretion could potentially curb the overproduction of interleukin-18 in septic patients.\n",
      "   text: Target-14660039\n",
      "   table: None\n",
      "\n",
      "2. question: How does glyburide affect the release of interleukin-18 from peripheral blood mononuclear cells?\n",
      "   answer: Glyburide inhibits interleukin-18 release by acting as a modulator of ion transport and an inhibitor of ATP-binding cassette transporter 1. This action suggests that glyburide could play a role in reducing interleukin-18 overproduction in inflammatory conditions such as sepsis.\n",
      "   text: Target-14660039\n",
      "   table: None\n",
      "\n",
      "3. question: What role does lipopolysaccharide/ATP play in the activation of monocytes regarding interleukin-18 release?\n",
      "   answer: Lipopolysaccharide/ATP activates monocytes, leading to the release of interleukin-18. This process is significant in inflammatory conditions like sepsis, where augmented levels of interleukin-18 are observed in patients' sera.\n",
      "   text: Target-14660039\n",
      "   table: None\n",
      "\n",
      "4. question: What is the significance of pharmacological agents such as KN-62 or glyburide in the treatment of sepsis?\n",
      "   answer: Pharmacological agents like KN-62 or glyburide are significant in treating sepsis because they can modulate the release of interleukin-18 by interfering with cytokine secretion. This modulation has the potential to curb the overproduction of interleukin-18, a key feature of inflammatory conditions such as sepsis.\n",
      "   text: Target-14660039\n",
      "   table: None\n",
      "\n",
      "5. question: What is the potential therapeutic implication of modulating interleukin-18 release in septic patients?\n",
      "   answer: The potential therapeutic implication of modulating interleukin-18 release in septic patients includes reducing excessive inflammation associated with sepsis. By using agents like KN-62 or glyburide to interfere with cytokine secretion, it may be possible to manage and control the inflammatory response, thereby improving patient outcomes.\n",
      "   text: Target-14660039\n",
      "   table: None\n",
      "[{'question': 'What is the mechanism by which KN-62 suppresses interleukin-18 release in the context of inflammatory conditions like sepsis?', 'answer': 'KN-62 suppresses interleukin-18 release by inhibiting ATP-mediated cellular activation via the purinoreceptor subtype P(2x7). This pharmacological interference with cytokine secretion could potentially curb the overproduction of interleukin-18 in septic patients.', 'text': 'Target-14660039', 'table': 'None'}, {'question': 'How does glyburide affect the release of interleukin-18 from peripheral blood mononuclear cells?', 'answer': 'Glyburide inhibits interleukin-18 release by acting as a modulator of ion transport and an inhibitor of ATP-binding cassette transporter 1. This action suggests that glyburide could play a role in reducing interleukin-18 overproduction in inflammatory conditions such as sepsis.', 'text': 'Target-14660039', 'table': 'None'}, {'question': 'What role does lipopolysaccharide/ATP play in the activation of monocytes regarding interleukin-18 release?', 'answer': \"Lipopolysaccharide/ATP activates monocytes, leading to the release of interleukin-18. This process is significant in inflammatory conditions like sepsis, where augmented levels of interleukin-18 are observed in patients' sera.\", 'text': 'Target-14660039', 'table': 'None'}, {'question': 'What is the significance of pharmacological agents such as KN-62 or glyburide in the treatment of sepsis?', 'answer': 'Pharmacological agents like KN-62 or glyburide are significant in treating sepsis because they can modulate the release of interleukin-18 by interfering with cytokine secretion. This modulation has the potential to curb the overproduction of interleukin-18, a key feature of inflammatory conditions such as sepsis.', 'text': 'Target-14660039', 'table': 'None'}, {'question': 'What is the potential therapeutic implication of modulating interleukin-18 release in septic patients?', 'answer': 'The potential therapeutic implication of modulating interleukin-18 release in septic patients includes reducing excessive inflammation associated with sepsis. By using agents like KN-62 or glyburide to interfere with cytokine secretion, it may be possible to manage and control the inflammatory response, thereby improving patient outcomes.', 'text': 'Target-14660039', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 89%|████████▉ | 134/150 [10:54<01:40,  6.30s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the primary use of mitotane (o,p'-DDD) as described in the passage and what information about its FDA approval status can be derived from the tables provided?\n",
      "   answer: Mitotane (o,p'-DDD) is used as an adrenolytic agent for the treatment of adrenocortical carcinoma. The passage does not provide specific FDA approval information, and the related tables do not include data on mitotane, so its FDA approval status cannot be confirmed from this data.\n",
      "   text: Target-9118466\n",
      "   table: None\n",
      "\n",
      "2. question: Can you identify any biochemical targets of mitotane as mentioned in the passage and verify their presence in the related tables?\n",
      "   answer: The passage mentions that mitotane forms adducts with cytochrome P-450scc and adrenodoxin. These specific targets are not listed in the provided related tables, so their presence cannot be verified from this data.\n",
      "   text: Target-9118466\n",
      "   table: None\n",
      "\n",
      "3. question: How was the electrophoresis study on mitotane conducted according to the passage, and is there any additional information about the methodology from the tables?\n",
      "   answer: The electrophoresis study on mitotane was conducted using a 125I-labeled analog of mitotane, and gel electrophoresis patterns were obtained from adrenocortical preparations of bovine, canine, and human sources. The related tables do not provide additional information on the methodology of this study.\n",
      "   text: Target-9118466\n",
      "   table: None\n",
      "\n",
      "4. question: What differences, if any, are there between the electrophoresis separation patterns of mitotane adducts from various adrenocortical sources as described in the passage?\n",
      "   answer: The passage states that the electrophoresis separations were similar for all preparations, with bands at apparent molecular weights of 49.5 and 11.5 kDa. The tables do not provide further differentiation or details on these patterns.\n",
      "   text: Target-9118466\n",
      "   table: None\n",
      "\n",
      "5. question: Does the passage provide information on the use of mitotane in species other than humans, and do the tables offer any insights into its application in veterinary medicine?\n",
      "   answer: The passage mentions that electrophoresis patterns were obtained from bovine and canine adrenocortical preparations, indicating some level of study or application in these species. However, the tables do not provide additional insights into its veterinary use.\n",
      "   text: Target-9118466\n",
      "   table: None\n",
      "[{'question': \"What is the primary use of mitotane (o,p'-DDD) as described in the passage and what information about its FDA approval status can be derived from the tables provided?\", 'answer': \"Mitotane (o,p'-DDD) is used as an adrenolytic agent for the treatment of adrenocortical carcinoma. The passage does not provide specific FDA approval information, and the related tables do not include data on mitotane, so its FDA approval status cannot be confirmed from this data.\", 'text': 'Target-9118466', 'table': 'None'}, {'question': 'Can you identify any biochemical targets of mitotane as mentioned in the passage and verify their presence in the related tables?', 'answer': 'The passage mentions that mitotane forms adducts with cytochrome P-450scc and adrenodoxin. These specific targets are not listed in the provided related tables, so their presence cannot be verified from this data.', 'text': 'Target-9118466', 'table': 'None'}, {'question': 'How was the electrophoresis study on mitotane conducted according to the passage, and is there any additional information about the methodology from the tables?', 'answer': 'The electrophoresis study on mitotane was conducted using a 125I-labeled analog of mitotane, and gel electrophoresis patterns were obtained from adrenocortical preparations of bovine, canine, and human sources. The related tables do not provide additional information on the methodology of this study.', 'text': 'Target-9118466', 'table': 'None'}, {'question': 'What differences, if any, are there between the electrophoresis separation patterns of mitotane adducts from various adrenocortical sources as described in the passage?', 'answer': 'The passage states that the electrophoresis separations were similar for all preparations, with bands at apparent molecular weights of 49.5 and 11.5 kDa. The tables do not provide further differentiation or details on these patterns.', 'text': 'Target-9118466', 'table': 'None'}, {'question': 'Does the passage provide information on the use of mitotane in species other than humans, and do the tables offer any insights into its application in veterinary medicine?', 'answer': 'The passage mentions that electrophoresis patterns were obtained from bovine and canine adrenocortical preparations, indicating some level of study or application in these species. However, the tables do not provide additional insights into its veterinary use.', 'text': 'Target-9118466', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 90%|█████████ | 135/150 [11:02<01:41,  6.74s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What was the primary aim of the Danish Breast Cancer Cooperative Group trial 89D regarding epirubicin?\n",
      "   answer: The primary aim of the Danish Breast Cancer Cooperative Group trial 89D was to evaluate the predictive value of HER2 and topoisomerase IIalpha gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients.\n",
      "   text: Target-16234514\n",
      "   table: None\n",
      "\n",
      "2. question: How was epirubicin used in the Danish Breast Cancer Cooperative Group trial 89D?\n",
      "   answer: In the Danish Breast Cancer Cooperative Group trial 89D, epirubicin was used as part of the CEF regimen, which included cyclophosphamide, epirubicin, and fluorouracil. This regimen was administered to 480 patients in the study.\n",
      "   text: Target-16234514\n",
      "   table: None\n",
      "\n",
      "3. question: What percentage of tumors were HER2-positive in the study, and was this a predictive marker for epirubicin sensitivity?\n",
      "   answer: In the study, 33% of the 805 investigated tumors were HER2-positive. However, HER2-positivity was not found to be a predictive marker for epirubicin sensitivity.\n",
      "   text: Target-16234514\n",
      "   table: None\n",
      "\n",
      "4. question: What were the findings regarding TOP2A changes in the tumors, and how did these changes affect the efficacy of epirubicin?\n",
      "   answer: The study found that 23% of the 773 investigated tumors had TOP2A changes, with 12% having amplifications and 11% having deletions. Patients with TOP2A amplification had an increased response to epirubicin.\n",
      "   text: Target-16234514\n",
      "   table: None\n",
      "\n",
      "5. question: What was the comparison between the number of patients receiving CMF and CEF in the trial, and what does CEF stand for?\n",
      "   answer: In the trial, 500 patients were allocated to receive CMF (cyclophosphamide, methotrexate, and fluorouracil), while 480 patients received CEF (cyclophosphamide, epirubicin, and fluorouracil).\n",
      "   text: Target-16234514\n",
      "   table: None\n",
      "[{'question': 'What was the primary aim of the Danish Breast Cancer Cooperative Group trial 89D regarding epirubicin?', 'answer': 'The primary aim of the Danish Breast Cancer Cooperative Group trial 89D was to evaluate the predictive value of HER2 and topoisomerase IIalpha gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients.', 'text': 'Target-16234514', 'table': 'None'}, {'question': 'How was epirubicin used in the Danish Breast Cancer Cooperative Group trial 89D?', 'answer': 'In the Danish Breast Cancer Cooperative Group trial 89D, epirubicin was used as part of the CEF regimen, which included cyclophosphamide, epirubicin, and fluorouracil. This regimen was administered to 480 patients in the study.', 'text': 'Target-16234514', 'table': 'None'}, {'question': 'What percentage of tumors were HER2-positive in the study, and was this a predictive marker for epirubicin sensitivity?', 'answer': 'In the study, 33% of the 805 investigated tumors were HER2-positive. However, HER2-positivity was not found to be a predictive marker for epirubicin sensitivity.', 'text': 'Target-16234514', 'table': 'None'}, {'question': 'What were the findings regarding TOP2A changes in the tumors, and how did these changes affect the efficacy of epirubicin?', 'answer': 'The study found that 23% of the 773 investigated tumors had TOP2A changes, with 12% having amplifications and 11% having deletions. Patients with TOP2A amplification had an increased response to epirubicin.', 'text': 'Target-16234514', 'table': 'None'}, {'question': 'What was the comparison between the number of patients receiving CMF and CEF in the trial, and what does CEF stand for?', 'answer': 'In the trial, 500 patients were allocated to receive CMF (cyclophosphamide, methotrexate, and fluorouracil), while 480 patients received CEF (cyclophosphamide, epirubicin, and fluorouracil).', 'text': 'Target-16234514', 'table': 'None'}]\n",
      "No table mapping found for passage Target-19188392\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 91%|█████████▏| 137/150 [11:11<01:15,  5.79s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does the CYP2C8 gene influence the pharmacokinetics of paclitaxel, and which alleles were studied for this effect?\n",
      "   answer: The CYP2C8 gene influences the pharmacokinetics of paclitaxel through its polymorphisms, which result in interindividual differences in drug metabolism. The study evaluated three CYP2C8 allelic variants (CYP2C8.2, CYP2C8.3, and CYP2C8.4) alongside the wild-type CYP2C8 (CYP2C8.1), assessing their effects on the metabolism of paclitaxel.\n",
      "   text: Target-23536207\n",
      "   table: None\n",
      "\n",
      "2. question: What role does CYP2C8 play in the metabolism of ibuprofen, and how was this evaluated in the study?\n",
      "   answer: CYP2C8 plays a significant role in the metabolism of ibuprofen enantiomers. The study assessed the genotype-phenotype correlations of various CYP2C8 alleles on the metabolism of ibuprofen enantiomers by expressing the allelic variants and wild-type CYP2C8 with human cytochrome P450 oxidoreductase (POR) and cytochrome b5 in an insect cell expression system.\n",
      "   text: Target-23536207\n",
      "   table: None\n",
      "\n",
      "3. question: What are the differences in the intrinsic clearance (CLint) values for paclitaxel among CYP2C8 allelic variants compared to the wild-type?\n",
      "   answer: The intrinsic clearance (CLint) values for paclitaxel were found to be different among the CYP2C8 allelic variants compared to the wild-type CYP2C8.1. Specifically, CYP2C8.2 had a CLint value of 47.7%, CYP2C8.3 had 64.3%, and CYP2C8.4 had 30.2% of that of CYP2C8.1, with all differences being statistically significant (p<0.01).\n",
      "   text: Target-23536207\n",
      "   table: None\n",
      "\n",
      "4. question: How does the metabolism of repaglinide differ between the CYP2C8 alleles compared to the wild-type CYP2C8?\n",
      "   answer: The study found that the CLint values for repaglinide metabolism differed among CYP2C8 alleles compared to the wild-type CYP2C8.1. CYP2C8.2 had 77.9% and CYP2C8.4 had 80.2% of the CLint value of CYP2C8.1, with these differences being statistically significant (p<0.05).\n",
      "   text: Target-23536207\n",
      "   table: None\n",
      "\n",
      "5. question: What methodology was used to express CYP2C8 allelic variants in the study, and what was the purpose of co-expressing them with human cytochrome P450 oxidoreductase and cytochrome b5?\n",
      "   answer: In the study, CYP2C8 allelic variants were expressed using a baculovirus-assisted insect cell expression system. They were co-expressed with human cytochrome P450 oxidoreductase (POR) and cytochrome b5 to evaluate the effects of genotype-phenotype correlations on the metabolism of paclitaxel, repaglinide, and ibuprofen enantiomers.\n",
      "   text: Target-23536207\n",
      "   table: None\n",
      "[{'question': 'How does the CYP2C8 gene influence the pharmacokinetics of paclitaxel, and which alleles were studied for this effect?', 'answer': 'The CYP2C8 gene influences the pharmacokinetics of paclitaxel through its polymorphisms, which result in interindividual differences in drug metabolism. The study evaluated three CYP2C8 allelic variants (CYP2C8.2, CYP2C8.3, and CYP2C8.4) alongside the wild-type CYP2C8 (CYP2C8.1), assessing their effects on the metabolism of paclitaxel.', 'text': 'Target-23536207', 'table': 'None'}, {'question': 'What role does CYP2C8 play in the metabolism of ibuprofen, and how was this evaluated in the study?', 'answer': 'CYP2C8 plays a significant role in the metabolism of ibuprofen enantiomers. The study assessed the genotype-phenotype correlations of various CYP2C8 alleles on the metabolism of ibuprofen enantiomers by expressing the allelic variants and wild-type CYP2C8 with human cytochrome P450 oxidoreductase (POR) and cytochrome b5 in an insect cell expression system.', 'text': 'Target-23536207', 'table': 'None'}, {'question': 'What are the differences in the intrinsic clearance (CLint) values for paclitaxel among CYP2C8 allelic variants compared to the wild-type?', 'answer': 'The intrinsic clearance (CLint) values for paclitaxel were found to be different among the CYP2C8 allelic variants compared to the wild-type CYP2C8.1. Specifically, CYP2C8.2 had a CLint value of 47.7%, CYP2C8.3 had 64.3%, and CYP2C8.4 had 30.2% of that of CYP2C8.1, with all differences being statistically significant (p<0.01).', 'text': 'Target-23536207', 'table': 'None'}, {'question': 'How does the metabolism of repaglinide differ between the CYP2C8 alleles compared to the wild-type CYP2C8?', 'answer': 'The study found that the CLint values for repaglinide metabolism differed among CYP2C8 alleles compared to the wild-type CYP2C8.1. CYP2C8.2 had 77.9% and CYP2C8.4 had 80.2% of the CLint value of CYP2C8.1, with these differences being statistically significant (p<0.05).', 'text': 'Target-23536207', 'table': 'None'}, {'question': 'What methodology was used to express CYP2C8 allelic variants in the study, and what was the purpose of co-expressing them with human cytochrome P450 oxidoreductase and cytochrome b5?', 'answer': 'In the study, CYP2C8 allelic variants were expressed using a baculovirus-assisted insect cell expression system. They were co-expressed with human cytochrome P450 oxidoreductase (POR) and cytochrome b5 to evaluate the effects of genotype-phenotype correlations on the metabolism of paclitaxel, repaglinide, and ibuprofen enantiomers.', 'text': 'Target-23536207', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 92%|█████████▏| 138/150 [11:15<01:05,  5.49s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does the deletion of CTR1 affect the uptake of cisplatin (DDP) in the experimental design mentioned in the passage?\n",
      "   answer: The deletion of CTR1 reduces the uptake of cisplatin (DDP) in the experimental design. This conclusion was determined by knocking down CTR2 expression in a mouse embryo fibroblast line where both CTR1 alleles had been deleted, which resulted in decreased uptake of Cu, DDP, and CBDCA and increased resistance to these drugs.\n",
      "   text: Target-19509135\n",
      "   table: None\n",
      "\n",
      "2. question: What method was used to quantify cisplatin (DDP) in the study?\n",
      "   answer: Cisplatin (DDP) was quantified using inductively coupled plasma mass spectrometry in the study.\n",
      "   text: Target-19509135\n",
      "   table: None\n",
      "\n",
      "3. question: What is the role of copper transporter CTR2 in relation to platinum-containing drugs like cisplatin and carboplatin?\n",
      "   answer: Copper transporter CTR2 mediates the uptake of Cu(+1) by mammalian cells and regulates the sensitivity to platinum-containing drugs such as cisplatin and carboplatin by affecting their influx, intracellular trafficking, and efflux.\n",
      "   text: Target-19509135\n",
      "   table: None\n",
      "\n",
      "4. question: Which experimental techniques were employed to assess CTR2 levels in the study?\n",
      "   answer: The study used quantitative reverse transcription-PCR and Western blot analysis to determine CTR2 levels.\n",
      "   text: Target-19509135\n",
      "   table: None\n",
      "\n",
      "5. question: What experimental model was used to study the role of CTR2 in platinum drug sensitivity?\n",
      "   answer: The study used an isogenic pair of mouse embryo fibroblasts consisting of a CTR1(+/+) line and a CTR1(-/-) line with both CTR1 alleles deleted to examine the role of CTR2 in platinum drug sensitivity.\n",
      "   text: Target-19509135\n",
      "   table: None\n",
      "[{'question': 'How does the deletion of CTR1 affect the uptake of cisplatin (DDP) in the experimental design mentioned in the passage?', 'answer': 'The deletion of CTR1 reduces the uptake of cisplatin (DDP) in the experimental design. This conclusion was determined by knocking down CTR2 expression in a mouse embryo fibroblast line where both CTR1 alleles had been deleted, which resulted in decreased uptake of Cu, DDP, and CBDCA and increased resistance to these drugs.', 'text': 'Target-19509135', 'table': 'None'}, {'question': 'What method was used to quantify cisplatin (DDP) in the study?', 'answer': 'Cisplatin (DDP) was quantified using inductively coupled plasma mass spectrometry in the study.', 'text': 'Target-19509135', 'table': 'None'}, {'question': 'What is the role of copper transporter CTR2 in relation to platinum-containing drugs like cisplatin and carboplatin?', 'answer': 'Copper transporter CTR2 mediates the uptake of Cu(+1) by mammalian cells and regulates the sensitivity to platinum-containing drugs such as cisplatin and carboplatin by affecting their influx, intracellular trafficking, and efflux.', 'text': 'Target-19509135', 'table': 'None'}, {'question': 'Which experimental techniques were employed to assess CTR2 levels in the study?', 'answer': 'The study used quantitative reverse transcription-PCR and Western blot analysis to determine CTR2 levels.', 'text': 'Target-19509135', 'table': 'None'}, {'question': 'What experimental model was used to study the role of CTR2 in platinum drug sensitivity?', 'answer': 'The study used an isogenic pair of mouse embryo fibroblasts consisting of a CTR1(+/+) line and a CTR1(-/-) line with both CTR1 alleles deleted to examine the role of CTR2 in platinum drug sensitivity.', 'text': 'Target-19509135', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 93%|█████████▎| 139/150 [11:20<00:58,  5.31s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How does probenecid affect uric acid excretion in the treatment of gout?\n",
      "   answer: Probenecid is used in the treatment of gout by acting on an organic anion transporter to block urate reuptake, thereby affecting uric acid excretion in the kidneys. This action helps in managing the levels of uric acid in patients with gout.\n",
      "   text: Target-18596212\n",
      "   table: None\n",
      "\n",
      "2. question: What is the mechanism by which probenecid discriminates between pannexin and connexin channels?\n",
      "   answer: Probenecid inhibits currents mediated by pannexin 1 channels but does not affect channels formed by connexins. This selective inhibition allows probenecid to discriminate between the two types of channels.\n",
      "   text: Target-18596212\n",
      "   table: None\n",
      "\n",
      "3. question: What evidence supports the involvement of pannexin 1 channels in ATP release, as observed in the study on probenecid?\n",
      "   answer: The study demonstrated that probenecid inhibited currents mediated by pannexin 1 channels in the same concentration range as observed for inhibition of transport processes, suggesting that large membrane channels, such as pannexin 1, may be involved in nonvesicular ATP release.\n",
      "   text: Target-18596212\n",
      "   table: None\n",
      "\n",
      "4. question: What role does probenecid play in distinguishing between different ion channel types?\n",
      "   answer: Probenecid allows for the discrimination between ion channels formed by connexins and those formed by pannexins, as it selectively inhibits pannexin 1 channels without affecting connexin channels.\n",
      "   text: Target-18596212\n",
      "   table: None\n",
      "[{'question': 'How does probenecid affect uric acid excretion in the treatment of gout?', 'answer': 'Probenecid is used in the treatment of gout by acting on an organic anion transporter to block urate reuptake, thereby affecting uric acid excretion in the kidneys. This action helps in managing the levels of uric acid in patients with gout.', 'text': 'Target-18596212', 'table': 'None'}, {'question': 'What is the mechanism by which probenecid discriminates between pannexin and connexin channels?', 'answer': 'Probenecid inhibits currents mediated by pannexin 1 channels but does not affect channels formed by connexins. This selective inhibition allows probenecid to discriminate between the two types of channels.', 'text': 'Target-18596212', 'table': 'None'}, {'question': 'What evidence supports the involvement of pannexin 1 channels in ATP release, as observed in the study on probenecid?', 'answer': 'The study demonstrated that probenecid inhibited currents mediated by pannexin 1 channels in the same concentration range as observed for inhibition of transport processes, suggesting that large membrane channels, such as pannexin 1, may be involved in nonvesicular ATP release.', 'text': 'Target-18596212', 'table': 'None'}, {'question': 'What role does probenecid play in distinguishing between different ion channel types?', 'answer': 'Probenecid allows for the discrimination between ion channels formed by connexins and those formed by pannexins, as it selectively inhibits pannexin 1 channels without affecting connexin channels.', 'text': 'Target-18596212', 'table': 'None'}]\n",
      "No table mapping found for passage Target-14576103\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 94%|█████████▍| 141/150 [11:24<00:35,  3.94s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the mechanism of action of tegaserod in treating constipation-predominant irritable bowel syndrome?\n",
      "   answer: Tegaserod is a novel drug that treats constipation-predominant irritable bowel syndrome by acting as a selective partial agonist of serotonin receptor type 4 (5-HT4) receptors located in the enteric nervous system. This mechanism is linked to its prokinetic effect.\n",
      "   text: Target-17510552\n",
      "   table: None\n",
      "\n",
      "2. question: What are the IC50-values for tegaserod's inhibition of SERT-, DAT-, and NET-mediated transport, and how do these values reflect its interaction with these transporters?\n",
      "   answer: Tegaserod inhibits SERT-, DAT-, and NET-mediated transport with IC50-values of 11.7, 20.7, and 3.2 micromol/l, respectively. These values suggest that tegaserod has varying levels of inhibition across these transporters, with the strongest inhibition demonstrated in NET-mediated transport.\n",
      "   text: Target-17510552\n",
      "   table: None\n",
      "\n",
      "3. question: Does tegaserod interact with the human serotonin reuptake transporter (hSERT) and the uptake transporters for dopamine (hDAT) and norepinephrine (hNET)?\n",
      "   answer: Yes, the study investigated tegaserod's interaction with these transporters and found that it inhibits SERT-, DAT-, and NET-mediated transport, indicating its interaction with the human serotonin reuptake transporter (hSERT) and the uptake transporters for dopamine (hDAT) and norepinephrine (hNET).\n",
      "   text: Target-17510552\n",
      "   table: None\n",
      "[{'question': 'What is the mechanism of action of tegaserod in treating constipation-predominant irritable bowel syndrome?', 'answer': 'Tegaserod is a novel drug that treats constipation-predominant irritable bowel syndrome by acting as a selective partial agonist of serotonin receptor type 4 (5-HT4) receptors located in the enteric nervous system. This mechanism is linked to its prokinetic effect.', 'text': 'Target-17510552', 'table': 'None'}, {'question': \"What are the IC50-values for tegaserod's inhibition of SERT-, DAT-, and NET-mediated transport, and how do these values reflect its interaction with these transporters?\", 'answer': 'Tegaserod inhibits SERT-, DAT-, and NET-mediated transport with IC50-values of 11.7, 20.7, and 3.2 micromol/l, respectively. These values suggest that tegaserod has varying levels of inhibition across these transporters, with the strongest inhibition demonstrated in NET-mediated transport.', 'text': 'Target-17510552', 'table': 'None'}, {'question': 'Does tegaserod interact with the human serotonin reuptake transporter (hSERT) and the uptake transporters for dopamine (hDAT) and norepinephrine (hNET)?', 'answer': \"Yes, the study investigated tegaserod's interaction with these transporters and found that it inhibits SERT-, DAT-, and NET-mediated transport, indicating its interaction with the human serotonin reuptake transporter (hSERT) and the uptake transporters for dopamine (hDAT) and norepinephrine (hNET).\", 'text': 'Target-17510552', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 95%|█████████▍| 142/150 [11:35<00:44,  5.61s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What role does P-glycoprotein play in the efficacy of corticosteroids used for inflammatory bowel disease treatment?\n",
      "   answer: P-glycoprotein, expressed in the apical membrane of certain cells, potentially affects the efficacy of corticosteroids like budesonide and prednisone by acting as a drug efflux pump. This could contribute to variable therapeutic effects in treating inflammatory bowel disease, such as Crohn's disease, by affecting drug transport and resistance.\n",
      "   text: Target-15472518\n",
      "   table: drugbank-transporters\n",
      "\n",
      "2. question: How was the transport of corticosteroids studied to assess their interaction with P-glycoprotein?\n",
      "   answer: The transport of [3H]budesonide and [3H]prednisone was studied using polarized basal to apical transport in monolayers of L-MDR1 cells and Caco-2 cells, both expressing P-glycoprotein. The study measured drug transport over 4 hours at a substrate concentration of 5 microM to evaluate their potential as P-glycoprotein substrates.\n",
      "   text: Target-15472518\n",
      "   table: drugbank-transporters\n",
      "\n",
      "3. question: Why is steroid resistance a significant concern in the management of Crohn's disease?\n",
      "   answer: Steroid resistance poses a significant challenge in managing Crohn's disease because it is associated with increased expression of P-glycoprotein, which may lead to a poor response to corticosteroid therapy. Understanding the interaction of corticosteroids with P-glycoprotein is crucial for addressing this resistance.\n",
      "   text: Target-15472518\n",
      "   table: drugbank-transporters\n",
      "\n",
      "4. question: What hypothesis was tested regarding the corticosteroids budesonide and prednisone in the study?\n",
      "   answer: The study tested the hypothesis that budesonide and prednisone are substrates of P-glycoprotein, which could contribute to the variable therapeutic effects observed in inflammatory bowel disease treatment.\n",
      "   text: Target-15472518\n",
      "   table: drugbank-transporters\n",
      "\n",
      "5. question: In the context of the passage, which cells were used to study the transport of corticosteroids and what is their significance?\n",
      "   answer: The study used L-MDR1 cells (LLC-PK1 cells stably transfected with human MDR1 cDNA) and Caco-2 cells to study the transport of corticosteroids. These cells are significant because they express P-glycoprotein in their apical membrane, making them suitable models to investigate the role of P-glycoprotein in drug transport and resistance.\n",
      "   text: Target-15472518\n",
      "   table: drugbank-transporters\n",
      "[{'question': 'What role does P-glycoprotein play in the efficacy of corticosteroids used for inflammatory bowel disease treatment?', 'answer': \"P-glycoprotein, expressed in the apical membrane of certain cells, potentially affects the efficacy of corticosteroids like budesonide and prednisone by acting as a drug efflux pump. This could contribute to variable therapeutic effects in treating inflammatory bowel disease, such as Crohn's disease, by affecting drug transport and resistance.\", 'text': 'Target-15472518', 'table': 'drugbank-transporters'}, {'question': 'How was the transport of corticosteroids studied to assess their interaction with P-glycoprotein?', 'answer': 'The transport of [3H]budesonide and [3H]prednisone was studied using polarized basal to apical transport in monolayers of L-MDR1 cells and Caco-2 cells, both expressing P-glycoprotein. The study measured drug transport over 4 hours at a substrate concentration of 5 microM to evaluate their potential as P-glycoprotein substrates.', 'text': 'Target-15472518', 'table': 'drugbank-transporters'}, {'question': \"Why is steroid resistance a significant concern in the management of Crohn's disease?\", 'answer': \"Steroid resistance poses a significant challenge in managing Crohn's disease because it is associated with increased expression of P-glycoprotein, which may lead to a poor response to corticosteroid therapy. Understanding the interaction of corticosteroids with P-glycoprotein is crucial for addressing this resistance.\", 'text': 'Target-15472518', 'table': 'drugbank-transporters'}, {'question': 'What hypothesis was tested regarding the corticosteroids budesonide and prednisone in the study?', 'answer': 'The study tested the hypothesis that budesonide and prednisone are substrates of P-glycoprotein, which could contribute to the variable therapeutic effects observed in inflammatory bowel disease treatment.', 'text': 'Target-15472518', 'table': 'drugbank-transporters'}, {'question': 'In the context of the passage, which cells were used to study the transport of corticosteroids and what is their significance?', 'answer': 'The study used L-MDR1 cells (LLC-PK1 cells stably transfected with human MDR1 cDNA) and Caco-2 cells to study the transport of corticosteroids. These cells are significant because they express P-glycoprotein in their apical membrane, making them suitable models to investigate the role of P-glycoprotein in drug transport and resistance.', 'text': 'Target-15472518', 'table': 'drugbank-transporters'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 95%|█████████▌| 143/150 [11:47<00:50,  7.16s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the mechanism of action of pironetin in relation to tubulin binding, and how does this differ from drugs targeting beta-tubulin like vindesine and paclitaxel?\n",
      "   answer: Pironetin is a potent inhibitor of microtubule assembly that covalently binds to alpha-tubulin at Lys352, whereas drugs like vindesine and paclitaxel target beta-tubulin. This unique mechanism allows pironetin to overcome resistance in cell lines that are resistant to beta-tubulin-targeting drugs.\n",
      "   text: Target-17465195\n",
      "   table: None\n",
      "\n",
      "2. question: How does pironetin's efficacy against multidrug-resistant human leukemic cells compare to its effects on parental cells?\n",
      "   answer: Pironetin was found to inhibit the growth of both multidrug-resistant K562/ADM human leukemic cells, which have mdr1 gene expression, and the parental K562 cell lines. It causes complete mitotic arrest and induces apoptosis in these cell lines at concentrations of 30 and 100 nM.\n",
      "   text: Target-17465195\n",
      "   table: None\n",
      "\n",
      "3. question: What was the outcome of using pironetin on small cell lung cancer cell lines, including those resistant to vindesine and paclitaxel?\n",
      "   answer: Pironetin was found to be effective against human small cell lung cancer H69 cells, including cell lines resistant to the microtubule-targeted drugs vindesine (H69/VDS) and paclitaxel (H69/Txl). It caused complete mitotic arrest and induced apoptosis in both resistant and parental cell lines.\n",
      "   text: Target-17465195\n",
      "   table: None\n",
      "[{'question': 'What is the mechanism of action of pironetin in relation to tubulin binding, and how does this differ from drugs targeting beta-tubulin like vindesine and paclitaxel?', 'answer': 'Pironetin is a potent inhibitor of microtubule assembly that covalently binds to alpha-tubulin at Lys352, whereas drugs like vindesine and paclitaxel target beta-tubulin. This unique mechanism allows pironetin to overcome resistance in cell lines that are resistant to beta-tubulin-targeting drugs.', 'text': 'Target-17465195', 'table': 'None'}, {'question': \"How does pironetin's efficacy against multidrug-resistant human leukemic cells compare to its effects on parental cells?\", 'answer': 'Pironetin was found to inhibit the growth of both multidrug-resistant K562/ADM human leukemic cells, which have mdr1 gene expression, and the parental K562 cell lines. It causes complete mitotic arrest and induces apoptosis in these cell lines at concentrations of 30 and 100 nM.', 'text': 'Target-17465195', 'table': 'None'}, {'question': 'What was the outcome of using pironetin on small cell lung cancer cell lines, including those resistant to vindesine and paclitaxel?', 'answer': 'Pironetin was found to be effective against human small cell lung cancer H69 cells, including cell lines resistant to the microtubule-targeted drugs vindesine (H69/VDS) and paclitaxel (H69/Txl). It caused complete mitotic arrest and induced apoptosis in both resistant and parental cell lines.', 'text': 'Target-17465195', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 96%|█████████▌| 144/150 [11:51<00:38,  6.34s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the bioavailability of Escitalopram, and how is its absorption affected by food intake?\n",
      "   answer: Escitalopram has a bioavailability of 80%, and its absorption is not affected by food intake. \n",
      "   text: Target-17916059\n",
      "   table: None\n",
      "\n",
      "2. question: How does the potency of Escitalopram compare to Citalopram in terms of serotonin re-uptake inhibition?\n",
      "   answer: Escitalopram is more potent and selective than Citalopram in inhibiting serotonin re-uptake in the CNS.\n",
      "   text: Target-17916059\n",
      "   table: None\n",
      "\n",
      "3. question: Which enzyme is a concern when Escitalopram is coadministered with other drugs, and can you give an example of such a drug?\n",
      "   answer: Caution is necessary when Escitalopram is coadministered with drugs metabolised by CYP2D6, such as metoprolol.\n",
      "   text: Target-17916059\n",
      "   table: None\n",
      "\n",
      "4. question: What are the differences in receptor binding between Escitalopram and Citalopram?\n",
      "   answer: Escitalopram is six times less potent than Citalopram in binding to histamine H1 and muscarinic receptors.\n",
      "   text: Target-17916059\n",
      "   table: None\n",
      "\n",
      "5. question: What factors contribute to the low potential for drug interactions with Escitalopram?\n",
      "   answer: Escitalopram has low protein binding and is metabolised by three CYP isozymes, reducing the likelihood of significant effects on metabolic clearance if one isozyme's activity is impaired.\n",
      "   text: Target-17916059\n",
      "   table: None\n",
      "[{'question': 'What is the bioavailability of Escitalopram, and how is its absorption affected by food intake?', 'answer': 'Escitalopram has a bioavailability of 80%, and its absorption is not affected by food intake.', 'text': 'Target-17916059', 'table': 'None'}, {'question': 'How does the potency of Escitalopram compare to Citalopram in terms of serotonin re-uptake inhibition?', 'answer': 'Escitalopram is more potent and selective than Citalopram in inhibiting serotonin re-uptake in the CNS.', 'text': 'Target-17916059', 'table': 'None'}, {'question': 'Which enzyme is a concern when Escitalopram is coadministered with other drugs, and can you give an example of such a drug?', 'answer': 'Caution is necessary when Escitalopram is coadministered with drugs metabolised by CYP2D6, such as metoprolol.', 'text': 'Target-17916059', 'table': 'None'}, {'question': 'What are the differences in receptor binding between Escitalopram and Citalopram?', 'answer': 'Escitalopram is six times less potent than Citalopram in binding to histamine H1 and muscarinic receptors.', 'text': 'Target-17916059', 'table': 'None'}, {'question': 'What factors contribute to the low potential for drug interactions with Escitalopram?', 'answer': \"Escitalopram has low protein binding and is metabolised by three CYP isozymes, reducing the likelihood of significant effects on metabolic clearance if one isozyme's activity is impaired.\", 'text': 'Target-17916059', 'table': 'None'}]\n",
      "No table mapping found for passage Target-2729995\n",
      "No table mapping found for passage Target-19845433\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 98%|█████████▊| 147/150 [11:57<00:12,  4.01s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: How do HIV-1 protease inhibitors affect DU145 prostate cancer cells, and what role does CYP3A4 play in their action?\n",
      "   answer: HIV-1 protease inhibitors, including ritonavir, saquinavir, and indinavir, inhibited the growth of DU145 androgen-independent prostate cancer cells as measured by a clonal proliferation assay. Ritonavir, in particular, is known to inhibit the cytochrome P450 3A4 enzyme (CYP3A4) in liver microsomes, which is involved in drug metabolism and acquisition of drug resistance. This suggests that ritonavir's action on inhibiting CYP3A4 could contribute to its effectiveness in enhancing the antiproliferative effects when used with other anticancer drugs like docetaxel.\n",
      "   text: Target-15492266\n",
      "   table: None\n",
      "\n",
      "2. question: What experimental evidence supports the use of ritonavir in combination with docetaxel for prostate cancer treatment?\n",
      "   answer: In the study, DU145 cells were cultured with docetaxel either alone or in combination with ritonavir. Ritonavir enhanced the antiproliferative and proapoptotic effects of docetaxel in the hormonally independent DU145 prostate cancer cells in vitro, as shown by the clonogenic soft agar assay and detection of the activated form of caspase-3. This evidence suggests that the combination of ritonavir with docetaxel could be beneficial in treating androgen-independent prostate cancer.\n",
      "   text: Target-15492266\n",
      "   table: None\n",
      "\n",
      "3. question: What are the known actions of ritonavir beyond its HIV-1 protease inhibition, specifically related to drug interactions?\n",
      "   answer: Beyond its role as an HIV-1 protease inhibitor, ritonavir is known to inhibit the cytochrome P450 3A4 enzyme (CYP3A4) in liver microsomes. This inhibition is significant as CYP3A4 is involved in drug metabolism and the acquisition of drug resistance, which can affect the pharmacokinetics and efficacy of other medications when used concurrently with ritonavir.\n",
      "   text: Target-15492266\n",
      "   table: None\n",
      "[{'question': 'How do HIV-1 protease inhibitors affect DU145 prostate cancer cells, and what role does CYP3A4 play in their action?', 'answer': \"HIV-1 protease inhibitors, including ritonavir, saquinavir, and indinavir, inhibited the growth of DU145 androgen-independent prostate cancer cells as measured by a clonal proliferation assay. Ritonavir, in particular, is known to inhibit the cytochrome P450 3A4 enzyme (CYP3A4) in liver microsomes, which is involved in drug metabolism and acquisition of drug resistance. This suggests that ritonavir's action on inhibiting CYP3A4 could contribute to its effectiveness in enhancing the antiproliferative effects when used with other anticancer drugs like docetaxel.\", 'text': 'Target-15492266', 'table': 'None'}, {'question': 'What experimental evidence supports the use of ritonavir in combination with docetaxel for prostate cancer treatment?', 'answer': 'In the study, DU145 cells were cultured with docetaxel either alone or in combination with ritonavir. Ritonavir enhanced the antiproliferative and proapoptotic effects of docetaxel in the hormonally independent DU145 prostate cancer cells in vitro, as shown by the clonogenic soft agar assay and detection of the activated form of caspase-3. This evidence suggests that the combination of ritonavir with docetaxel could be beneficial in treating androgen-independent prostate cancer.', 'text': 'Target-15492266', 'table': 'None'}, {'question': 'What are the known actions of ritonavir beyond its HIV-1 protease inhibition, specifically related to drug interactions?', 'answer': 'Beyond its role as an HIV-1 protease inhibitor, ritonavir is known to inhibit the cytochrome P450 3A4 enzyme (CYP3A4) in liver microsomes. This inhibition is significant as CYP3A4 is involved in drug metabolism and the acquisition of drug resistance, which can affect the pharmacokinetics and efficacy of other medications when used concurrently with ritonavir.', 'text': 'Target-15492266', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 99%|█████████▊| 148/150 [12:02<00:08,  4.17s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the receptor profile of rotigotine, and what are its affinities for dopamine receptors?\n",
      "   answer: Rotigotine, a non-ergoline dopamine agonist used for Parkinson's disease, has the highest affinity for the dopamine D3 receptor with a Ki of 0.71 nM. Its affinities for other dopamine receptors are as follows: D4.2 (3.9 nM), D4.7 (5.9 nM), D5 (5.4 nM), D2 (13.5 nM), D4.4 (15 nM), and D1 (83 nM). Additionally, it shows significant affinities for alpha-adrenergic (alpha2B, Ki=27 nM) and serotonin receptors (5-HT1A, Ki=30 nM).\n",
      "   text: Target-18704368\n",
      "   table: None\n",
      "\n",
      "2. question: How does rotigotine function as an agonist in comparison to dopamine at dopamine receptors?\n",
      "   answer: Rotigotine acts as a full agonist at dopamine receptors, with a higher potency compared to dopamine. Its rank order of activity is D3>D2L>D1=D5>D4.4, demonstrating potencies 2,600 and 53 times higher than dopamine at dopamine D3 and D2L receptors, respectively.\n",
      "   text: Target-18704368\n",
      "   table: None\n",
      "\n",
      "3. question: What delivery system is used for administering rotigotine for Parkinson's disease treatment, and what is its benefit?\n",
      "   answer: Rotigotine is administered using a transdermal delivery system (patch) for the once-daily treatment of Parkinson's disease. This system provides continuous drug delivery over 24 hours, which can help maintain consistent therapeutic levels and potentially improve patient compliance.\n",
      "   text: Target-18704368\n",
      "   table: None\n",
      "[{'question': 'What is the receptor profile of rotigotine, and what are its affinities for dopamine receptors?', 'answer': \"Rotigotine, a non-ergoline dopamine agonist used for Parkinson's disease, has the highest affinity for the dopamine D3 receptor with a Ki of 0.71 nM. Its affinities for other dopamine receptors are as follows: D4.2 (3.9 nM), D4.7 (5.9 nM), D5 (5.4 nM), D2 (13.5 nM), D4.4 (15 nM), and D1 (83 nM). Additionally, it shows significant affinities for alpha-adrenergic (alpha2B, Ki=27 nM) and serotonin receptors (5-HT1A, Ki=30 nM).\", 'text': 'Target-18704368', 'table': 'None'}, {'question': 'How does rotigotine function as an agonist in comparison to dopamine at dopamine receptors?', 'answer': 'Rotigotine acts as a full agonist at dopamine receptors, with a higher potency compared to dopamine. Its rank order of activity is D3>D2L>D1=D5>D4.4, demonstrating potencies 2,600 and 53 times higher than dopamine at dopamine D3 and D2L receptors, respectively.', 'text': 'Target-18704368', 'table': 'None'}, {'question': \"What delivery system is used for administering rotigotine for Parkinson's disease treatment, and what is its benefit?\", 'answer': \"Rotigotine is administered using a transdermal delivery system (patch) for the once-daily treatment of Parkinson's disease. This system provides continuous drug delivery over 24 hours, which can help maintain consistent therapeutic levels and potentially improve patient compliance.\", 'text': 'Target-18704368', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-drugs_links.csv', 'drugbank-drug.csv', 'drugbank-targets.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 99%|█████████▉| 149/150 [12:13<00:05,  5.78s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the role of Etoposide (VP-16) as a chemotherapeutic agent, and how does its combination with other drugs affect its efficacy?\n",
      "   answer: Etoposide (VP-16) is a topoisomerase-II (topo II) inhibitor used in chemotherapy. Studies have shown that when VP-16 is combined with other drugs, it demonstrates better clinical responses. Specifically, the combination of moxifloxacin (MXF) and VP-16 enhances cellular topo II inhibitory activity and reduces band depletion of topo II, which suggests an increased efficacy in drug-treated cells.\n",
      "   text: Target-20596674\n",
      "   table: None\n",
      "\n",
      "2. question: How does the combination of moxifloxacin (MXF) and Etoposide (VP-16) affect the cell cycle and apoptosis in HT-29 cells?\n",
      "   answer: The combination of moxifloxacin (MXF) and Etoposide (VP-16) enhances cell cycle arrest at the G2/M phase and increases the appearance of the subG1 peak, which is associated with increased apoptosis in HT-29 cells. This indicates that the combination has a more pronounced effect on inhibiting cell proliferation and inducing cell death compared to either drug alone.\n",
      "   text: Target-20596674\n",
      "   table: None\n",
      "\n",
      "3. question: What methodologies were used in the study to evaluate the effects of moxifloxacin (MXF) and Etoposide (VP-16) on cellular processes?\n",
      "   answer: The study employed several methodologies to evaluate the effects of moxifloxacin (MXF) and Etoposide (VP-16), including decatenation assay, band depletion and Western blot analysis, cytotoxic assay (MTT), flow cytometric studies (for cell cycle and survivin expression), apoptosis assessment (using DAPI-sulforhodamine staining and caspase 3 activity), and measurement of IL-8 and VEGF secretion.\n",
      "   text: Target-20596674\n",
      "   table: None\n",
      "\n",
      "4. question: What is the significance of the combination treatment of MXF and VP-16 on topo II activity in drug-treated cells?\n",
      "   answer: The combination treatment of MXF and VP-16 significantly enhances the inhibition of cellular topo II activity in nuclear extracts derived from drug-treated cells. This results in a reduction of band depletion of topo II, indicating a stronger inhibitory effect on the enzyme's function, which is crucial for effective cancer treatment.\n",
      "   text: Target-20596674\n",
      "   table: None\n",
      "[{'question': 'What is the role of Etoposide (VP-16) as a chemotherapeutic agent, and how does its combination with other drugs affect its efficacy?', 'answer': 'Etoposide (VP-16) is a topoisomerase-II (topo II) inhibitor used in chemotherapy. Studies have shown that when VP-16 is combined with other drugs, it demonstrates better clinical responses. Specifically, the combination of moxifloxacin (MXF) and VP-16 enhances cellular topo II inhibitory activity and reduces band depletion of topo II, which suggests an increased efficacy in drug-treated cells.', 'text': 'Target-20596674', 'table': 'None'}, {'question': 'How does the combination of moxifloxacin (MXF) and Etoposide (VP-16) affect the cell cycle and apoptosis in HT-29 cells?', 'answer': 'The combination of moxifloxacin (MXF) and Etoposide (VP-16) enhances cell cycle arrest at the G2/M phase and increases the appearance of the subG1 peak, which is associated with increased apoptosis in HT-29 cells. This indicates that the combination has a more pronounced effect on inhibiting cell proliferation and inducing cell death compared to either drug alone.', 'text': 'Target-20596674', 'table': 'None'}, {'question': 'What methodologies were used in the study to evaluate the effects of moxifloxacin (MXF) and Etoposide (VP-16) on cellular processes?', 'answer': 'The study employed several methodologies to evaluate the effects of moxifloxacin (MXF) and Etoposide (VP-16), including decatenation assay, band depletion and Western blot analysis, cytotoxic assay (MTT), flow cytometric studies (for cell cycle and survivin expression), apoptosis assessment (using DAPI-sulforhodamine staining and caspase 3 activity), and measurement of IL-8 and VEGF secretion.', 'text': 'Target-20596674', 'table': 'None'}, {'question': 'What is the significance of the combination treatment of MXF and VP-16 on topo II activity in drug-treated cells?', 'answer': \"The combination treatment of MXF and VP-16 significantly enhances the inhibition of cellular topo II activity in nuclear extracts derived from drug-treated cells. This results in a reduction of band depletion of topo II, indicating a stronger inhibitory effect on the enzyme's function, which is crucial for effective cancer treatment.\", 'text': 'Target-20596674', 'table': 'None'}]\n",
      "Debug - Available tables: dict_keys(['drugbank-drug_trans_links', 'drugbank-enzymes_polypeptides_ext_id', 'drugbank-drug_manufacturers', 'drugbank-drug_sequences', 'drugbank-drug_external_links', 'drugbank-drug_international_brands', 'drugbank-drug_mixtures', 'drugbank-drug_packagers', 'drugbank-drug_reactions_enzymes', 'drugbank-drug_enzymes_articles', 'drugbank-targets', 'drugbank-drug_carriers_textbooks', 'drugbank-drug_trans_textbooks', 'drugbank-carriers_polypeptides_ext_id', 'drugbank-drugs_attachments', 'drugbank-drug_carriers_articles', 'drugbank-enzymes_polypeptides', 'drugbank-drug_trans_articles', 'drugbank-drug_experimental_properties', 'drugbank-transporters_polypeptides_ext_id', 'drugbank-drug_dosages', 'drugbank-drug_syn', 'drugbank-drug_targ_textbooks', 'drugbank-drug_enzymes_attachments', 'drugbank-drug_carriers_links', 'drugbank-drug_salts', 'drugbank-drugs_articles', 'drugbank-targets_actions', 'drugbank-drug_patents', 'drugbank-drug_affected_organisms', 'drugbank-query_ddi_table', 'drugbank-drug_pharmacology', 'drugbank-transporters_polypeptides_go', 'drugbank-carriers_polypeptides_go', 'drugbank-transporters_actions', 'drugbank-snp_adverse_reactions', 'drugbank-drug_food_interactions', 'drugbank-drugs_textbooks', 'drugbank-drug', 'drugbank-drug_enzymes_textbooks', 'drugbank-drug_targ_articles', 'drugbank-enzymes_actions', 'drugbank-transporters_polypeptides_syn', 'drugbank-drug_prices', 'drugbank-drugs_links', 'drugbank-carriers', 'drugbank-targets_polypeptides_ext_id', 'drugbank-drug_products', 'drugbank-drug_reactions', 'drugbank-drug_classifications', 'drugbank-transporters', 'drugbank-drug_external_identifiers', 'drugbank-transporters_polypeptides_pfams', 'drugbank-drug_groups', 'drugbank-drug_ahfs_codes', 'drugbank-carriers_polypeptides_syn', 'drugbank-targets_polypeptides_syn', 'drugbank-drug_snp_effects', 'drugbank-carriers_polypeptides', 'drugbank-enzymes_polypeptides_syn', 'drugbank-transporters_polypeptides', 'drugbank-carriers_polypeptides_pfams', 'drugbank-drug_atc_codes', 'drugbank-carriers_actions', 'drugbank-drug_pathway_enzymes', 'drugbank-enzymes', 'drugbank-enzymes_polypeptides_pfams', 'drugbank-drug_enzymes_links', 'drugbank-drug_targ_attachments', 'drugbank-drug_drug_interactions', 'drugbank-targets_polypeptides_go', 'drugbank-drug_targ_links', 'drugbank-drug_pathway', 'drugbank-drug_carriers_attachments', 'drugbank-drug_pathway_drugs', 'drugbank-drug_categories', 'drugbank-drug_pdb_entries', 'drugbank-targets_polypeptides', 'drugbank-drug_trans_attachments', 'drugbank-drug_calculated_properties', 'drugbank-enzymes_polypeptides_go', 'drugbank-targets_polypeptides_pfams'])\n",
      "Debug - Looking for table_names: ['drugbank-transporters.csv', 'drugbank-drugs_links.csv', 'drugbank-drug.csv']\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 150/150 [12:20<00:00,  4.93s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. question: What is the function of apomorphine as described in the passage, and how does it relate to dopamine receptors?\n",
      "   answer: Apomorphine is a nonselective dopamine D1/D2 receptor agonist used to treat symptoms resulting from dopaminergic degeneration associated with Parkinson's disease. It functions by rapidly and reversibly increasing vesicular dopamine uptake in nerve terminals, a process that is blocked by a dopamine D2 receptor antagonist, eticlopride.\n",
      "   text: Target-15178358\n",
      "   table: None\n",
      "\n",
      "2. question: How does apomorphine affect vesicular monoamine transporter-2 (VMAT-2) function according to the passage?\n",
      "   answer: Apomorphine increases vesicular dopamine uptake by causing a redistribution of VMAT-2 protein within nerve terminals, which suggests its potential neuroprotective effects in models of dopaminergic degeneration.\n",
      "   text: Target-15178358\n",
      "   table: None\n",
      "\n",
      "3. question: What experimental evidence is provided in the passage regarding the action of apomorphine on vesicular dopamine uptake?\n",
      "   answer: The passage states that apomorphine rapidly and reversibly increased vesicular dopamine uptake in purified striatal vesicles obtained from treated rats. This effect was observed in both postnatal day 40 and postnatal day 90 rats and was inhibited by pretreatment with eticlopride, a dopamine D2 receptor antagonist.\n",
      "   text: Target-15178358\n",
      "   table: None\n",
      "[{'question': 'What is the function of apomorphine as described in the passage, and how does it relate to dopamine receptors?', 'answer': \"Apomorphine is a nonselective dopamine D1/D2 receptor agonist used to treat symptoms resulting from dopaminergic degeneration associated with Parkinson's disease. It functions by rapidly and reversibly increasing vesicular dopamine uptake in nerve terminals, a process that is blocked by a dopamine D2 receptor antagonist, eticlopride.\", 'text': 'Target-15178358', 'table': 'None'}, {'question': 'How does apomorphine affect vesicular monoamine transporter-2 (VMAT-2) function according to the passage?', 'answer': 'Apomorphine increases vesicular dopamine uptake by causing a redistribution of VMAT-2 protein within nerve terminals, which suggests its potential neuroprotective effects in models of dopaminergic degeneration.', 'text': 'Target-15178358', 'table': 'None'}, {'question': 'What experimental evidence is provided in the passage regarding the action of apomorphine on vesicular dopamine uptake?', 'answer': 'The passage states that apomorphine rapidly and reversibly increased vesicular dopamine uptake in purified striatal vesicles obtained from treated rats. This effect was observed in both postnatal day 40 and postnatal day 90 rats and was inhibited by pretreatment with eticlopride, a dopamine D2 receptor antagonist.', 'text': 'Target-15178358', 'table': 'None'}]\n",
      "Generated 408 question-answer pairs\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "if __name__ == \"__main__\":\n",
    "    main()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "cmdl",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
